The development of a novel native prothrombin assay for the more efficient management of oral anticoagulation therapy by Sylvester, Adrian Jose
Cranfield University  
Cranfield Biomedical Centre 
Institute of Bioscience and Technology  
PhD Thesis 
Academic Years 2000 - 2004 
 
Adrian Jose Sylvester 
 
 
The Development of a Novel Native Prothrombin Assay for the 
More Efficient Management of Oral Anticoagulation Therapy 
 
 
Supervisor: Professor Anthony C Woodman 
 
 
May 2004 
 
This thesis is submitted in partial fulfilment of the requirements for 
the degree of Doctor of Philosophy © Cranfield University 2004.  All rights reserved.  No part of this publication may be reproduced 
without written consent from the copyright owner. 
Abstract 
 
Disturbances of the natural balance between pro-coagulant and anticoagulant 
systems, due to hereditary or acquired factors may result in haemorrhagic or 
thrombotic diseases. 
 
Currently the INR/ISI coagulation monitoring system, introduced in 1983 by the 
World Health Organisation (WHO), is that of choice for most anticoagulation 
management clinics. Patients undergoing anticoagulation therapy must 
regularly attend specialised outpatient clinics for the close monitoring and 
maintenance of their INR.  The automated laboratory caters for rapid online 
simultaneous analysis of multiple blood samples, resulting in the calculation of a 
patient’s INR from the recorded prothrombin time.  The insensitivity of the 
prothrombin time test has been well documented, requiring a reduction in the 
prothrombin concentration of 45 % prior to the materialisation of clinically 
significant prothrombin times. 
 
The project aims to employ three avenues of biotechnology to aid in the 
development of an immuno or molecular imprinted polymer (MIP) based 
anticoagulation assay.  The project will utilise computational molecular 
modelling in an attempt to visualise the tertiary structure of human prothrombin, 
which will allow the rational selection of antigenic sites for molecular imprinting 
or antibody production.   
 
An aqueous, prothrombin-imprinted homo-polymer was grafted to the gold 
surface of a surface plasmon resonance biosensor (Biacore).  The Biacore 
allowed the real time monitoring of imprinted polymer binding characteristics to 
i 
homogeneous protein solutions.  As a direct comparison of two technologies, 
molecular imprinting and immuno technology, polyclonal antibodies showing 
specificity towards the same prothrombin antigen were immobilised onto 
Biacore chips.  The imprinted polymer graft and polyclonal antibody based 
assays recognised homogeneous solutions of prothrombin at a concentration 
range of 0.01 nM to 14.2 nM and 0.01 nM to 0.5 nM respectively.  A randomised 
preliminary clinical trial was initiated to compare the two assays’ ability to 
differentiate plasma samples with a variety of INR values.   
 
The results thus far show promise for the development of a new anticoagulation 
assay using molecularly imprinted polymer technology.  The ultimate aim for 
this project is to develop a consistently more accurate point-of-care 
anticoagulation therapy monitoring kit, incorporating this new technology, which 
can replace or be used concomitantly with the INR/ISI system currently in use.  
This thesis raises more questions regarding the efficacy of oral anticoagulation 
therapy (OACT) and argues for and against the necessity of a novel OACT 
management assay. 
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1.1 Haemostasis 
 
The circulatory system is an independent organ within the body; it has to be 
self-sealing to prevent life threatening injury.  Haemostasis comprises three 
independent processes and culminates in the prevention of substantial blood 
loss from the enclosed coagulation system. 
1. Initially, platelets adhere to damaged blood vessels and to themselves to 
form a platelet plug, which can stem the flow of blood from the damaged 
area.  This process is mediated by von Willebrand factor (vWF), a 104 kDa 
multimeric plasma protein comprising 225 kDa subunits, which binds to 
collagen, a specific platelet membrane receptor and to other components 
of the subendothelial membrane. 
2. The platelet aggregation activates the release of physiologically active 
substances, such as serotonin (5-hydroxytryptamine) and thromboxane 
A2, which stimulate vasoconstriction thereby reducing the flow of blood to 
damaged areas. 
3. The aggregation of platelets and damaged endothelium initiate the major 
defence against bleeding, blood coagulation.  
 
1.1.1 Von Willebrand factor  
 
Von Willebrand factor is a 300-kDa polypeptide that is processed in the Golgi 
apparatus to approximately 250-kDa.  These 250-kDa monomers can join 
together to form polymers of between 1000-kDa and 20000-kDa.  After 
synthesis in the endothelial cells and the megakaryocytes, vWF is stored in 
the Weibel-Palade bodies and the α-secretory granules of platelets 
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respectively.  The smaller molecular weight vWF polymers are secreted 
constitutively into the circulation where they act as carrier proteins for factor 
VIII, protecting it from premature degradation (1/2-life with vWF=8-12 hrs, 
without vWF=2-3 hrs) and delivering it to the site of vascular injury.  Thrombin 
activates breaks down the non-covalent interaction between factor VIII and 
vWF thereby allowing factor VIII to participate in the coagulation cascade on 
the platelet surfaces.   
 
Apart from the carrier protein role it plays in haemostasis, vWF has several 
other important primary haemostatic roles: 
• Platelet adhesion.  VWF acts as a bridge or glue between the platelet 
receptor GPIb-IX and subendothelial collagen or elastin microfibrils to 
mediate the binding of platelets to the subendothelium in areas of high 
shear rate, i.e. microvasluature. 
• Platelet spreading.  VWF attaches to matrix proteins and the platelet 
integrin receptor GPIIb/IIIa on platelet surfaces, which promotes 
platelet spreading on the subendothelial matrix. 
• Platelet aggregation.  Essentially a fibrinogen role, however vWF binds 
GPIIb/IIIa on adjacent platelets, essentially acting as a bridge between 
platelets, important in afibrinogenemic patients. 
• Platelet plug stabilization.  This is done by vWF by binding to GPIb-IX 
on platelets and onto fibrin, therefore incorporating fibrin into the 
platelet plug. 
 
Because of the close interaction of vWF and factor VIII, von Willebrand 
disease (vWD) shows similar bleeding characteristics to the haemophilia’s.  
3 
Chapter 1.  Review of the Literature  Adrian Sylvester 
However, vWD can be determined by measurement of the vWF activity 
(Ristocetin or Botrocetin), vWF antigen (vWF:Ag ELISA), factor VIII activity 
(one stage coagulation assay using FVIII deficient plasma) and bleeding time.   
Classification of the severity of the disease is achieved by determination of 
the multimeric composition of plasma vWF. 
 
1.1.2 Platelets and the platelet plug 
 
Circulating platelets are maintained in a non-reactive state by three methods. 
• Aggregation inhibition compounds, such as nitric oxide and prostacyclin 
are released from endothelial cells. 
• The negatively charged surface of platelets prevents their interaction with 
erythrocytes, leucocytes and the vascular endothelium. 
• The intact endothelium provides a barrier to the platelets, preventing their 
interaction with the adhesive substrates in the subendothelial connective 
tissue matrix, i.e. collagen. 
 
Endothelial disruption, by trauma or disease allows platelets to come into 
contact with and adhere to the subendothelial matrix.  Platelets tend to 
adhere to any rough surface, such as glass, the exposed ends of injured 
blood vessels or particularly to the collagen in the subendothelial layer 
surrounding the blood vessel.  Platelets are an integral part of the 
haemostatic process as they initiate via adhesion to the vessel wall, they form 
the platelet aggregate and they provide the activated surface for the 
acceleration of coagulation, culminating in the stabilisation of the fibrin/platelet 
aggregate.  These processes are regulated by the platelet surface located 
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glycoprotein receptors, namely GP-1b-IX-V, which through its interaction with 
vWF mediates the initial deposition of platelets on the subendothelium 
(Andrews et. al., 1997).   
 
1.1.3 Integrins   
 
Integrins are extracellular, transmembrane bound, heterodimeric glycoprotein 
receptors that are of crucial importance in the correct functioning of inter and 
extra-cellular communication and interaction.  They are comprised of one 
alpha and one beta subunit out of 24 and 9 subunits respectively.  Integrin 
ligand specificity varies partly due to the large number of different alpha and 
beta subunits, which creates a large amount of functional redundancy, and 
also due to alternative splicing of integrin messenger RNA.  Diffuse 
distribution of integrins over the cell surface prevents ligand binding; adhesion 
occurs due to a stimulus (thrombin or adrenalin) that promotes the migration 
of integrins to a hemidesmosome or focal contact point on the cell surface 
(Luscher and Weber, 1993).  The low binding affinity (106 – 109 litres mol-1) 
and the migration of integrins to a focal contact promotes multiple weak 
interactions, which allow strong binding for the cell to remain in contact with 
the extracellular matrix; but also weak enough to allow appropriate cellular 
flexibility.  Common ligands for integrins include fibronectin and laminin, which 
are both part of the extracellular matrix, they are both recognised by multiple 
integrins.  In the platelets resting state the integrin GP-IIb-IIIa binds fibrinogen 
only to a limited extent (Kieffer et. al., 1992), however when agonists (such as 
thrombin) activate the platelet, the integrin receptor changes conformation 
and binds fibrinogen, vWF and fibronectin (Sims et. al., 1991).  There is a 
5 
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clustering effect of the GP IIb/IIIa fibrinogen receptor, which inevitably causes 
an aggregation of fibrinogen on the platelet surface; this has been seen using 
immunocytochemical (Hourdille et. al., 1985) and electron microscopy (Suzuki 
et. al., 1991; Painter et. al., 1985) methods. 
 
1.1.4 Biochemical coagulation cascade 
 
Blood coagulation involves the proliferation of a biochemical cascade of 
circulating proteolytic enzymes and cofactors.  This process culminates in the 
cleavage of thrombin from prothrombin by a complex comprising of activated 
factor X and V with calcium on phospholipid surfaces.  The formation and 
stabilisation of the platelet aggregates at the site of injury with fibrin 
monomers occurs due to the action of the activated Factor Xa/Va complex.  
Thrombin is a serine protease that converts soluble plasma fibrinogen into 
fibrin, which in turn converts the unstable primary platelet occlusions into firm, 
stable haemostatic plugs at the sites of cellular and/or vascular damage.  
Disturbances of the natural balance between the procoagulant and 
anticoagulant systems due to genetic or an acquired factor usually results in 
varying severity of bleeding or thrombotic diseases (Dahlback, 2000). 
 
Circulating proteolytic enzymes involved in the coagulation cascade include 
serine proteases such as factor II (Prothrombin), factor VII (proconvertin), 
factor IX (Christmas factor), factor X (Stuart-Prower factor), factor XI (plasma 
thromboplastin antecedent), factor XII (Hageman or contact factor) and 
Prekallikrein (Fletcher factor).  All have serine at their active centre, which 
confers the ability to hydrolyse peptide bonds.  Cofactors include tissue factor 
(TF or factor III), factor V (labile factor), factor VIII (antihaemophilic factor) and 
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high molecular weight kininogen (HMWK or Fitzgerald factor).  Factors VIII 
and V are involved in the amplification of the cascade, once activated by 
thrombin the cofactors amplify the cleavage of factor X and prothrombin 
respectively.  Factor XIII is a transglutaminase, which when activated (XIIIa) 
by thrombin acts to stabilise fibrin polymers by forming covalent cross-links 
between glutamine residues. 
 
Initiation of the cascade in-vivo occurs through the exposure of TF to blood 
due to cellular and/or vascular damage, the extrinsic pathway.  The serine 
protease factor VIIa (a small fraction circulates as the active form in the 
blood) when incorporated into a complex with TF and Ca2+ on a phospholipid 
surface activates factor X.  Factor Xa alone triggers the small-scale cleavage 
of thrombin as well as the promotion of factor IX activation in the intrinsic 
pathway.  Thrombin now has several major roles in the completion and 
regulation of the cascade: 
 
1. Thrombin cleaves fibrin subunits A and B from fibrinogen. 
2. Thrombin activates factor XIII, the transglutaminase that converts the 
immature platelet aggregate into a stable haemostatic plug.  
3. Thrombin also has a positive feedback effect on the cascade by activating 
co-factors V and VIII.  The prothrombinase and the tenase complexes, factors 
Va/Xa and factors VIIIa/IXa respectively, together with Ca2+ on the 
phosphatidylserine-phospholipid surface, amplify the cascade by promoting 
further cleavage of prothrombin and the activation of factor X.  
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4. Thrombin also has a stimulatory role in the promotion of factor XI 
activation in the intrinsic or contact pathway.  This pathway assumes the 
dominant role in the development of the stable fibrin clot. 
5. Thrombin also has an anticoagulant role in an intact vascular system, as it 
binds to thrombomodulin, which activates protein C (Dahlback, 2000). 
 
Contact reactions between HMWK and kallikrein promote the activation of 
factor XII; factors XI and IX are subsequently activated.  Factor IXa promotes 
the activation efficiency of factor VIIIa, which further activates factor X.  The 
coagulation process is further regulated using certain physiological protective 
mechanisms. 
 
Circulating plasma inhibitors bind to active serine proteases, such as 
thrombin, to localise their effect to the site of injury.  Antithrombin (or 
antithrombin III), the most potent plasma inhibitor binds to free serine 
proteases i.e. those that have strayed from the site of thrombus formation, 
forming a stable high molecular weight complex, which eliminates their 
proteolytic effect (Rosenberg and Damus, 1973).  Antithrombin is in itself a 
relatively inefficient protease inhibitor therefore the heparin-like proteins on 
the endothelial cell surface potentiate antithrombin’s effect markedly as does 
heparin itself (Triplett, 2000; Dahlback, 2000; Hoffbrand et al., 1993).  Other 
inhibitors include heparin cofactor II (accentuated by dermatan sulphate), α2-
macroglobulins, α2-antiplasmin and α2-antitrypsin (Triplett, 2000; Hoffbrand et 
al, 1993), which create inactive, stable, high molecular weight complexes with 
the active serine protease using peptide bonding. 
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Circulating plasma inhibitors of factors V and VIII also work to control blood 
coagulation (Hoffbrand et al., 1993).  Thrombomodulin is an endothelial cell 
surface receptor, which when complexed with thrombin activates the vitamin 
K dependent serine protease protein C.  Activated protein C (APC) has the 
ability to modulate the activity of factors Va and VIIIa when associated with 
another vitamin K dependent protein; protein S attached to the platelet cell 
surface.  APC and protein S form the membrane bound complex, which 
cleaves factors Va and VIIIa, even when they are elements of the 
prothrombinase and tenase active complexes.  Only 30% of plasma protein S 
is free, the rest is associated with the complement regulatory protein C4b-
binding protein.   
 
 
 
 
 
 
 
 
 
 
Factor Half Life 
(Hours) 
  
II (Prothrombin) 60 
VII 4-6 
IX 24 
X (Stuart Prower Factor) 48-72 
Protein C ~8 
Protein S ~30 
Table 1.1.1 represents the plasma half lives in hours of some of the major 
coagulation factors; prothrombin has the longest plasma half-life (adapted 
from Erban, 1999). 
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The APC pathway is not so straightforward.  Factor VIII and VIIIa are 
complexed with Von Willebrand factor or in the tenase complex with factor 
IXa.  Whereas factor Va as well as factor V, binds to phospholipids allowing 
APC to cleave the intact form of factor V.  Factor V is cleaved by APC and 
functions in synergy with protein S as an anticoagulant cofactor to APC in the 
cleavage of factor VIIIa from its tenase complex.  Therefore factor V has both 
procoagulant and anticoagulant properties, and is thought to be an important 
factor in the regulation of the tenase complex.  Homozygous deficiency in the 
APC pathway leads to severe even lethal thrombotic disease shortly after 
birth in both mice and humans.  Mice lacking normal thrombomodulin gene 
functionality have a more severe disease and die during embryogenesis 
before the functional cardiovascular system has fully developed (Dahlback, 
2000). 
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Figure 1.1.1 the human blood coagulation cascade (Adapted from Hoffbrand et al., 1993)
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Tissue factor pathway inhibitor (TFPI) can also regulate the in-vivo pathway 
by binding to factors Xa and VIIa (Hoffbrand et al., 1993; Triplett, 2000; 
Dahlback, 2000).  TFPI is mostly bound to LDL in plasma or to heparan 
sulphate when interacting with the endothelial cell surfaces.  There is no 
evidence available, which suggests that lack of TFPI activity is compatible 
with human life, this is supported by the fact that TFPI-gene knockout mice 
have a lethal phenotype (Dahlback, 2000).  Therefore, TFPI is an important 
factor in the regulation of the intrinsic pathway and coagulation.  
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Figure 1.1.2 natural down regulation of activated factors V and VIII by the protein C and S 
system (Adapted from Hoffbrand et al., 1993) 
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Blood flow is another physiological mechanism that regulates coagulation; the 
rapid dilution of activated factors is achieved before fibrin production away 
from the site of thrombus formation.  Liver parenchymal cells, kupffer cells 
and other reticuloendothelial cells degrade activated factors and remove 
circulating particulate matter, such as platelet aggregate (Hoffbrand et al., 
1993).  Many of the factors and cofactors in the coagulation cascade have 
similar structural and biological properties.  Some of the serine proteases 
e.g.: factors II, VII, IX, X, protein C and protein S are dependent on vitamin K 
for their activity.  Vitamin K is responsible for the post-translational 
carboxylation of amino-terminal glutamate residues, which allows the vitamin 
K dependent proteins to bind Ca2+.  This is important for the correct folding of 
the ‘Gla’ domain (Dahlback, 2000) and the localisation and complexation on 
platelet surface phospholipid.  Termed the Gla region, the terminal 
carboxyglutamyl residues are essential to the coagulation factors’ orientation 
and concentration within the cascade.  A major biochemical abnormality with 
patients deficient in vitamin K metabolism is the minimal rate of prothrombin 
to thrombin conversion. 
 
Other important inter-factor structural homologies within the cascade, 
especially the serine proteases, include epidermal growth factor (EGF) like 
kringle domains and aromatic amino acid stack domains, which function to 
localise and orientate the proenzyme prior to activation.  Structural and 
functional regions of prothrombin and similar coagulation factors will be 
discussed later in the report. 
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Disturbances of the natural balance between pro-coagulant and anticoagulant 
systems due to hereditary or acquired factors may result in haemorrhagic or 
thrombotic diseases. 
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Figure 1.1.3 shows the action of Vitamin K in the γ-carboxylation of glutamic acids in 
coagulation factors, which are then able to bind calcium and attach to the platelet 
phospholipid. 
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1.2 Prothrombin and thrombin 
 
Prothrombin (P00734) is a single chain glycoprotein, which plays a central 
role in the mammalian blood coagulation cascade, both stimulative and 
suppressive.  Having a molecular weight of 72,000 Da, prothrombin is 
synthesised in the liver and has a normal plasma concentration in the range 
0.11-0.23 mg ml-1.  Thrombin (EC 3.4.21.5) has a molecular weight of 39,000 
Da is composed of two polypeptide chains A and B, 49 and 259 residues in 
length respectively, which are held together by a single disulphide bond.  
Prothrombin and the enzymatically active thrombin have diverse roles, which 
include the stimulation of platelets to change shape and the regulation of 
endothelial and other cell proliferation.  Thrombin is involved in the 
haemostatic inflammatory and proliferative responses to wounding, indicating 
a prominent role in the mediation of wound healing.  Prothrombin is also a 
chemotaxic agent and has been shown to be mitogenic towards 
macrophages and monocytes, also able to increase DNA synthesis of such 
cells.  The addition of thrombin to monocytes has been shown to increase the 
cytosolic Ca2+ and promote the rapid cytoskeletal association of cytosolic 
actin; both are initial signs characteristic in chemotaxic stimulation of 
inflammatory cells (Degen et al., 1983).  Thrombin’s procoagulant roles 
include proteolytic cleavage of fibrino-peptides A and B from fibrinogen, the 
stimulation of factors V and VIII and the activation of factor XIII, which initiates 
cross-linkage of fibrin clot and platelet aggregation (chemotaxis) (Degen and 
Sun, 1998). 
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The proteolytic conversion of prothrombin to thrombin is catalysed by the 
prothrombinase enzyme complex, which comprises the serine protease 
activity of factor Xa, its cofactor Va, phospholipids and Ca2+.  The reaction 
splits prothrombin into three fragments: fragment 1 (F1) (consisting of the Gla 
domain and kringle 1), fragment 2 (F2) (consisting of kringle 2) and the 
catalytic domain (thrombin).  Intermediate fragments such as prethrombin 1 
(also termed meizothrombin) and prethrombin 2 (single chain thrombin) are 
produced during the proteolytic cleavage of prothrombin.  Prethrombin 1 
remains after the cleavage of fragment 1 from prothrombin, further proteolytic 
cleavage produces prethrombin 2 and fragment 2.  The cleavage of 
prethrombin 2 between residues 320 and 321 (prothrombin numbering) 
liberates disulphide bonded, double chain thrombin (Butowski et al., 1977).  
Studies have suggested that the interaction of F2 with factor Va is necessary 
for the enhancement of its catalytic efficiency within the prothrombinase 
complex (Kotkow et al., 1994), however it has recently been shown that this is 
not the case (Liaw et al., 1998).  The proposed function of F2 in prothrombin 
is the alteration of proenzyme conformation to allow factor Xa easier access 
to prothrombins scissile bonds (Liaw et al., 1998).  Thrombin interacts with 
and binds to several macromolecules already present in plasma including 
fibrinogen, the PAR-1 receptor, thrombomodulin, thrombin activated 
fibrinolysis inhibitor (TAFI), heparin cofactor II and anion binding exosites I 
and II.  PAR-1 is a seven-transmembrane spanning G-coupled protein 
receptor to which thrombin binds and is located in the cellular membranes of 
platelets, endothelial cells and nervous system cells.  The activation of PAR-1 
through the specific proteolytic cleavage of an extracellular (basic) peptide 
bond allows circulating thrombin to mediate its procoagulant haemostatic 
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responses.  Thrombomodulin is an endothelial membrane receptor that 
mediates thrombin’s anticoagulant response, through the activation of protein 
C in the presence of protein S (Degen and Sun, 1998). 
 
Vitamin K is required for the synthesis of the active protein; its oxidation and 
reduction pathway provides the microsomal carboxylase activity (Figure 
1.4.3, Page 36) that enables the correct synthesis of prothrombins Gla (γ-
carboxyglutamic acid) domain (Figure 1.4.2, Page 35).  Mature human 
prothrombin is 8 % carbohydrate and contains 579 amino acids, 10 of which 
are γ-carboxylated glutamyl (gla) residues.  Protein sequence analysis and 
the analysis of cDNA clones enabled groups such as Magnusson et al., 
Butowski et al., Degen and Sun, and MacGillivray and Davie to deduce the 
entire primary sequence of human prothrombin (Degen and Sun, 1998; 
MacGillivray and Davie, 1984; Degen et al., 1983; Butowski et al., 1977; 
Magnusson et al., 1975).  Mature prothrombin contains several tertiary 
structure functional domains, which include the Gla domain, two kringle 
structures and a serine protease domain.  The gla domain in prothrombin is 
required for its correct binding to Ca2+ ions and hence its localisation to 
phospholipid surfaces (Li et al., 1995), therefore in the absence of vitamin K 
prothrombin circulates in an under/non-carboxylated form with reduced, often 
minimal functionality.  There are regions of homology in other vitamin K 
dependent proteins containing between 8 and 13 gla residues (see Figure 
1.4.2), the Gla domains of such haemostatic proteins have been shown to 
possess phospholipid binding properties (Kotkow et al., 1995).   
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The kringle domains, of which there are two in prothrombin, consist of 
approximately 80 amino acids with internal homology around three disulphide 
bonds.  Kringle domains, first discovered in prothrombin, are also present in 
other proteins and exhibit homologies of 50 % and above.  The primary role of 
the kringle domain appears to be that of interaction with proteins (Kotkow et 
al., 1995), cofactors, substrates or receptors, the second kringle in 
prothrombin binds to factor Va (Degen and Sun, 1998).  The catalytic serine 
protease domain, which shows homology to trypsin is located in the carboxy-
terminal of prothrombin and is activated by factor Xa.  Thrombin is liberated 
from the Gla and kringle-containing amino-terminal of prothrombin, which 
stays attached to the phospholipid membrane.  The active site of thrombin is 
composed of the amino acid triad His-363 (H), Asp-419 (D) and Ser-525 (S) 
as illustrated in Figure 1.2.1; the serine protease activity allows cleavage at 
basic amino acids (Degen and Sun, 1998). 
 
The anion binding exosites are areas of positively charged amino acids 
located on the protein surface some distance away from the active site.  
Anion binding exosite I is believed to be responsible for the substrate 
specificity of thrombin.  Anion binding exosite II is responsible for heparin 
binding and for thrombin’s localisation to specific areas on cell surfaces, 
whilst keeping the active site available to substrates, cofactors and inhibitors 
(Degen and Sun, 1998).  Conformational changes, which alter the catalytic 
environment at thrombins active site and anion binding exosite 1, develop 
through an interaction with prothrombin fragment 2.  F2 binding also inhibits 
heparin catalysed thrombin inactivation by antithrombin four-fold; it enhances 
the esterolytic activity but also inhibits the clotting activity of thrombin (Liaw et 
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al., 1998).  The amino acid sequence DGDEE, residues 68-72 of the inner 
loop of the kringle domain of prothrombin fragment 2 forms non-covalent salt 
bridges with Arg residues in thrombins heparin binding region.  Co-
crystallisation studies have shown that the complete kringle structure is not 
necessary for the above interaction, the binding domain has been localised to 
the inner loop (residues 64-93) and a terminal carboxy connecting peptide 
(residues 94-116) (Liaw et al., 1998). 
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Figure 1.2.1 is a schematic diagram showing the primary structure of human prothrombin.  The 
Gla domain contains 10 γ-carboxyglutamate residues.  The kringle structures are labelled K1 and 
K2, the sequence DGDEE is highlighted in kringle 2 to show the region that forms salt bridges with 
thrombins heparin binding region (not shown).  Cysteine residues are highlighted to show 12 
disulphide bonds, 3 in each kringle, 2 in fragment 1, 3 in thrombin chain B and 1 holding thrombin 
chain A to B.  The active site amino acid triad H-363, D-419 and S-525 is labelled as shown. 
Factor Xa cleavage sites are marked with          . (Data adapted from Degen and Sun, 1998). 
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1.3 Diseases of haemostasis  
 
1.3.1 Hereditary haemorrhagic diseases 
 
Haemophilia A is one of the most common hereditary haemostatic disorders, 
it is a bleeding disorder which has a UK population incidence of 1 in 10, 000 
(Peyvandi et. al., 2002).  Although showing sex-linked inheritance, 33% of 
patients do not show any family history.  The defect manifests itself through 
the absence or reduced levels of plasma factor VIII, which normally combines 
with factor IXa on the phospholipid surface together with Ca2+ to propagate 
the activation of factor X and the common coagulation pathway (See Figure 
1.1.1). 
 
Clinical features of the disease include recurrent painful haemarthroses and 
muscle haematomas in severely affected individuals becoming painful and 
destructive if not treated (Bolton-Maggs and Pasi, 2003).  Haematuria is more 
common than gastrointestinal bleeding; dental extraction and post-operative 
trauma can often cause prolonged bleeding occurrences in mildly and 
severely affected patients (Hoffbrand et al, 1993), consequently intra-cerebral 
and intra-cranial haemorrhage can account for 25% of haemophiliac 
morbidity.  The disease correlates well with the extent of coagulation protein 
deficiency where factor VIIIa activities vary from <1% to 20% of the normal 
activity.  The severity of the disease is maximal when the activity of factor 
VIIIa is <1%, large gene deletions or other gene inactivation mutations must 
predominate.  Milder forms of the disease are characterised by factor VIIIa 
activities between 1%-5% and 5%-20% (Hoffbrand et al., 1993). 
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Coagulation products are used to control haemorrhages in haemophiliacs, 
concentrates of factors VIIIa and IX are produced from donated blood for 
transfusion.  However many haemophiliacs show clinical features of hepatitis 
C and some infected adults show slow progression to cirrhosis of the liver 
(Makris et. al. 1996; Lee and Dusheiko 2002; Goedert et. al. 2002).  Due to 
infected blood and coagulation products from the late 1970s early 1980s, it is 
estimated that up to 50% of haemophiliacs treated in the USA and Europe 
have HIV and hepatitis antibodies in their blood.  Therefore, AIDS is now 
thought to be responsible for a large proportion of haemophiliac morbidity, in 
the UK between 1970 and 1985 more than 1200 individuals were infected 
with HIV through blood transfusions.  More than half of the patients infected 
between ‘79-‘85 have now died but no new transfusion borne HIV infections 
have been detected since 1986 (Bolton-Maggs and Pasi, 2003).  Donor 
testing and two viral inactivation steps during concentrate preparation and the 
use of genetic engineering to produce inherently infection-free recombinant 
coagulation concentrates now prevent HIV and hepatitis infection during 
therapy (Hoffbrand et al., 1993).  There is suspicion that the variant 
Creutzfeldt-Jakob disease could be transmitted through infusion of plasma 
products, however there has not been any evidence of such transmission to 
date. 
 
Haemophilia B is a similar disease of coagulation affecting factor IX, it is also 
known as Christmas disease or just factor IX deficiency.  The clinical features 
of the disease are almost identical to haemophilia A; however, the incidence 
of affected people is only 1 in 50, 000 (Peyvandi et. al., 2002). 
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Von Willebrand disease (vWD) is a very common hereditary haemostatic 
disorder showing autosomal dominant inheritance; its prevalence in the 
general world population is estimated to be 1% (Rodeghiero, 2002).  Pre-
pubertal clinical presentations include bruising and epistaxis (nosebleeds).  
Epistaxis decreases during and after puberty however females can become 
menorrhagic, which can often be incorrectly diagnosed as uterine cancer.  
Better patient management and earlier diagnoses will prevent the need for 
unnecessary hysterectomies.  
 
vWD affects the multifunctional multimeric protein von Willebrand factor 
(vWF), which promotes platelet-to-platelet cohesion under high shear stress 
and the adhesion of platelets to exposed endothelial surfaces.  The A1 
domain of vWF contains binding sites for the Platelet Glycoprotein 1b along 
with binding sites for the snake venom protein botrocetin, heparin and minor 
binding sites for collagen (Sadler et. al. 2000).  Platelet Glycoprotein IIb-IIIa 
on activated platelets interacts with an RGDS sequence at the carboxyl-
terminus of the C2 domain of vWF.  The 2050 amino acid mature vWF also 
prevents the premature degradation of factor VIII prior to its activation and 
complexation with factor IXa; therefore the activity of factor VIIIa is also 
compromised in vWD patients (Rodeghiero, 2002).  The low factor VIIIa and 
vWF activities combined with a lack of platelet adhesion causes varying 
severity of bleeding, mainly due to post-traumatic and operative 
haemorrhages.   
 
As with haemophilia A, there are three distinguishable states of disease 
severity, termed types I, II and III; type III presenting as the most severe form 
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of the disease.  Type I vWD is the most predominant form of the disease, 
generally comprising between 60-80% of all vWD cases (Sadler et. al., 2000). 
Type I vWD is characterised by a partial, quantitative deficiency of vWF, 
nevertheless the distribution of vWF multimers appears normal or nearly 
normal and the residual plasma vWF appears to have normal activity.   A 
number of different subgroups of type I have been identified; these are based 
on the different levels of plasma and platelet vWF (Hoyer et. al., 1983).   
 
Type II vWD is concerned with qualitative defects of vWF and is divided in to 
four variants IIA, IIB, IIM and IIN.  Type IIA vWD provides patients with an 
increased number of smaller vWF subunits with compromised functionality.  
There are two mechanisms that produce type IIA characteristic vWF 
multimers.  The mechanism of group 1 causes defective intracellular 
transportation together with impairment of assembly and storage of vWF 
multimers in the plasma and platelet compartments.  Group 2 renders the 
vWF multimers ultra-sensitive to proteolysis in plasma, therefore transforming 
vWF into small non-functional vWF multimers (Reviewed in Sadler, 1994 and 
Sadler et. al. 2000).  The classification of group II vWD phenotypes is 
summarised in Table 1.3.1 below. 
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Type 
2A 
 
Qualitative defects causing decreased platelet dependent function 
due to absence of HMW vWF multimers caused by their impaired 
synthesis or increased degradation. 
Type 
2B 
 
Qualitative defects due to multimers possessing increased affinity 
for platelet glycoprotein Ib.  VWF antigen usually higher than in IIA. 
Type 
2M 
 
Multimer: Qualitative defects causing decreased platelet dependent 
function not due to lack of HMW vWF multimers. Possible mutations 
in vWF domain A1.  
Type 
2N 
 
Normandy: Corresponds to all qualitative variants with markedly 
decreased affinity for factor VIII.  Factor VIII binding site mutants! 
 
 
 
Table 1.3.1 summarises the group II vWD subtypes and their corresponding defects.  Type 
IIA vWD includes the previous type IIA category as well as types IB, IIC, IID, IIE, IIF, IIG, IIH, 
II-I, IIA-1, IIA-2 and IIA-3 (Reviewed in Sadler, 1994 and Sadler et. al. 2000). 
 
Type 3 vWD is pathophysiolgically similar to vWD type 1 in that it is a 
quantitative defect.  However, due to its symptoms being so much more 
severe and having much more distinct therapy requirements it was assigned 
to a completely different category.  A total deficiency of vWF is the 
determining characteristic of type 3 vWD, whereby the vWF activity is 
reduced to less than 10%, which leads to spontaneous bleeding into joints 
and soft tissues.  As in type 2N the absence of vWF-FVIII binding may 
introduce blood clotting as a secondary haemostatic defect in more severe 
cases.  Its inheritance is usually autosomal recessive; hence symptoms are 
normally only present in homozygous or compound heterozygous patients, 
heterozygous relatives may present with normal or mildly reduced levels of 
vWF and thus asymptomatic or occasionally present with mild bleeding 
symptoms.  In many cases of type 3 vWD patients develop alloantibodies to 
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vWF due to the vWF-containing plasma they are given; these antibodies 
render this therapy ineffective and can increase the risk of anaphylactic shock 
on introduction of therapy.   
 
1.3.2 Acquired haemorrhagic diseases 
 
Vitamin K deficiency may be caused by inadequate diet, malabsorption of 
Vitamin K in the gut or the use of coumarins and inanediones, which act as 
vitamin K antagonists during anticoagulation therapy.  The disease is 
associated with the decrease in the functional activity of factors II, VII, IX, X 
and proteins C and S, however immunological methods show normal levels of 
these proteins in haemorrhagic patients.  The non-functional proteins, termed 
PIVKA – Proteins Induced by Vitamin K Absence, are present due to the fact 
that absence of vitamin K inhibits the post-translational carboxylation of 
specific glutamate residues in the amino terminal domain of each protein.  
The carboxylation process involves the recycling of Vitamin K to vitamin K 
epoxide and back, using a carboxylase and reductases respectively.  
Warfarin is thought to interfere with the reduction of vitamin K epoxide, which 
produces a functional vitamin K deficiency, however this concept may need 
some revision (Hoffbrand et al., 1993). 
 
Haemorrhagic disease of the newborn is an acquired vitamin K 
haemorrhagic disease, which may manifest itself in the first 4 days of life.  
Contributing factors include poor placental transfer of vitamin K, immature 
liver cells, and a sterile gut, which precludes the utilisation of bacterial 
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sources of the vitamin and breast milk is also relatively deficient in vitamin K 
(Suttie, 1992).  
 
Prophylaxis of 1 mg vitamin K (phytomenadione) is given intramuscularly to 
all newly born babies immediately after birth, except those likely to be 
glucose-6-phosphate dehydrogenase (G6PD) deficient.  Bleeding infants are 
given 1 mg intramuscular vitamin K every 6 hours and initially fresh frozen 
plasma if bleeding is severe.  Children and adults with obstructive jaundice 
(impaired absorption of vitamin K), pancreatic or small bowel disease may 
have resulting vitamin K deficiency, which may also increase the risk of 
haemorrhagic episodes (Hoffbrand et al., 1993).  Treatment is again with daily 
oral prophylaxis of vitamin K.  The prothrombin time (PT) is prolonged in 
newly born and in adult cases, low plasma levels of the active vitamin K 
dependent factors would also be expected. 
 
Liver disease is the broad term used to describe symptoms manifested due 
to disfunctionality of the liver.  The liver is the largest gland in the body 
weighing in at approximately 1.2-1.6 kg.  Being very complex it has many 
varied functions including the production and secretion of bile into the gall 
bladder and duodenum, the liver is also an important site for metabolism of 
carbohydrates, proteins and fats.  The liver regulates the blood glucose levels 
converting excess glucose to glycogen, and removes excess amino acids by 
breaking them down into ammonia and finally urea.  It is also the site of 
synthesis of fibrinogen and vitamin K dependent coagulation factors and 
heparins, as well as a site for metabolism and storage of vitamin K itself.  
Therefore, due to the liver’s essential role in control of normal blood 
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coagulation, deficiency in all or part of its function leads to among others, 
coagulation disorders.  Decreased synthesis of vitamin K dependent proteins 
may be brought about by biliary obstruction.  In severe hepatocellular disease 
factor V and fibrinogen levels are depleted and there are increased levels of 
tissue plasminogen activator, leading to the suppression of normal 
coagulation processes. 
 
Haemorrhagic complications may occur due to overdose with oral 
anticoagulants.  These can be vitamin K antagonists and may result in 
severe deficiency of coagulation factors II, VII, IX and X. Poorly controlled 
heparin or systemic thrombolytic agent therapies may result in coagulation 
difficulties and subsequent bleeding episodes.  Due to its poor preservation 
properties, massive transfusion of stored blood may serve to dilute the 
already depleted levels of platelets, coagulation factors and inhibitors.  
Platelets aggregate and function poorly after 24 hours at 4 oC, the labile 
coagulation factors V and VIII function poorly after 3-4 days storage.  Minor 
activation of coagulation factors, microaggregates and degenerate cells all 
contribute to massive transfusion syndrome. 
28 
Chapter 1.  Review of the Literature  Adrian Sylvester 
 
 Platelet 
Count 
Prothrombin 
Time (PT) 
Activated Partial 
Thromboplastin 
Time (aPTT) 
Thrombin Time 
(TT) 
Liver Disease Low Prolonged Prolonged Normal         
(rarely prolonged)
DIC Low Prolonged Prolonged Grossly Prolonged
Massive 
Transfusion 
Low Prolonged Prolonged Normal 
Oral 
Anticoagulants 
Normal Grossly 
Prolonged 
Prolonged Normal 
Heparin Normal 
(rarely low) 
Mildly 
Prolonged 
Prolonged Prolonged 
Circulating 
Anticoagulant 
Normal Normal or 
Prolonged 
Prolonged Normal  
 
Table 1.3.2 a summary of the typical haemostatic test results obtained in screening for acquired 
bleeding disorders (Taken from Hoffbrand et al., 1993). 
 
Thrombosis is the condition in which the blood changes from a liquid to a 
solid state producing a clot or thrombus (pl. thrombi).  Pathogenic implications 
of abnormal thrombus formation arise due to narrowing (ischaemia) of blood 
vessels through local vascular obstruction or embolization and obstruction of 
a distal part of the circulation.  Assuming that thrombosis forms a dominant 
role in the pathogenesis of conditions such as myocardial infarction, 
cerebrovascular disease and deep vein occlusion, thrombosis becomes one 
of the most important medical problems facing the western world today 
(Hoffbrand et al., 1993).  The incidence of thrombosis increases with age and 
is usually associated with certain risk factors such as, operations and 
pregnancy, although some thrombophilic individuals may develop thrombi at a 
younger age through acquired or hereditary predispositions.  Multiple thrombi 
in the microcirculation result in the disorder known as disseminated 
intravascular coagulation (DIC) as discussed below. 
 
29 
Chapter 1.  Review of the Literature  Adrian Sylvester 
The pathogenesis of thrombi in different parts of the blood system is similar, 
although formation of thrombi is different.  In arterial thrombosis 
(atherosclerosis), thrombi develop from platelet reaction and aggregation due 
to vessel wall damage, atherosclerosis and plaque rupture.  The major 
predictive risk factors related to the development of atherosclerosis are high 
plasma factor VII and fibrinogen levels, a positive family history and being 
male.  Venous thrombosis is brought about due to the accumulation of 
thrombin in areas of lethargic blood flow, leading to coagulation of blood in 
these areas. 
 
1.3.3 Acquired haemostatic/thrombotic diseases 
 
Disseminated intravascular coagulation (DIC) (or intravascular coagulation 
and fibrinolysis (ICF) (Bowie et al., 1983) is a condition resulting from over 
stimulation of the blood clotting mechanisms in response to disease or injury.  
Examples include severe infection, liver disease, promyelocytic leukaemia, 
asphyxia, hypothermia, abrupto placentae (premature separation of the 
placenta) and intra-uterine foetal death.  Gram-negative and meningococcal 
septicaemia, certain virus infections (purpura fulminans) and severe burns 
cause widespread endothelial damage and platelet aggregation.  Patients 
present with generalised coagulation throughout the blood system, especially 
in the small vessels, and excessive consumption of coagulation factors due to 
the release of procoagulant material into the blood stream, such as amniotic 
fluid, some snake venoms and mucins from adenocarcinomas.  Inevitably, the 
consumption of platelets due to bleeding episodes associated with DIC leads 
to a reduction in blood platelet count or thrombocytopenia.  Fibrinogen levels 
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in DIC associated patients are generally low, circulating fibrin monomers are 
produced by intravascular thrombin that form fibrinogen-fibrin complexes, 
which eliminates the fibrin monomers and fibrinogen from normal coagulation.  
Intravascular thrombin also causes intense fibrinolysis with the release of split 
products that interfere with fibrin polymerisation; these products may be 
detected in the blood serum and urine.  The prothrombin time and aPTT are 
prolonged and the activities of factors V and VIII are reduced (Fruchtman et 
al., 1986).   
 
Coagulation deficiency caused by circulating antibodies is occasionally 
seen; IgG antibodies to factor VIII, which may produce a bleeding syndrome, 
are seen in 5-10 % of haemophiliacs.  These antibodies are associated with 
certain immunological disorders such as rheumatoid arthritis and old age, but 
are seen rarely in newly born infants.  The most common acquired inhibitor of 
coagulation is the lupus anticoagulant (LA), which is a member of the anti-
phospholipid antibody (APA) family (Triplett, 2000).  LA is detected in 10 % of 
patients with systemic erythematosus (SLE) and in patients with other 
autoimmune diseases frequently presenting with antibodies to other lipid 
containing antigens, e.g. cardiolipin (Hoffbrand et al., 1993).  Most APAs seen 
in the setting of infections have no clinical complications (Triplett, 2000), but a 
large percentage of patients with underlying autoimmune disease present 
with arterial and venous thrombotic complications, and recurrent spontaneous 
abortion in women (Triplett, 2000; Hoffbrand et al., 1993).  The laboratory 
diagnosis of LA is based on the presentation of the clinical complications 
mentioned above and three laboratory screening procedures to test for LA 
and/or anti-cardiolipin antibodies (Triplett, 2000). 
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Normal healthy 
people 
 1% - 14% (age related) 
Infection 
 Syphilis, AIDS (93 %), Lyme disease (39 %), infectious 
mononucleosis (20 %), tuberculosis (20 %), Measles, chickenpox, 
mumps, hepatitis A 
Drug induced  Phenothiazines, procainamide, chlorpromazine, oral contraceptives etc 
Malignancy  Melanoma, renal cell carcinoma, lung carcinoma, lymphoma, and leukaemia 
Autoimmune 
diseases 
 SLE (15-50 %), Sjºgren’s syndrome (42 %), RA (≤ 33 %), psoriatic 
arthritis (28 %), scleroderma (25 %), MCTD (22 %), GCA/PMR (20 
%), Behets disease (0-50 %), ITP (30 %), juvenile chronic 
arthritis (55 %), haemolytic anaemia, idiopathic thrombocytopenic 
purpura, Crohn’s disease 
Neurologic 
diseases 
 Myasthenia gravis (68 %), multiple sclerosis (29 %), Guillain-Barr  
syndrome, transverse myelitis  
 
Table 1.3.3 prevalence of antiphospholipid antibodies (Taken from Fessler, 1997):  SLE = systemic lupus 
erythematosus, RA = rheumatoid arthritis, MCTD = mixed connective tissue disease, GCA = giant cell 
arteritis, PMR = polymyalgia rheumatica, ITP = immune thrombocytopenic purpura.  
1.3.4 Hereditary haemostatic diseases 
 
The prevalence of hereditary haemostatic disorders is at least as high as that 
of hereditary bleeding disorders.  Young patients suffering from spontaneous 
thrombosis or recurrent deep vein thromboses may be diagnosed with 
hereditary or familial thrombophilia, usually without an easily identifiable 
underlying cause.   
 
Antithrombin III deficiency was first recognised in 1965 as an autosomal 
dominant inherited disorder, further research has lead to the discovery of 
many different variants of the antithrombin III mutation.  At a young age 
patients present with recurrent venous thromboses with arterial thrombosis 
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only occasionally.  Antithrombin III concentrates’ are available for use to 
prevent thrombosis during childbirth or general surgery. 
 
Protein C deficiency is arguably the most common form of hereditary 
thrombophilia, having autosomal dominant inheritance and variable 
penetrance, occasional homozygous individuals present with severe DIC or 
purpura fulminans in early infancy.  Skin necrosis may develop in the first two 
days of warfarin therapy in some patients.  This is believed to be due to 
further reduction in plasma protein C concentration, before the levels of 
vitamin K dependent coagulation proteins are reduced under the influence of 
warfarin. 
  
Factor V deficiency, Leiden gene mutation is a very common cause of 
increased risk of thrombosis responsible for approximately 20 % of all cases.  
The factor V gene mutation confers a resistance to protein C inactivation 
upon factor V (Hoffbrand et al., 1993), which leads to the uncontrolled 
propagation of the coagulation cascade. 
 
Protein S deficiency also autosomal dominant in its inheritance has been 
recognised in some families with thrombophilia.  Abnormal fibrinogens and 
plasminogens have also been recognised as being causative of rare 
hereditary or acquired thrombophilia, as well as elevated levels of fibrinogen 
and factor VII. 
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1.4 Vitamin K 
 
1.4.1 The Quinones 
 
Henrik Dam; a Danish nutritional biochemist, discovered vitamin K in the 
1930s as an anti-haemorrhagic agent capable of curing a certain bleeding 
disorder in chicks fed on a lipid free diet (Suttie, 1992).  The majority of 
vitamin K in the human diet is contained in green plants and is in the 
phylloquinone (Figure 1.4.1) or vitamin K1 form, vitamin K2 or menaquinone 
(Figure 1.4.1) is bacterially synthesised and comprises an unknown (but 
small) portion of the human diet.  In 1970, Rietz and associates demonstrated 
the presence, in human livers, of menaqinone-7, 8, 9(2H), 9(4H), 10 and 11 in 
addition to phylloquinone; suggesting that the presence of vitamin K 
homologs within the mammalian liver reflects the dietary and the bacterial 
sources of the vitamin in the gut (Olson, 1984). 
 
 
 
 
 
 
 
 
 
O
O
3 
O 
O 
B: Menadione - vitamin K2
2-methyl-1, 4-napthoquinone 
A: Phylloquinone - vitamin K1
2-methyl-3-phytyl-1, 4-napthoquinone  
 
Figure 1.4.1 shows the structures of the biologically active forms of vitamin K, phylloquinone from green 
plants and menadione from bacteria (now used only in animal feed).  Vitamin K2 was originally characterised 
as a series of multiprenyl menaquinones with unsaturated side chains (structures taken from Suttie, 1992). 
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The biochemical function of vitamin K was not revealed until the 1970s when 
it was discovered that a dietary lack of vitamin K not only led to the increased 
dysfunction of prothrombin but of clotting factors VII, IX and X.  Investigations 
also led to the discovery of the previously uncharacterised amino acid γ-
carboxyglutamic acid or gla, which arises through a vitamin K dependent 
post-translational carboxylation of glutamic acid residues through the action of 
a liver microsomal carboxylase enzyme.  There are 10 gla residues present in 
the amino terminal of factor II and VII, 11 gla residues in the homologous 
region of factor X and there are 12 gla residues present in the N terminal 
region of factor IX, these regions are illustrated in Figure 1.4.2.   
 
 1    5      10     15     
Prothrombin Ala Asn Lys Thr Phe Leu Gla Gla - Val Arg Lys Gly Asn Leu Gla Arg Gla Cys Val 
Factor X Ala Asn Ser Phe Phe Leu Gla Gla - Lys Lys - Gly His Leu Gla Arg Gla Cys Met 
Protein C Ala Asn Ser - Phe Leu Gla Gla - Leu Arg Pro Gly Asn Val Gla Arg Gla Cys Ser 
Factor IX Tyr Asn Ser Gly Lys Leu Gla Gla Phe Val Gln - Gly Asn Leu Gla Arg Gla Cys Met 
Factor VII Ala Asn - Ala Phe Leu Gla Gla Leu Arg - Pro Gly Ser Leu Gla Arg Gla Cys Lys 
 20     25     30     35     
Prothrombin Gla Gla Thr Cys Ser Tyr Gla Gla Ala Phe Gla Ala Leu Gla Ser Ser Thr Ala Thr Asp 
Factor X Gla Gla Thr Cys Ser Tyr Gla Gla Ala Arg Gla Val Phe Gla Asp Ser Asp Lys Thr Asn 
Protein C Gla Gla Val Cys ? Phe Gla Gla Ala Arg Gla Ile Phe ? Asn Thr ? ? Thr  
Factor IX Gla Gla Lys Cys Ser Phe Gla Gla Ala Arg Gla Val Phe Gla Asn Thr Gla Arg Thr Thr 
Factor VII Gla Gla Gln Cys Ser Phe Gla Gla Ala Arg Gla Ile Phe Lys Asp Ala Gla Arg Thr Lys 
 40     45   Key:          
Prothrombin Val Phe Trp Ala Lys Tyr   Gla  Gamma – carboxyglutamic acid 
Factor X Gla Phe Trp Asn Lys Tyr   Amino Acids  Regions of Homology 
Protein C         Amino Acids  Non Homologous regions 
Factor IX Gla Phe Trp Lys Gln Tyr   ?  Amino Acid not known 
Factor VII Leu Phe Trp Ile Ser Tyr   -  No Amino Acid  Figure 1.4.2 shows the amino acid homology in the NH2-terminal portions of human prothrombin, factor VII, IX 
and X and protein C.  The numbering is that of prothrombin and the other proteins have been aligned to show 
the homology.  The sequences of prothrombin, factor VII, X and IX were taken from the “ExPaSY SWISS-PROT” 
web site.  Accession numbers for the proteins are prothrombin - P00734, factor VII – P08709, factor IX – P00740 
and factor X – P00742.  The sequence for protein C was taken from Stenflo et al., 1977. 35 
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Figure 1.4.3 shown below, the vitamin K epoxide cycle is a salvage pathway for vitamin K, a vitamin present 
in nanomolar concentrations in the liver, skin and muscles.  It suggests that vitamin K is converted to vitamin 
K-epoxide by an epoxidase activity that may be identical or linked to the glutamate carboxylase activity.  The 
epoxide is converted back to the quinone (vitamin K) using an epoxide reductase activity, which is a site of 
inhibition by warfarin.  The cycle continues with the reduction of the quinone to the hydroquinone, which in turn 
reacts with oxygen forming the epoxide; this step brings about the carboxylation of glutamic acid (adapted 
from Olson, 1984). 
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Absorption of vitamin K requires bile and pancreatic juices for maximum 
effectiveness, dietary sources are absorbed in the small bowel and they are 
incorporated into chylomicrons that enter the lymphatic system.  Absorption 
efficiency has been measured at between 40-80 % depending on the 
absorption vehicle.  Orally administered vitamin K may appear in the plasma 
within 20 minutes and as much as 20 % may appear in the liver within 2 
hours, whereas 50 % of parenterally administered vitamin K may appear in 
the liver within 1 hour (Olson, 1984).  During the period 48-72 hours post 
absorption the plasma concentration of vitamin K declines exponentially, this 
is due to its transfer from chylomicrons to the liver, where it is incorporated 
into very low-density lipoproteins (VLDL) and distributed to tissues via low 
density lipoproteins (LDL).  The turnover of the human vitamin K body-pool 
was estimated to be 2 ½ hours (Bjornssen et al., 1979), body-pool sizes were 
estimated from approximate daily intake to be 50-100µg, which is 
exceptionally low for a fat-soluble vitamin. 
 
Vitamin K 2,3-epoxide was reported and characterised as a metabolite of 
vitamin K in 1970.  In 1941, it was shown that the epoxide rapidly converts to 
vitamin K in normal animals and in 1970 Matschiner demonstrated the 
accumulation of warfarin in treated rats.  Matschiner also demonstrated that 
the biological activity of vitamin K was equal to that of its epoxide, except in 
warfarin treated animals (Matschiner et al., 1970).  The suggestion was that 
warfarin inhibited the reductase, which converted vitamin K-epoxide back to 
its quinone form; this hypothesis was established in the early 1970s through 
the work of Bell, Sadowski, Matschiner and Caldwell (Bell et al., 1972; Bell et 
al., 1973).   
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Vitamin K-2,3-epoxide reductase activity converts vitamin K-2,3-epoxide back 
to vitamin K, this activity is repressed by the action of warfarin.  DT 
diaphorase was purified from liver microsomes by affinity chromatography 
and was shown to be the physiologically relevant vitamin K (quinone) 
reductase in the epoxide cycle, later shown to be more sensitive to warfarin 
(Wallin et al., 1978).  The cyclic interconversion of the vitamin to its epoxide 
and back is required for its glutamate carboxylation activity; warfarin exerts its 
inhibitory effect on prothrombin synthesis through the inhibition of epoxide 
and quinone reductases within the cycle.  Warfarin resistance has been 
demonstrated in rats in northern Europe and the activity of vitamin K epoxide 
in these rats was shown to be less sensitive to warfarin, however more 
hydrophobic 4-hydroxy-coumarin drugs (e.g. difenacoum) inhibit epoxide 
reduction equally well in resistant rats (Olson, 1984). 
 
1.4.2 Nutritional vitamin K requirements  
 
Human requirement for vitamin K, up to 50 % of which may derive from gut 
microflora, has been calculated to be approximately 2 µg kg-1 (body weight) 
day-1, therefore the dietary requirement is 1 µg kg-1 day-1 (Olson, 1984; Suttie, 
1992; Booth et al., 1998).  This was calculated using the assumptions; an 
intravenous dose of 1 µg kg-1 is needed to raise depressed vitamin K levels to 
normal for 1 day, and the gut absorbs approximately 50 % of dietary vitamin 
K.  In the US a normal mixed diet has been calculated to contain 
approximately 300-500 µg (of vitamin K) day-1 (Olson, 1984), which far 
exceeds the recommended daily allowance for the vitamin.  However, more 
recent studies have suggested that the mean intake of vitamin K in young 
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(<45 yrs) and old (>55 yrs) adults range from 60-110 µg and 80-210 µg 
respectively per day in the US (Booth et al., 1998).  The increase in vitamin K 
content in the diet of older adults may be attributed to the increased vegetable 
content of their diet.  These estimates are closer to the RDA; however some 
individuals fail to meet even this lower level on a daily basis, which may lead 
to vitamin K deficiencies and possible haemorrhagic complications. 
 
The two sources of vitamin K, as mentioned previously, are the diet and 
intestinal microflora.  Menaquinones have been reported to comprise up to 50 
% of the daily supply of vitamin K (Olson, 1984), however a recent publication 
states that the microflora of the gut provide only a minor portion of the vitamin 
K RDA (Booth et al., 1998).  Another publication states that the 
menaquinones, originally thought to provide the complete vitamin K RDA, are 
now thought to be of rather less nutritional significance (Suttie, 1990).  
Numerous case reports of antibiotic induced vitamin-K responsive 
hypoprothrombinaemias have argued for the importance of menaquinones in 
the human diet and others argue against their nutritional significance.  
However, more recent evidence suggests that menaquinones only partially 
satisfy the human nutritional requirement for vitamin-K (Suttie, 1995).  
Because of the interest in haemorrhagic disease of the newborn, the 
phylloquinone content of human breast milk has been studied.  The estimated 
requirement of 1 µg kg-1 cannot be met with a diet of breast milk alone, taking 
into consideration the variability between vitamin K content of the mother, 
ranges from 1-3 µg L-1.  Milk-formula-fed infants show a lower incidence of 
haemorrhagic complications due to the higher phylloquinone content of cows-
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milk; the vitamin is concentrated within the lipid portion of the milk, making 
high-fat dairy products also high in vitamin K (Suttie, 1992). 
 
Green leafy vegetables such as kale and parsley contain the highest vitamin 
K concentrations, reported to be in excess of 500 µg 100 g-1, which may 
comprise 40-50 % of daily intake.  Oils such as soybean, cottonseed, canola 
and olive contain between 200 and 400 µg 100 g-1, whereas fruit and cereals 
have low concentrations and dairy products contribute intermediate amounts 
of vitamin K.  Skeletal meat may contribute less than 5 µg 100 g-1 and in 
some cases less than 1 µg 100 g-1, however the liver being the major vitamin 
K storage organ may contribute between 20 and 100 µg 100 g-1, depending 
on the vitamin K intake of the animal prior to slaughter.  Mixed dishes and 
certain meals, due to the high phylloquinone content of the oils used in their 
preparation, comprise 15 % of the total dietary phylloquinone intake (Booth et 
al., 1998).  Some foods such as tomatoes and carrots do not contain large 
amounts of phylloquinone, but they are ranked as good providers due to the 
large amounts consumed.  Due to its low dietary requirement it is difficult to 
compile a daily diet adequate in other nutrients that contributes less than 80 
µg of vitamin K, therefore satisfying the daily requirement (Suttie, 1992). 
Tobacco is one of the richest sources of vitamin K known, containing up to 5 
mg in 100 g; a small percentage of this vitamin K is volatised when smoking 
and absorbed through the mucous membrane in the pharynx and bronchi.   
 
Menaquinones, supplied by the microflora of the gut, are also reported to be 
present in certain animal products including chicken egg yolk and butter; 
various cheeses contain MK-8 and MK-9 at concentrations of 5-20 µg 100 g-1.  
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Fermented soybean products, such as Natto, contain large amounts of MK-6, 
MK-7 and MK-8, which may be of high nutritional value to populations 
consuming this class of food e.g. the Japanese (Suttie, 1995).  Menaquinone 
absorption in the lower bowel however is rather limited; therefore, the 
contribution of dietary menaquinone to total vitamin K intake is less well 
understood (Booth et al., 1998).  MK-4 has been indicated to possess a 
unique role in vitamin K metabolism; this short chain menaquinone is not 
produced in significant amounts by the intestinal microflora, it has been 
reported however to be present in significant amounts in extra-hepatic tissues 
such as brain, pancreas, salivary gland and sternum.  It was concluded in the 
1960s that the bacteria in the gut remove the phytyl chain of phylloquinone 
releasing menadione, which was absorbed and converted to MK-4.  This 
tissue specific localisation of MK-4 and pathway for its metabolism from 
phylloquinone suggest it has a unique and yet unknown function that is 
detached from that currently recognised for vitamin K (Booth et al., 1998). 
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1.4.3 Oral anticoagulants and drug therapy  
 
Warfarin is a soluble vitamin K antagonist that was developed through the 
discovery of dicoumarol (bis-hydroxy-coumarin) (Campbell et al., 1941) as the 
active agent in spoilt sweet clover, which caused a haemorrhagic disease in 
cattle in 1922 (Olson, 1984; Suttie, 1990).  Derivatives of 4-hydroxy-coumarin 
or phenindandione have been synthesised and tested on humans and 
animals as vitamin K antagonists, many more hydrophobic hydroxy-
coumarins have been used as rodenticides, such as difenacoum and 
brodifacoum.  Oral anticoagulants, which regulate the synthesis of 
prothrombin and other vitamin K dependent proteins in the liver, also induce 
hypoprothrombinaemia and other factor deficiencies at specific rates when 
given in saturating doses.  The effective concentration of the antagonist 
causes the synthesis of vitamin K dependent proteins to cease.  Hydroxylated 
inactive products are created through the degrading action of liver microsomal 
enzymes, a process that may take hours or days depending on the half-life of 
the hydroxy-coumarin.  Hydroxy-coumarins exert their indirect inhibitory effect 
on prothrombin synthesis by blocking the recycling of vitamin K epoxide back 
to the quinone form of the vitamin; both reductase enzymes are inhibited by 
warfarin (Olson, 1984).   
 
Other commonly used anticoagulants include unfractionated heparin (UH) (a 
mixture of anionic glycosaminoglycans with molecular weights in the range 
3000-30,000 kDa) and low molecular weight heparin (LMWH) (molecular 
weights in the range 4500-6000 kDa).  The heparins exert their anticoagulant 
effect by catalysing the inactivation of factor Xa (UH and LMWH) and 
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thrombin (LMWH) by antithrombin III.  The catalysis of antithrombin III 
inactivation of factor Xa occurs due to the conformational change induced 
upon its binding to UH or LMWH, which causes an increase in the rate of 
reaction with factor Xa.  The catalysis of the antithrombin III/thrombin 
inactivation occurs due to the stabilisation of a ternary inhibitory complex, in 
which thrombin is tethered to antithrombin III.  LMWH is usually administered 
subcutaneously in an unmonitored fixed-dose fashion, whereas due to its 
lower subcutaneous bioavailability, UH is administered intravenously and 
requires frequent monitoring and dose adjustment (Shafer, 1998). 
 
Salicylate is another drug that may be used to control the coagulative state of 
a patient; hypoprothrombinaemia is induced in the use of doses greater than 
6 g per day.  The mechanism of action is different to that of the hydroxy-
coumarins in that DT-diaphorase is inhibited, although there is indirect 
elevation of epoxide concentration.  In-vitro however there is no effect of 
salicylate on vitamin K epoxide reductase.  Ticrynafen is a nonsulfonamide 
diuretic, uricosuric and antihypertensive agent, which causes 
hypoprothrombinaemia in humans; the mechanism of action is similar to that 
of salicylate in that it markedly inhibits DT-diaphorase and tends to increase 
hepatic epoxide: quinone ratios.  Toxic doses of butylated hydroxytoluene 
(BHT) have been reported to cause haemorrhagic death in rats; BHT is 
thought to prevent the uptake of vitamin K by the liver and intestinal cells 
(Olson, 1984).   
 
Vitamins A and E are known vitamin K antagonists, hypervitaminosis A in the 
rat lead to haemorrhages and hypoprothrombinaemia, which can be 
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prevented by administration of vitamin K.  Similarly a patient undergoing 
warfarin (5 mg per day) and megavitamin E therapy (1200 I.U. per day) 
showed bleeding tendencies and prolonged prothrombin times, which were 
alleviated upon discontinuation of megavitamin E therapy.  Smaller doses of 
vitamin E (42 I.U per day for 30 days) do not potentiate the effects of warfarin 
(Olson, 1984).  Sterilisation of the bowel with sulpha drugs, neomycin and 
other broad-spectrum antibiotics may induce a haemorrhagic syndrome due 
to the reduction in vitamin K supply from gastrointestinal flora (Olson, 1984).  
In addition, cephalosporin antibiotics inhibit DT-diaphorase, which reduces 
the amount of quinone to hydroquinone conversion in the vitamin K 
recycling/salvage pathway, thus further reducing the supply of active vitamin 
K. 
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1.5 Oral anticoagulation and its monitoring 
 
1.5.1 Warfarin  
 
Warfarin sodium anticoagulation induces an anticoagulative state by causing 
a reduction in the vitamin K dependent modification of certain coagulation 
factors, such as prothrombin, factor X and factor VII, thereby lowering the 
potential for blood coagulation.  The precise monitoring of patients on oral 
anticoagulation therapy (OACT) is of critical importance in maintaining an 
effective course of treatment, predominantly due to the narrow therapeutic 
range of the drugs used.  Current monitoring techniques employ the 
functional, prothrombin time (PT) and the activated partial thromboplastin time 
(aPTT) tests, which measure the clotting time of blood/plasma on addition of 
thromboplastin, phospholipid and calcium.  The warfarin dose can be titrated 
by maintaining the patients INR between 2 and 3 with a target of 2.5, or 
between 2 and 3.5 with a target of 2.7 or above (Pengo et al., 2001). 
 
Developments of the clotting time monitoring system and coagulation 
management since the 1980s, such as the introduction of the international 
normalised ratio (INR) and the international standard index (ISI), and the 
implementation of dedicated coagulation monitoring clinics have reduced 
some of the problems associated with early coagulation monitoring.  Due to 
the multi-conglomerate manufacture of thromboplastins and reagents for the 
functional tests, the World Health Organisation introduced the INR/ISI system 
in 1983, with the aim to standardise and improve the oral anticoagulation 
therapy (OACT) risk/benefit profile.  Each thromboplastin produced was given 
an ISI relative to the reference thromboplastin rTF/95; the prothrombin time 
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index (PTI) could then be converted to the INR (Kahn et al., 1998).  The INR 
is the ratio between the patients PT and the mean laboratory normal PT, 
raised to the power of the international standard index (ISI) of the 
thromboplastin used.  This standardisation of PT thromboplastins relative to 
the reference material attempted to limit the effects of their varying 
sensitivities, especially apparent in orally anticoagulated patients.  Even with 
the strictest monitoring regimen there is still a 20 % incidence of thrombotic or 
haemorrhagic complications with patients on long-term OACT.  Low dose 
anticoagulation treatments are still not controlled well using the INR system 
suggesting that the INR/ISI system is far from perfect.   
 
1.5.2 Thromboplastins  
 
Thromboplastins used in clotting time tests are produced from the brain tissue 
of humans and animals, and in the 1980s the use of human brain and plasma 
derived anticoagulation reagents declined. This was due to elevated fears 
over the increase in the incidence of Creutzfeld Jacob Disease (CJD) and the 
fact that the HIV antibody was regularly found in some of the plasma derived 
reagents (O’Donnell et al., 1987).  Efforts were made to produce reagents 
without viral contaminants and to explore new methods of anticoagulation 
monitoring.  Prothrombin is the most important factor in the coagulation 
pathway, it is the largest protein in the cascade at 70 KDa and it has the 
longest blood/plasma half-life.  Thrombin generation is determined by the 
concentration of prothrombin in the plasma, therefore addition of factors VII, 
IX or X to factor deficient plasma has no influence on thrombin generation (Xi 
et al., 1989).  With these facts in mind it is not unreasonable to consider that 
prothrombin concentration or activity may be a good indicator of coagulative 
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state.  Therefore, in the search for new approaches to anticoagulation control, 
it might be wise to develop a method whereby the concentration/activity of 
prothrombin in the blood/plasma could be quantified. 
 
1.5.3 Alternative functional tests 
 
A functional test that uses the native biochemical transformation of normal 
prothrombin to thrombin, the XaPC method, may be used to monitor the 
coagulative state of blood/plasma samples.  This method uses already 
present factors Xa and V together with phospholipid and calcium to convert 
normal prothrombin into thrombin, the active serine protease.  Thrombin can 
subsequently be quantified by adding a chromogenic substrate such as 
S2238, which is catalytically degraded by thrombin (Widdershoven et al., 
1987).  A reduction in the concentration of native, fully carboxylated and 
calcium bound prothrombin, caused by warfarin therapy could be detected 
using the XaPC method.   
 
A similar test based on the principal of native prothrombin to thrombin 
conversion, is the Carcinactivase-1 (CA-1) method.  Carcinactivase was 
isolated from the snake venom of Echis carinatus leucogaster because of its 
ability to specifically cleave the native calcium bound conformer of 
prothrombin to thrombin.  The amount of p-nitroaniline liberated by the 
cleavage of the amino acid and nitroaniline-derived substrate Boc-Val-Pro-
Arg-pNA by Carcinactivase, is directly proportional to the concentration of 
thrombin, and thus native prothrombin present in the sample (Iwahashi et al., 
2001).   
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The functional tests, i.e. those that do not measure the factor in question 
(prothrombin), but an endpoint of a biochemical pathway, such as the clot or 
thrombin itself, are not ideal for anticoagulation control.  This is due to a loss 
in accuracy due to the relatively high number of variables in each test; 
therefore there are more points at which errors may occur than in a single 
step/factor direct assay.  The ideal situation would present a specific and 
accurate test for the direct quantification of the factor in question i.e. 
prothrombin and also the detection of those patients with the hypercoagulable 
state. 
 
1.5.4 The native prothrombin antigen 
 
The use of the native prothrombin antigen in coagulation monitoring has 
achieved much more efficient control and prediction of the hypercoagulable 
state, with up to an 85 % reduction in complications compared to prothrombin 
time (Furie et al., 1990).  It had already been demonstrated that the 
prothrombin antigen correlated closely with prothrombin coagulant activity 
both with normal and warfarin anticoagulated plasma (Blanchard et al., 1983), 
therefore potentially useful in the control of OACT.  Furie and colleagues in 
1984 developed a radioimmunoassay specific for the native prothrombin 
antigen, using monospecific polyclonal antibodies (Furie et al., 1984).  The 
assay performed much better than the established PT in randomised clinical 
trials, with greater accuracy in the prediction of bleeding and thrombotic 
complications.  This study also demonstrated that abnormal prothrombin 
concentration is less closely correlated to complications arising from OACT 
than native prothrombin (Furie et al., 1984), possibly due to the generation of 
heterogeneous abnormal prothrombin species.   
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The radioimmunoassay detected native prothrombin levels in non-
anticoagulated patients of 108 ±19 µgml-1, compared to the therapeutic range 
of 12-24 µgml-1 in anticoagulated patients (Furie et al., 1990).  Patients 
monitored with the NPA assay developed complications with a rate of 1.5 % 
per patient year, which contrasted greatly with the complication rate of 9.5 % 
per patient year, using the PT assay (Furie et al., 1990).  The NPA assay 
monitored patients on OACT with 85 % less complications than the 
established PT assay (Furie et al., 1990).  Analysis of complications 
associated with INR monitored OACT showed that 30 % occurred in patients 
with INRs in the therapeutic range of 1.5-2.0, 25 % of the complications 
associated with low dose OACT were also within the therapeutic range of 1.5-
1.8 (Furie et al., 1990, Kornberg et al., 1993). 
 
Fatal Major Major/Minor Reference 
    
1.6 
(Vascular death + 
Fatal bleed) 
1.8 
(Major bleed + 
Non fatal 
Ischeamic stroke) 
4.4 
(Minor bleed) 
Pengo et al., 
2001 
 
0.8 4.9 15 Landefeld et 
al.,1993 
0-4.8 2.4-8.1 - Levine et al., 
1992  
 
 
Table 1.5.1 shows some haemorrhagic complication rates associated with oral 
anticoagulation therapy as monitored using standard prothrombin time and international 
normalised ratios.  
Due to methodological limitations, accurate data on true OACT complication 
rates are lacking.  Studies have been undertaken however, and figures for 
OACT complication rates have been calculated, some are shown in Table 
1.5.1. 
49 
Chapter 1. Review of the Literature   Adrian Sylvester 
In 1993, Abraham Kornberg and his group compared the NPA with the PT for 
OACT monitoring, using a similar assay to that developed by Furie and 
colleagues in 1984 (Kornberg et al., 1993).  The radioimmunoassay (Furie et 
al., 1990) was replaced with an enzyme-linked immunoassay (ELISA) specific 
for native Ca2+ prothrombin (Kornberg et al., 1993) and used in the 
comparison of the NPA with PT for OACT monitoring.  The mean normal 
prothrombin concentration was estimated using the ELISA to be 164 ±32 
µgml-1 (Kornberg et al., 1993), which was in contrast to the much lower 
concentration of 108 ±19 µgml-1, measured by radio-immunoassay (Furie et 
al., 1990).  The therapeutic range (TR) of the NPA concentration during 
OACT measured by ELISA (50-80 µgml-1) was much higher than that 
measured by radioimmunoassay (Kornberg et al., 1993).  During surgery 
however, it was recommended that the NPA concentration should be raised 
above the TR, due to 3 patients in the study suffering post surgical 
haemorrhages, with mean NPA concentrations of 66 µgml-1 (Kornberg et al., 
1993). 
 
As the antibodies are similar in both assays, the higher therapeutic range for 
NPA measured by ELISA compared to RIA may be explained by the detection 
method.  The signal intensity in the RIA is time dependent (i.e. exposure of 
photographic film to radioactivity), therefore an increase in the exposure time 
may potentially lead to an increase in the TR.  The NPA/ELISA measures a 
parameter more closely related to thrombotic predisposition than the PT 
(Kornberg et al., 1993).  Prevention of thrombosis requires a reduction in the 
concentrations of Factor X and II, which both have relatively long half-lives.  A 
prolonged PT however, may be caused by the acute reduction of Factor VII 
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(short half-life), rather than the more effective, chronic reduction of factor II or 
X (Kornberg et al., 1993).  Low dose (LD) OACT is monitored relatively 
inefficiently with the PT, this is due to the relatively small TR of 1 to 1.25 that 
has to be maintained during this course of therapy.  As the INR increases 
from 0.8-1.5 the NPA concentration decreases fourfold from 200-50 µgml-1 
(Kornberg et al., 1993), therefore increasing the potential sensitivity of the 
NPA assay for LD-OACT.  Variations in the NPA concentration over the whole 
TR and beyond for OACT are detected extremely well by the NPA/ELISA, 
therefore making it a very sensitive alternative to the more established PT.  
All of the above-mentioned benefits suggest that the NPA assay would confer 
much safer monitoring and control over OACT than current PT/INR methods, 
including LD-OACT. 
 
1.5.5 Laboratory techniques for coagulation monitoring 
 
Morawitz in 1905 postulated that fibrinogen, prothrombin and calcium ions are 
required to form a blood clot; this theory was later found incomplete as more 
coagulation factors were discovered (Morawitz, 1905).  In 1913 the whole 
blood clotting time test was developed by Lee and White, this was to form the 
original backbone of the clotting investigation, however it is only used 
nowadays as a modified activated clotting time test (ACT) (Lee and White, 
1913).  Based on Morawitz’s theory, Armand Quick in 1935 developed the 
Quick’s time assay, now called the prothrombin time (PT), as prothrombin 
was the only known plasmatic factor to act on fibrinogen at the time (Quick et 
al., 1935).  Quick also noticed that the prolonged clotting times of aged 
plasma reverted back to normal when fresh plasma was added, this lead to 
the discovery of the labile factor, later named, using standard roman numeral 
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nomenclature, factor V.  Factor VII was discovered by Alexander et al. soon 
after, which was then followed by the discovery of factor X (Alexander et al., 
1951).  In 1953 Biggs and Douglas developed the thromboplastin generation 
test (TGT), which allowed the diagnosis of haemophilia types A, B and 
eventually C.  The TGT detected deficiencies in factors VIII, IX and XI 
respectively; TGT is not now used, as it is too technically complex to perform 
(Biggs and Douglas, 1953).  The Brinkhous group in 1953 developed the 
activated partial thromboplastin test (aPTT), which is one of the tests used to 
date (Langdell et al., 1953).  The use of plasma from patients known to have 
single coagulation factor defects in the aPTT allowed the simple diagnosis of 
the major haemophilic diseases and other major coagulation deficiencies.  
The discovery of the aPTT lead to the identification of other clotting factors in 
the contact phase or intrinsic coagulation pathway, such as prekallikrein and 
high molecular weight kininogen (HMWK) (Khan et al., 1998). 
 
1 1905 Morawitz’s theory: fibrinogen, prothrombin and calcium in blood lead to clot 
formation 
2 1935 Quick et al introduced Prothrombin Time 
3 1962 International committee in haemostasis and thrombosis revises clotting 
factor nomenclature 
4 1953 Biggs et al develop TGT illustrating the intrinsic system 
5 1953 Brinkhaus’s group describes aPTT, which at the time was not as popular as 
TGT 
6 1964 Macfarlane et al and Ratnoff and Davie suggest enzyme cascade 
hypothesis 
7 1995 Rappaport discovers that tissue factor can directly activate factor VII  
 
Figure 1.5.3 summarises the clinical implications for using the prothrombin time (PT) and the 
activated partial thromboplastin time (aPTT) (Khan et. al., 1998) 
Table 1.5.2 represents a summary of the development of oral anticoagulation therapy and it’s monitoring 
(Khan et. al., 1998). 
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1.5.6 The activated clotting time (ACT)  
 
The ACT is a test that measures the clotting time of non-anticoagulated whole 
blood; it is very useful in situations requiring a rapid turn around time for the 
result, situations where continuous monitoring and adjustments of heparin 
dosage are necessary.  ACT is used in cardiac catheterisation laboratories 
where the clotting time needs to be kept between 300-500 seconds and in 
monitoring heparin efficacy during open-heart surgery where the clotting time 
is kept within 400-800 seconds also in haemodialysis. 
 
Prothrombin time (PT) and aPTT are the most commonly used tests in 
coagulation therapy monitoring and for the detection of coagulation defects 
today.  They are both considered as being functional tests as they measure 
enzymatic activities that lead to clot formation.  The modern PT and aPTT 
tests are processed using automated technology in the laboratory, allowing 
approximately 10-15 minutes per sample (automated technology allows 
multiple and simultaneous sample processing).   
 
1.5.7 The activated partial thromboplastin time (aPTT)  
 
The aPTT is a test that determines the clotting time of citrated plasma 
(plasma with trisodium citrate), when activated by adding a partial 
thromboplastin or phospholipid reagent and calcium chloride.  The test is 
insensitive to factor VII due to the lack of tissue factor in the reagents.  This 
makes the test sensitive therefore to the factors in the intrinsic and common 
coagulation pathways and useful in the detection of deficiencies in factors 
VIII, IX, XI and XII and severe deficiencies in factor V, X, II or fibrinogen.  
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Modern determination of the aPTT involves the use of automated clot 
detection methods such as a fibrometer or photo-optical equipment, which 
measures the decrease in light transmission through a sample as the clot 
forms.  Many different reagent types can vary in the type of activator, the 
platelet/phospholipid mixture, the calcium chloride concentration used and the 
times of incubation of plasma with activator phospholipid mixture.  The variety 
of reagents available on the market may lead to inter-laboratory discrepancies 
in clotting time results, due to varying sensitivities of the reagents to heparin 
and detection of coagulation factor deficiencies.  This problem may be 
overcome by the implementation of a standardisation of thromboplastin 
reagents against an international reference material, currently however such 
a standard is not available for use with the aPTT. 
 
The aPTT is used widely to monitor the effects of heparin, certain 
considerations need to be taken into account however when processing such 
test results.  The time of sample collection in relation to heparin administration 
is critical, as unfractionated heparin has a relatively short half-life of 11/2 hrs.  
Using aPTT therefore, to monitor heparin therapy requires swift determination 
due to the rapid diminishing of heparins effect with time.  Other factors that 
may give erroneous results include the variability of the aPTT reagents with 
the type of heparin (unfractionated vs. low molecular weight heparins), the 
mode of administration of heparin (intravenous vs. subcutaneous) and the clot 
detection methodology used.  The aPTT may however be prolonged with out 
any clinical defect, coagulation inhibitor or heparin.  In a prospective study of 
100 prolonged aPTT cases referred for consultation, only 50 % showed any 
coagulation factor deficiency.  Of the remaining 50 % the degree of 
abnormality did not correlate sufficiently with the haemostatic defect; 36 % 
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were of no clinical significance and 14 % were artefactual (Khan et al., 1998).  
The clinical significance of a shorter aPTT or PT is however currently not fully 
understood. 
 aPTT test 
1 Heparin Monitoring 
2 Work-up of patients with a history suggestive of hereditary or acquired coagulation 
defects 
3 Pre-operative testing with a positive bleeding history 
4 Haemorrhage after surgery or invasive procedure with no clear aetiology 
5 Suspicion of coagulation inhibitors especially lupus inhibitor and factor VIII inhibitor 
 PT test 
1 Warfarin monitoring 
2 Pre-operative testing with a positive bleeding history 
3 Haemorrhage after surgery or invasive procedure with no clear aetiology 
4 Patients with liver disease  
 
Figure 1.5.3 summarises the clinical implications for using the prothrombin time (PT) and the 
activated partial thromboplastin time (aPTT) (Khan et. al., 1998)  
1.5.8 The prothrombin time (PT) 
 
The PT is another coagulation time determining test that is sensitive to the 
extrinsic and common coagulation pathways, i.e. to factor VII and factor II, V, 
X and abnormally low fibrinogen.  As indicated in Table 1.5.3 the PT is used 
for monitoring patients on warfarin therapy or long-term coagulation inhibition, 
it is not used for the monitoring of heparin therapy due to a negative 
correlation between the results and the degree of heparinisation.  As with 
aPTT, there are many thromboplastic reagents on the market specific for use 
with the PT.  In contrast with the aPTT, PT reagents have all been 
standardised against an international reference thromboplastin (rTF/95), 
which has an international standard index (ISI).  Due to the multi-
conglomerate manufacture of widely varying sensitivity thromboplastins, the 
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INR/ISI system, introduced by the World Health Organisation (WHO) in 1983, 
allowed the standardisation and improvement of the oral anticoagulation 
therapy risk/benefit profile (WHO, 1983).  Therefore, all PT results are 
expressed as an international normalised ratio (INR), which is the PT ratio 
that would be observed if the thromboplastin used was the international 
reference material.  This standardisation of thromboplastins relative to a 
reference material was necessary due to the varying sensitivities of reagents, 
especially in orally anticoagulated patients.  In the laboratory situation 
computerised automated equipment allows the rapid online calculation of the 
INR from the recorded PT (Khan et al., 1998).  
 
Indications  Prophylaxis and/or treatment of venous thrombosis and its 
extension, and pulmonary embolism 
  Prophylaxis and/or treatment of thromboembolic complications 
associated with atrial fibrillation and/or cardiac valve 
replacement 
  Reducing the risk of death, recurrent myocardial infarction, and 
thromboembolic events such as stroke or systemic embolization 
after myocardial infarction  
 
Table 1.5.4 illustrates the indications for the initiation of warfarin therapy (Information taken from 
Erban, 1999). 
Contra-
indications 
 Pregnancy Warfarin crosses the placenta and can cause fatal 
haemorrhage or embryopathy 
  Active 
bleeding or 
haemorrhagic 
tendencies 
Especially GI or GU tracts, CNS haemorrhage, 
aortic or cerebral aneurysms, pericarditis or 
pericardial effusion and bacterial endocarditis 
  Recent or 
contemplated 
surgery 
Especially surgery of CNS, eye, or major trauma 
  Other invasive 
procedures 
Especially lumbar puncture or other procedures 
with potential for uncontrollable bleeding  
  Prior sensitivity 
to warfarin 
E.g. warfarin skin necrosis (Homozygous) 
 Table 1.5.5 illustrates the contraindications for the initiation of warfarin therapy; warfarin therapy is 
contraindicated whenever the potential risks outweigh the potential benefits (Information taken 
from Erban, 1999). 
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Prior to the initiation of warfarin therapy, a risk-benefit assessment profile 
must be performed.  The indications and the existing or potential 
contraindications should all be taken into consideration, together with the 
patient’s concerns and understanding of the treatment and its potential 
adverse reactions.  Regardless of the final decision, the rationale should be 
clearly communicated to the patient and documented in the medical record 
(Erban, 1999).  The measurement of a patient’s PT is achieved by adding a 
specific amount of thromboplastin (to initiate clot formation) to a sample of a 
patient’s plasma, which was obtained from the centrifugation of a sample of 
whole blood.  The time taken for the thromboplastin to form the clot, usually 
11-15 seconds in normally coagulated individuals, is the PT.   
 
1.5.9 The international normalised ratio (INR) 
 
This value is then used in the INR equation as follows:
 
I
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 INR= (Patients PT (sec) ÷ laboratory mean normal PT (sec)) ISalue of 1.0, assuming the ISI is also 1.0, indicates that the individual 
ly coagulated; INRs of 2 and 3 indicate clotting times twice and three 
t of the normal.  For patients on anticoagulation therapy the INR is 
d within the range 2-3, any lower and the effects of the warfarin are 
 any higher and bleeding complications can occur.  Using the PT 
ithout the ISI exponential can lead to very varied results.  
57 
Chapter 1. Review of the Literature   Adrian Sylvester 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.1 shows the dependence of prothrombin time on prothrombin concentration, with the 
threshold concentration illustrated at 50 % of the normal.  Normal human plasma was mixed with 
plasma from a warfarin treated patient (25 % of normal prothrombin) in varying amounts to 
produce a series of plasma samples containing 25-100 % of the normal concentration of 
prothrombin.  Standard clinical prothrombin times were then determined (adapted from Suttie, 
1992). 
 
 
The insensitivity of the prothrombin time test has been well documented and 
is illustrated in Figure 1.5.1.  There is a threshold prothrombin concentration, 
above which the prothrombin time stays constant; therefore, the prothrombin 
concentration has to be reduced to 55 % before the prothrombin time starts to 
be clinically significant.  As can be seen from Figure 1.5.1 a plasma sample 
with only 50 % prothrombin (compared to the human normal plasma 
concentration of 1.1-2.3 mg ml-1) still has a normal prothrombin time.   
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Much more sensitive chromogenic and immunologic vitamin K dependent 
protein assays have been developed for the quantification of certain individual 
factors.  Clot based assays are functional modifications of the aPTT and the 
PT therefore they can be used to detect both quantitative and qualitative 
coagulation factor defects.  To qualitatively detect a factor defect, patients 
plasma is mixed with commercially available plasma deficient in a single 
factor; if the defects do not match then there will be a reciprocal correction of 
the prolonged clotting time.  In the quantitative test, the plasmas are mixed 
together in equal known volumes and the clotting time is compared to that of 
a serially diluted normal control, the percentage factor defect may be 
estimated by comparing the clotting times.  Tests used to detect factors VII, II, 
X and V are PT based assays and aPTT based assays are used to detect 
factors VIII, IX, XI and XII. 
 
1.5.10 Developments in oral anticoagulation therapy 
 
Three major developments have decreased the risks of oral anticoagulation 
therapy over the last few years.  These include the introduction of the ISI/INR 
standard, the definition of the indications of anticoagulation and improvement 
of its management by the development of anticoagulation management 
services.  However it still has a high risk/benefit profile due to three further 
factors: warfarin has a narrow therapeutic index, clinical outcomes are 
influenced by patient-specific characteristics, and dose adjustment and 
patient communication are often mismanaged.  Excessive or inadequate 
anticoagulation is proven to lead to serious consequences in the warfarinised 
patient. Fluctuations in the systemic warfarin concentration or changes (due 
to other factors) in the pharmacodynamic response to warfarin, in spite of the 
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stable warfarin concentration can lead to haemorrhagic or thrombotic 
complications.   
 
Hylek et al in 1994 demonstrated a 5-fold increase in intracranial 
haemorrhage as the INR exceeded 4.5, compared to a 17-fold increase in 
stroke as the INR falls below 2.0 and approaches 1.0 (Hylek et al., 1994).  
Cannegieter’s group in 1995 discovered a broader INR therapeutic range of 
2.5-4.9 in over 1608 patients with mechanical heart valve prostheses; 
increasing incidences of haemorrhage or thrombosis were observed above 
and below the range respectively (Cannegieter et al., 1995).  Patient specific 
factors may also be responsible for thrombotic and haemorrhagic events 
during anticoagulation.  Positive correlations exist between risk of major 
haemorrhage and morbidities such as heart, liver or kidney dysfunction, 
cancer or severe anaemia, stroke and gastrointestinal bleed history, atrial 
fibrillation or combinations of three or more.   
 
It has been observed that anticoagulation patients cared for in specialised 
anticoagulation management services (AMS/C) or anticoagulation clinics fare 
between 50-75 % better than patients under routine medical care (RMC).  
The AMS/C model of care provides efficient dosing management and 
determination of the therapies appropriateness; it also serves to communicate 
with other providers of a patients health care whilst providing ongoing patient 
evaluation and education.  Savings of $800-1000 per patient, per year of 
therapy have been made in the USA, due to a decrease in the incidence of 
anticoagulation related complications by the implementation of AMS health 
care models (Ansell, 1999).  The ongoing development of AMS care models 
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will lead to the reduction of adverse coagulation events, a reduction in the use 
of hospital resources and a saving of vital health care funds.   
 
Many reliable and accurate yet considerably more expensive point-of-care 
devices have been developed for the measurement of aPTT and PT.  Whole 
blood samples may be taken up into the device by capillarity, as 
anticoagulation of samples in heparinised tubes is unnecessary prior to 
testing.  This allows the use of ‘fingerstick’ sampling of blood (pinprick 
sampling), which is much more comfortable for the patient and allows for less 
complicated processing.  Described below are some of the major point-of-
care devices available on the market.  The Ciba Corning 512 system (Ciba 
Corning Diagnostics Corp., Medfield, MA) uses a drop of whole blood that is 
placed on a disposable plastic cartridge.  Capillary action draws the blood into 
a reaction chamber and clot detection is by a laser optical system.  The 
Hemochron 801 system (International Technidyne Corp., Edison, NJ) uses a 
small magnet containing glass tube system in which the whole blood sample 
is mixed with the reagents.  The tubes are rotated and heated until a firm clot 
is formed, displacing the magnet within the tube and triggering a proximity 
switch, which stops the time measurement.  The bedside coagulation 
monitors listed below are similar in theory to the standard laboratory tests, 
however they use different detection methodology, reagents, activators and 
sample volumes (Reich et al., 1993).  The bedside monitors were calibrated 
through their clinical comparison with standard laboratory tests before they 
were more widely used preoperatively, where efficient and accurate 
coagulation monitoring is necessary.  
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Four alternative tests that may be utilised in the monitoring of a patients 
warfarin therapeutic range are described in further detail below.  The tests 
described below provide quantitative and qualitative data on the amount of 
abnormal prothrombin (also termed PIVKA II (protein induced by vitamin K 
absence II) des-γ-carboxyprothrombin, isoprothrombin, paraprothrombin, 
dicoumarol-induced prothrombin, atypical-prothrombin and 
acarboxyprothrombin (Olson, 1984) in a blood sample.  Measurements of 
abnormal prothrombin may involve calculation of the total prothrombin 
combined with subtraction of the functional prothrombin; this will give an 
indirect measurement of the abnormal prothrombin.  To measure total 
prothrombin the snake venom from Echis carinatus is used to convert 
prothrombin, including inactive prothrombin, to thrombin.  The resulting 
thrombin proteolytically cleaves the p-nitroaniline derived chromogenic 
substrate S2238, the amount of p-nitroaniline liberated correlates to the 
amount of thrombin present.  Functional prothrombin is measured using the 
XaPC method, where factor V, already present in the plasma sample, 
converts functional prothrombin into thrombin using already present factor Xa, 
phospholipid and calcium.  The name of the test derives from the latter three 
substrates mentioned.  The active thrombin is then chromogenically 
measured again using Kabi Vitrum or substrate S2238.  The abnormal 
prothrombin measurement is then calculated as the ratio XaPC/ECar; a ratio 
of ≤0.86 conclusively establishes the presence of abnormal prothrombin, 
whether it is due to vitamin K deficiency or problems with the liver 
(Widdershoven et al., 1987).    
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The XaPC method may also be used to calculate total prothrombin.  Normal 
plasma has been proven to be abnormal prothrombin free, therefore pooled 
normal plasma maybe used in place of the total prothrombin measurement, 
as all the prothrombin present will theoretically be active.  So if the 
prothrombin activity in a patients’ plasma is ≤86 % of that of the pooled 
normal plasma or that calculated using the ECar method then further tests 
should be implemented to determine the cause of the low prothrombin activity 
(Widdershoven et al., 1987).  The relative accuracy of the XaPC ratio or 
Xa/ECar ratio methods of abnormal prothrombin detection may be calculated 
as 0.95 x 0.95 = 0.90 = 90 %.  This implies that if the true ratio of Xa/ECar is 
1, then due to the precision of the method alone a variability of 0.90 – 1.10 
would be produced.  Therefore, abnormal prothrombin concentrations of less 
than 10% of the total prothrombin may escape detection using this method 
(Widdershoven et al., 1987; Von Kries et al., 1992).  The question now arises; 
are such abnormal prothrombin concentrations cause for concern and 
indicative of future bleeding complications during anticoagulative therapy? 
 
The second method for assaying des-ϒ-carboxyprothrombin is by removing 
active carboxylated prothrombin from the plasma sample and measuring the 
remaining prothrombin.  Carboxylated prothrombin is adsorbed onto barium 
carbonate (Ba2CO3), sulphate (BaSO4) or aluminium hydroxide gel columns.  
The remaining under carboxylated prothrombin, which is not always 
completely de-carboxylated (Olson 1984), may be assayed using the ECar or 
XaPC methods as described above, quantitative/qualitative immunochemical 
methods may also be implemented (Widdershoven et al., 1987). 
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A method using electrophoresis and subsequent immunofixation may be used 
to provide semi-quantitative measurements of abnormal prothrombin in 
serum.  After electrophoresis of plasma on a Cellogel® membrane, a cellulose 
strip coated with rabbit antiserum to human prothrombin may be placed over 
the gel and left overnight.  Immunofixative strips can then be placed on the 
gel with goat antiserum to rabbit immunoglobulin, which intensifies the 
primary immunofixative reaction.  After thorough washing in saline solutions 
for two days and a staining/destaining procedure of Amido Black 
B10/methanol: acetic acid: water (5:1:4 by vol.) together with clearing and 
drying procedure, presence of abnormal prothrombin is indicated by two 
bands on the gel.  This procedure was described above as being only semi-
quantitative; the amount of immunoprecipitate is not only sensitive to the 
amounts of abnormal prothrombin and prothrombin but also to the quality of 
the antisera used.  The procedure as described by Widdershoven et al., 1987 
also had a three and a half day time scale, which is unsuitable for use as a 
quantitative/qualitative diagnostic test for abnormal prothrombin. 
 
1.5.11 Snake venom proteins 
 
Snake venom activator proteins are classified into four different groups 
according to their structures and functions.  Group A consists of the 
metalloprotease-type activators, whose action is not reliant on any other 
coagulation factors, they are also widely distributed in many genera of viper 
e.g. Echis and Bothrops species.  Group 1 enzymes are also considered to 
be the most toxic, due to their resistance to serpins (natural coagulation 
inhibitors) such as Antithrombin-III.  Group B enzymes resemble those of 
group A in that they are also metalloproteases, however they do require 
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calcium ions for their activity.  Group C enzymes physiologically resemble 
factor Xa, in that they contain Gla residues and require factor Va, 
phospholipids and calcium for their activation.  Group D enzymes are hybrids, 
in that they contain a catalytic subunit similar to that in factor Xa, and a 
regulatory subunit resembling that from factor Va, they also require 
phospholipids and calcium for their activation.   
 
Group B enzymes possess a metalloprotease catalytic subunit (similar to that 
of Ecarin A) and a regulatory subunit (similar to that of the Habu snake venom 
protein IX/X-bp), which confers the Ca2+ and Gla-domain binding specificity of 
these proteins.  Snake venom proteins such as the disintegrins and C-type 
lectins do not have any enzymatic activity, however they still have 
haemostatic properties.  The disintegrins are low molecular weight 
polypeptides present within snake venom, they posess RGD sequence motifs 
that allow them to specifically bind and interact with endogenous integrins (i.e. 
GPIIb-IIIa), therefore occupying platelets and preventing aggregation 
(Kamiguti et. al., 1996).  C-type lectins are approximately 30 kDa in size and 
comprise of a pair of homologous polypeptides also containing a 
characteristic carbohydrate recognition domain.  The lectins are known to 
interact with proteases; therefore it is likely that they play a major role in the 
targetting of the protease to key proteins with critical haemostatic function 
(Braud et. al., 2000).  
 
Studies of the metalloprotease group of venom proteins have shown that they 
play an important part in the degradation of all the major protein components 
of the extracellular matrix (ECM) (Baramova et. al., 1989; Baramova et. al., 
1990).  Haemorrhage caused by metalloprotease venom proteins is effective 
65 
Chapter 1. Review of the Literature   Adrian Sylvester 
within minutes, however the degradation of the ECM proteins takes much 
longer, suggesting that the mechanism of haemorrhagic action is quite 
complex.  Many snake venom proteins have haemostatic related properties, 
which make them interesting for use in studies of haemostasis and blood 
coagulation control. 
Class Cofactor 
Requirement 
Examples Former 
Class 
 
Group A None Ecarin Group 1A 
Group B Ca2+ Carcinactivase and Multactivase Group 1B 
Group C Ca2+ + phospholipids Oscutarin, Pseutarin Group II 
Group D Ca2+, phospholipids 
+ factor Va 
Trocarin, Notecarin, Hopsarin. Group III  
 
Table 1.5.6 Shows the classification of the snake venom prothrombin activator proteins (Kini 
et. al., 2001). 
 
 
Various venom proteins have been utilised in the development of diagnostic 
tools for diseases and problems of haemostasis as described in Table 1.5.7.   
Diagnostic Test Biological function 
Test  Diagnostic Test Protein Function 
    
Reptilase™ Titration of fibrinogen-fibrin 
reaction 
Batroxobin Release of 
fibrinopeptide A from 
fibrinogen 
Ecarin Detection of abnormal 
prothrombin species 
Ecarin Activation of 
Prothrombin 
Stypven® Measurement of FX level RVV-X Activation of Factor X 
Protac®   Titration of protein C and S ACC-C Activation of protein S
Botrocetin Diagnostic of vWD and 
Bernard-Soulier syndrome 
Botrocetin Agglutination of 
platelets in the 
presence of vWF  
 
 
Table 1.5.7 lists some of the diagnostic tests based on the incorporation of snake venom 
proteins that influence haemostasis (RVV, Russell’s Viper Venom; ACC, A.c.Contortrix) 
(adapted from Braud et. al., 2000).  
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Snake venom proteins have various diagnostic uses, due to the direct 
influence they have on haemostasis, this has been reviewed in Marsh, 2001.  
Prothrombin is an interesting target for characterisation and diagnostic 
determination with regard to snake venoms and the fact prothrombin is one of 
the main controlling factors of the human coagulation cascade.  To develop 
an assay for prothrombin, that could distinguish between normal and native 
prothrombin species, would assist in the diagnostic evaluation of abnormal 
prothrombin species, and potentially more important allow the rapid 
monitoring of oral anticoagulation therapy.  Commercially available snake 
venom prothrombin activator proteins exist such as Ecarin from the saw 
scaled viper (Echis carinatus), textarin from the Australian brown snake 
(Pseudonaja textilis) and an enzyme from the taipan (Oxyuranus s. 
scutellatus) (Marsh, 2001).  These venom proteins however are not so useful 
for the monitoring of wafarin anticoagulation, because they activate all 
species of prothrombin including the decarboxylated forms present in warfarin 
treated patients. 
 
The group B snake venom prothrombin activators carinactivase-1 from Eachis 
carinatus leucogaster (Yamada et. al., 1996) and multiactivase from Echis 
multisquamatus (Yamada and Morita, 1997) are potentially very useful in the 
monitoring of warfarin-oral anticoagulation therapy.  Their calcium dependent 
prothrombin activation properties allow the activation of fully carboxylated 
native prothrombin, even in a sample also containing partially or non-
carboxylated abnormal prothrombin species, i.e. warfarin treated blood 
samples (Yamada and Morita, 1999).  The gla-domain binding region of 
carinactivase-1 displays calcium dependent properties, which also shows 
substantial homogeneity to the snake venom protein IX/X-bp (Yamada et. al., 
67 
Chapter 1. Review of the Literature   Adrian Sylvester 
1996).  The IX/X-bp protein from the habu snake Trimeresurus flavoviridis has 
strong anticoagulant activity that effects the neutralisation of factors IX and X, 
by binding to their calcium complexed gla domains (Sekiya et. al., 1995).   
 
The saw scaled viper protein carinactivase-1 (CA-1) was incorporated into a 
native prothrombin assay designated the CA-1 method, for the fast and 
specific monitoring of native prothrombin levels in blood samples of warfarin 
treated patients.  Thrombin produced by the calcium dependent activation of 
native prothrombin by carinactivase-1, cleaved the thrombin specific 
chromogenic substrate t-butoxy-Val-Pro-Arg-p-nitroanilide.  The velocity of p-
nitroaniline production determined the level of native prothrombin in the 
sample.  Prothrombin levels determined by the CA-1 method correlated 
strongly with levels determined by the standard thrombotest and prothrombin 
time (Yamada and Morita, 1999; Iwahashi et. al., 2001).  The CA-1 therefore 
provides a novel method in which native prothrombin levels can be monitored 
in warfarin treated patients. 
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1.6 Immunoassay methods  
 
Immunoassay methods may be considered as an interesting approach to the 
evaluation of the functional properties of specific vitamin K dependent blood 
coagulation proteins in complex biological fluids such as blood, plasma and 
serum (Blanchard et al., 1983).  Ganrot and Nilehn demonstrated in 1968 the 
presence of a protein fraction in the plasma of warfarin treated human 
patients that reacted to antibodies against human prothrombin, but showed 
little or no biological activity in the standard assay using factor X and 
thromboplastin (Olson, 1984).  Antibodies towards abnormal prothrombin 
species have been created (Blanchard et. al., 1979; Owens et. al., 1984; 
Motohara et. al., 1985; Furie et. al., 1993; Belle et. al., 1995) for the 
development of ELISA’s and potential diagnosis of vitamin K 
deficiency/antagonism. 
 
Reduction of plasma vitamin K by dietary or chemical antagonism brings 
about the impairment of N-terminal glutamic acid post-translational 
modification of prothrombin and other vitamin K dependent proteins.  The 
decarboxylation of prothrombin by vitamin K antagonism often introduces 
partially decarboxylated ‘abnormal prothrombin’ species into the circulation 
(Esnouf and Prowse, 1977; Friedman et. al., 1977), each of which possesses 
heterogeneous antigenic properties.  In 1979 Blanchard and colleagues 
produced antibodies specific for abnormal prothrombin (Blanchard et. al., 
1979), similar antibodies produced by Muntean had specific emphasis for the 
diagnosis of vitamin K deficiency in newborns (Muntean et. al., 1979).  The 
proof that abnormal prothrombin was not stabilised by calcium ions as with 
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native prothrombin came about when Owens and colleagues developed 
monoclonal antibodies specific for the calcium free conformer of prothrombin 
(Owens et. al., 1984).  This work indicated that the only antigenic difference 
between native and abnormal prothrombin was the calcium stabilisation and 
subsequent conformational change in the gla domain.  
 
1.6.1 Abnormal prothrombin 
 
Abnormal prothrombin is that which is produced when hepatic vitamin K 
levels are depleted and the gamma carboxylation of the N-terminal region of 
prothrombin is repressed.  In the plasma of patients on long-term warfarin 
therapy, abnormal prothrombin species are present that do not bind, or bind 
poorly to anti-abnormal prothrombin antibodies.  These forms of abnormal 
prothrombin are thought to be partially decarboxylated as opposed to the 
abnormal prothrombin completely devoid of all its 10-gla residues.   Whether 
the fluctuation of these abnormal prothrombin species occurs at initiation or 
sometime during warfarin therapy is unclear, it is also unclear as to whether 
there is any marked individual variation between the concentration of the 
abnormal prothrombin species and a patients PT.   
 
Monoclonal antibodies specific for abnormal prothrombin have been isolated, 
also showing minimal cross reactivity with native prothrombin and other 
coagulation proteins.  Using these antibodies together with anti-prethrombin-1 
monoclonal antibodies, which bound abnormal prothrombin and normal 
prothrombin equivalently, assays were developed that may be used in 
qualitative/quantitative diagnostic tests for abnormal prothrombin in plasma 
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and serum.  Prothrombin and abnormal prothrombin were shown to bind 
equivalently to the prethrombin-1 antibodies; they also produced identical 
displacement curves in a competition assay against 125I-labelled abnormal 
prothrombin bound to anti-prethrombin-1 antibodies (Blanchard et al., 1983).  
Therefore, the anti-prethrombin-1 antibodies could be used in an EIA to 
quantify total prothrombin levels in plasma or serum samples.  The antibodies 
that were specific for native/functional prothrombin with minimal cross 
reactivity may be used in a separate assay to quantify normal prothrombin 
levels.  Theoretically, total prothrombin minus the normal prothrombin leaves 
the abnormal prothrombin.  The development of an EIA, using antibodies 
such as those mentioned above, allowing the direct quantification of abnormal 
prothrombin may be considered as a new approach to monitoring oral 
anticoagulant therapy alongside the coagulation time tests aPTT and PT. 
 
A diagnostic test for the detection of severe vitamin K deficiency was 
produced using a single antibody showing specificity for the most 
decarboxylated forms of prothrombin (Motohara et. al. 1985).  This abnormal 
prothrombin test, although beneficial for the diagnosis of severe vitamin K 
deficiency in newborns where the levels of carboxyglutamic acid (gla) have 
decreased below 5 gla mol-1, becomes less useful in the case of warfarin 
treated adult patients due to the increased plasma gla content of 
approximately 7.7 gla mol-1 (Motohara et. al. 1985).  A peroxidase linked EIA, 
similar to that developed by Motohara et al. in 1985, is the most sensitive 
abnormal prothrombin determination assay, requiring only 100 µl of plasma 
per test and providing a detection limit of 0.13 mg of prothrombin per litre of 
plasma (Widdershoven et al., 1987).  A monoclonal antibody (C4B6), again 
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specific for abnormal prothrombin, was developed by Belle and colleagues, 
and showed greater specificity and enhanced ELISA results compared to two 
other commercial antibodies from Stago and Esai Co.  The application here 
was also aimed at the diagnosis of newborn vitamin K deficiency (Belle et. al., 
1995). 
 
1.6.2 Native prothrombin 
 
Antibodies have been produced that show specificity towards the calcium 
stabilised native prothrombin antigen and show minimal cross reactivity with 
abnormal prothrombin (Tai et. al., 1980; Lewis et. al., 1983; Malhotra and 
Sudilovsky, 1987; Owens et al., 1984) for the specific application of native 
prothrombin assay.   
 
This observation may hinder the development of direct abnormal coagulation 
factor immuno-assays, due specific monoclonal antibodies being sensitive to 
the lack of structural consistency with abnormal prothrombin species’.  For 
this reason, an indirect calculation of the abnormal prothrombin within a 
sample, through subtraction of normal prothrombin from total prothrombin, 
may be a primary development route for this new type of assay.  In a 
preliminary report 89 % of “at risk” patients were identifiable using an 
immuno-assay method compared to 33 % using the standard PT (“at risk”: 
increased potential for bleeding or thrombotic complications during 
anticoagulative therapy) (Blanchard et al., 1983). 
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An enzyme linked sandwich immuno-assay was developed by Motohara et al. 
in 1985 that detected abnormal prothrombin in 50 µl of plasma from vitamin K 
deficient subjects, in the range 0.5-0.5 x10-2 µg of protein.  The immuno-assay 
also detected pure decarboxylated prothrombin in the range 0.5 x10-1 - 0.5 
x10-3 µg of protein, this discrepancy was attributed to the heterogeneity of 
abnormal prothrombin de-carboxylation in vitamin K deficient and warfarin 
treated individuals.  The monoclonal antibody, specific for des-carboxy 
prothrombin, used in the assay was isolated and characterised from a 
hybridoma cell line.  The cell line was created through the fusion of spleen 
cells, from an antigenated female BALB/C mouse, and P3U-1 myeloma cells 
with polyethylene glycol (Motohara et al., 1985).  The favoured monoclonal 
antibody for abnormal prothrombin detection was that which recognised 
prothrombin containing the least Gla residues or the antibody showing the 
greatest specificity. 
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1.7 Artificial Antibodies Prepared by Molecular Imprinting  
 
1.7.1 Definition of molecular imprinting 
 
“A template induces the self assembly of molecular components to 
allow reaction or transformation to take place in forming a novel 
molecular structure; thereafter the template is separated from the novel 
structure” (Steinke et. al., 1995). 
 
1.7.2 General introduction 
 
Molecular imprinting can be regarded as a templating approach, it is the 
process of template-induced formation of specific recognition sites (binding or 
catalytic) in a material where the template directs the positioning and 
orientation of the material’s structural components by a self-assembly 
mechanism (Piletsky et. al., 2001b).  These sites are created when functional 
monomers, bound to certain binding/recognition sites on a template molecule 
polymerise in the presence of a cross-linker.  The polymerisation can be 
initiated by the addition of a free radical forming initiator, for example 1,1’-
azobis (cyclohexanecarbonitrile), heating, or exposing the monomer mixture 
to UV irradiation.  Polymers, containing specific well-defined recognition 
cavities, predetermined by the chemical nature of the template, are produced 
on template removal as illustrated in Figure 1.7.1.  After polymerisation the 
reaction vessel is smashed and the polymer removed for grinding, typically 
40-60 % of the polymer particles are recovered as usable particles, 60-40 % 
is lost as particle fines due to sedimentation.  Attempts to improve particle 
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shape have been made by using the pores of pre-formed beaded silica and 
TRIM for imprinting, or by dispersion-polymerisation-techniques, using a 
solvent based continuous phase (Andersson, 2000).   
 
The choice of monomers contributes significantly to the success of imprinting 
polymerisation.  Functional monomer screening procedures including 
thermodynamic calculations and combinatorial screening approaches have 
produced polymers with good affinity and selectivity properties (Chianella et. 
al., 2002).  However, due to the increasing sizes of functional monomer 
databases current manual screening procedures have become uneconomical.  
Computational molecular modelling, which has been extensively utilised in 
rational drug discovery and design, has now been adapted for use in 
functional monomer screening (Piletsky et. al., 2001a).  Virtual functional 
monomer databases can be rapidly screened on all possible interactions of 
the molecular model of the template using molecular modelling software.  
This screening process calculates a binding score for each monomer in the 
database, and those with the highest scores are considered for use in the 
molecular imprinting of the target molecule.  This screening method has 
yielded polymers with the affinity and specificity similar or even superior to 
those of monoclonal and polyclonal antibodies (Chianella et. al., 2002).  A 
computationally designed MIP has separated ephedrine from its enantiomers 
with a separation factor higher than that obtained from commercially available 
chiral phases (Piletsky et. al., 2001a).   
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Figure 1.7.1 represents schematically the molecular imprinting process: i, ii and iii depict 
respectively complexation, polymerisation and template removal. The functional monomers
are represented by x, y and z. (Diagram adapted from Allender et. al., 1999; Ansell et. al., 
1996). 
 
Among the monomers identified as best suited for the preparation of 
imprinted polymers are: methacrylic acid (MAA) and itaconic acid (IA), 
acrylamide (AA), Diethyl aminoethyl methacrylate (DEAEMA), and 
hydroxyethyl methacrylate (HEMA).  The typical cross-linkers used in 
molecular imprinting are ethylene glycol dimethacrylate (EGDMA), N,N’-
methylenebisacrylamide (MBAA) and divinylbenzene (DVB). 
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Natural bio-molecules MIPs 
  
Low stability MIPs are stable at low/high pHs, 
pressure and temperature 
High cost of enzymes and receptors Inexpensive and easy to prepare 
Poor performance in organic solvents Good performance in organic solvents 
Good performance in aqueous media Poor performance in aqueous media as 
yet 
Can be used in the aqueous and solid 
phases 
For use in the solid phase only, as yet 
Preparation protocols have been 
optimised due to extensive usage 
There is currently an absence of a 
general MIP preparation protocol 
Natural molecules can emit signals on 
binding which can be easily translated 
and measured 
Difficulties have arisen in the translation 
of the MIP binding event into a readable 
signal and integration of the MIP binding 
signal with the transducer 
Integration of natural bio-molecules in 
multi sensor unit is difficult due to 
different operational requirements of 
each molecule (pH, ionic strength, 
temperature and substrate) 
Due to minimal operational requirements 
of MIPs, the design of a MIP multi-sensor 
is very easy 
Natural receptors and enzymes exist for 
a limited number of practically important 
analytes 
MIPs could be prepared for practically 
any compound 
Poor compatibility with micro-machine 
technology and miniaturisation 
The polymers are fully compatible with 
almost any compound 
 
 
 
Table 1.7.1 represents a comparison of the benefits of MIPs compared with natural molecules as 
they are applied for use in clinical, environmental and industrial sensor technology (Anonymous 
2001). 
 
A comparison of the benefits of MIPs and natural molecules is depicted in 
Table 1.7.1.  Advantages of MIPs include their impressive long-term stability 
at low and high temperatures; they can also be treated with extreme acid or 
alkaline solutions without any degradation of their recognition properties 
(Piletsky et. al., 2001b).  The imprinting procedure negates the use of 
animals, and is very time, energy and cost efficient in comparison to the 
generation of natural antibodies.  Excellent thermal, chemical and mechanical 
stability; their adaptability makes MIPs potential candidates for use as artificial 
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antibodies in affinity chromatography, solid phase extraction, solid phase 
binding assays, and sensors.  MIPs are also capable of recognising small 
variations in template structure, therefore enabling them to distinguish 
between different enantiomers or analogues of the same template (Kempe et. 
al., 1995).     
 
Currently, MIPs cannot be used in immuno-assays in which the antibodies are 
in their soluble form, such as immuno-diffusion, immuno-electrophoresis, 
immuno-blotting and tissue immuno-fluorescence.  Problems arose due to the 
polymeric nature of these materials, which make them insoluble in both 
organic and aqueous solvents.  Nevertheless polymeric suspension can be 
used successfully in solid phase based assays.  Radioligand assays were 
developed in aqueous media using morphine and [Leu5] enkephalin as the 
imprint molecule (Andersson et. al., 1995).  This study addressed two 
problems associated with adaptation of the relatively immature MIA 
technology to clinical analyses.  Among these problems is the need for 
additional extraction steps for transferring analyte from aqueous to organic 
phase.  As it was shown in this work, binding cross-reactivity of [Leu5] 
enkephalin-imprinted polymer in water was significantly higher than in organic 
solvents.  A second problem was a large amount of print molecule necessary 
for assay development, e.g. up to 12.5 mg of theophylline is needed to make 
an assay for this template (Mullett et. al., 1998).   
 
Some antibody immunoassay techniques currently require a clean-up step; 
therefore, the first criticism with the [Leu5] enkephalin-imprinted polymer was 
not a great problem.  MIPs possess certain inherent problems such as, the 
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low compatibility of the procedure with the aqueous environment, and the 
necessary use of large amounts of template in the imprinting procedure.  To 
this list, we may add the absence of a general preparation procedure for 
rational MIP design and the difficulty of macromolecular and protein 
imprinting.  All of these problems necessitate resolution before MIPs may 
replace natural antibodies in certain assays. 
 
1.7.3 Protein and macromolecular imprinting 
 
Macromolecular recognition, using MIPs has been achieved by the 
development of two different approaches.  The first, more common, utilises 
metal chelating agents, such as bis-imidazoles or functional monomers that 
form a small number of strong electrostatic interactions with a few specific 
binding sites on the template, usually with an organic or mixed solvent as the 
porogen.  The second approach to macromolecular imprinting utilises the 
ability of MIPs to recognise molecular shape.  The monomers used for 
development of shape-recognisable polymers are capable of forming multi 
point weak interactions such as hydrophobic or hydrogen bonds.  Bio-
analytical applications of MIPs usually necessitate aqueous conditions, 
however due to the strong hydrophobic interactions present in aqueous 
polymer systems, hydrophobic adsorption to the polymer surface can lead to 
strong non-specific binding.  Although it is less convenient, it is possible to 
prepare imprinted polymers in organic solvents, which promote strong non-
covalent/polar interactions such as hydrogen bonds (Andersson, 2000).  
Bovine serum albumin (BSA) and the enzyme urease have been imprinted 
using mixtures of 3-aminopropyltriethoxy-silane and tetraorthosilicate.  The 
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polymers showed some specificity towards their target, however they lacked 
the stability of traditional cross-linked polymers, and the method itself was 
non-reproducible (Burow and Minoura, 1996; Rachkov and Minoura, 2001).  
In another approach, acrylamide was used for imprinting glucose oxidase in 
water (Burow and Minoura, 1996).  The experiments showed that although 
the polymer had specificity initially, this was lost during drying and re-swelling; 
this was attributed to the lack of sufficient cross-linking in the polymer.  On the 
other hand, higher degrees of cross-linking might increase the level of protein 
denaturation. 
 
Critical issues in the imprinting procedure suited for protein imprinting include 
the stabilisation of the monomer-template complex in the pre-polymerisation 
mixture, removal of the template molecules and the choice of an appropriate 
format of the polymer.  Steric and thermodynamic effects hinder the synthesis 
of MIPs selective for macromolecules such as proteins.  The steric effect is 
because bulky proteins cannot slip in and out of the polymer network easily.  
The thermodynamic consideration indicates that the use of non-rigid protein 
templates yields less well-defined recognition sites (Rachkov and Minoura, 
2001).  One method of overcoming such hindrances, as well as the loss of 
yield and the destruction of affinity sites by grinding is to use a surface 
grafting technique.  Copper II chelating imidazole polymers have been grafted 
onto activated silica beads suitable for HPLC (Plunkett and Arnold, 1995).  
Polystyrene microtiter plates were grafted with a polymer prepared in 
aqueous solution in the presence of various protein templates (Bossi et. al., 
2001).  Such a polymer was prepared by the chemical oxidation of 3’-
aminophenylboronic acid (APBA).  The polymerisation product was grafted 
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tightly to the surface of the plates by aromatic ring electron pairing 
interactions.  Proteins such as horseradish peroxidase, lactoperoxidase, 
haemoglobin and microperoxidase have been imprinted by this method, and 
the resulting MIPs showed good specificity and affinity towards their 
templates.  The in-situ molecular imprinting of the triazine herbicide, 
desmetryn, in an aqueous system, onto commercial porous polypropylene 
membranes was achieved.  These membranes showed affinity towards the 
template and to other triazine herbicides, therefore presenting a quick and 
easy solid-phase extraction of triazine herbicides in water (Piletsky et. al., 
2000). 
 
The epitope approach is another method in which many of the hindrances of 
macromolecular imprinting are avoided.  As in nature, an antibody recognises 
and interacts with only the epitopes of an antigen; similarly, the imprinting of a 
small exposed fragment of a protein allows the recognition of not only the 
template, but also larger fragments containing the imprint fragment.  The 
recognition of the neurophyseal nona-peptide hormone, oxytocin was 
achieved through the imprinting of the tetra-peptide (YPLG), which was 
homologous to the hormones C-terminal region.  Methacrylic acid (MAA) and 
ethylene glycol dimethacrylate (EGDMA) were copolymerised in acetonitrile.  
Acetonitrile was used to promote the formation of intramolecular hydrogen 
bond interactions, which are known to stabilise the conformational folding of 
oxytocin.  In aqueous solutions, oxytocin is extremely flexible and it does not 
appear that intramolecular hydrogen bond plays a significant role in 
determining a molecule structure (Rachkov and Minoura, 2001). 
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1.7.4 Clinical applications of MIPs  
 
MIPs have been prepared against the steroids, cortisol and corticosterone 
and used in the analysis of the functional status of the adrenal cortex 
(Ramstrom et. al., 1996).  Due to the rigid fused ring system of the 
corticosteroids, the number of conformations produced by molecules 
interacting with recognition matrices is small, which is good for narrowing 
binding site diversity. The few polar interaction points on steroid molecule 
contributed to the complex formation making non-covalent molecular 
imprinting specific, and increasing the binding strength of such polymers.  In 
aqueous buffer systems, the polymers showed severely diminished 
specificities towards their targets, and the affinity of the reference polymers to 
the imprint molecules was similar to that of the imprinted polymers.  In the 
solvent-based assays, the cortisol and corticosterone imprinted polymers 
gave detection limits in the range 10-7 and 10-8 M respectively, which may be 
improved by the development of a more sensitive assay (Ramstrom et. al., 
1996).  
 
The imprints of drugs such as the anticoagulative metabolite 7’-
hydroxycoumarin (7’-OHC) (Walshe et. al., 1997) and bronchodilator 
theophylline (Mullett and Lai, 1998) have been used in solid-phase extraction 
and competition radioligand assay, respectively, to measure analytes in urine 
and blood samples.  A MIP specific for 7’-OHC was capable of extraction of 
template present in 10-50 µl ml-1 concentrations (Walshe et. al., 1997).  
Detection limits for the polymers used in the radioligand assays were defined 
as the concentration of ligand required for the displacement of 10 % bound 
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radio labelled compound. The calculated detection limit for theophylline was 
3.5 µmol L-1.  Cross reactivities of the MIPs were highly comparable with 
those of their natural antibody counterparts (Ansell et. al., 1996; Wulff, 1995).  
Molecular imprints of sugar derivatives have shown good enantiomeric 
selectivity and minimal cross-reactivity with similar compounds.  The imprint 
polymer of the β-adrenergic blocker, (S)-(-)-timolol was also used in 
chromatographic separation of the print molecule from similar structures 
(Ansell et al., 1996).   
 
The polymer produced from the imprint of octyl-α-D-glucoside preferentially 
bound methyl-α-D-glucoside with binding energy two orders of magnitude 
greater than that for methyl-α-D-galactoside, which differs only by the 
orientation of one hydroxyl group (Ansell et al., 1996).  Berglund and 
colleagues in 1996 (unpublished results) imprinted the α2-adrenoceptors 
yohimbine and coryanthine and the resulting polymers acted as receptor 
mimics that were both used in MIA analysis (reported in Ansell et al., 1996).  
The two structures differ only by the orientation at the carboxyl-bearing 
stereogenic centre, yet the mimics showed good selectivity towards the 
template molecule in solvent and aqueous solutions. 
 
MIP hydro-gels that displayed isomerically resolved glucose binding have 
been produced.  Binding capacities of 0.5 g of glucose per gram of dried gel 
were observed, such polymers worked well in aqueous media (Wizeman and 
Kofinas, 2001).  In 1997, Arnold’s group (Chen et. al., 1997) prepared a 
glucose imprinted metal complexing polymer, which preferentially bound 
glucose in porcine plasma.  The polymer functioned at alkaline pH and 
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released protons in proportion to the concentration of glucose bound, 
therefore had the potential to be adapted for use in a non-expensive, simple 
glucose assay.  The incorporation of the signal recognition element into the 
bulk of the composition matrix is an exciting area of MIP sensor development.  
As with the glucose imprinted polymer and some optical sensing systems, 
binding of the target analyte produces a change in the properties of a reporter 
monomer, such as proton release in the glucose polymer and fluorescence 
quenching in a cAMP imprinted polymer (Haupt and Mosbach, 2000). 
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1.8 Biosensors  
 
1.8.1 Introduction 
 
A typical biosensor assay comprises of a surface immobilised ligand to which 
a ligand in solution is bound.  A detector converts a signal from this binding 
event into readable electrical information that can be represented using 
computer software.  In terms of biosensors, a recognition element is usually 
one of a pair of biospecific interaction molecules, such as antibodies and 
antigen, hormones and receptors or drugs and proteins (Lundstrom, 1994).   
Molecular recognition elements can be divided into two different categories  
1. Catalytic, which include enzymes, microbes, cells and tissues  
2. Affinity, which includes antibodies, MIPs, nucleic acids and receptors.   
 
A surface-bound bioorganic derived or analogous recognition element 
coupled with a physico-chemical transducer is what constitutes a biosensor.  
They work by translating a recognised biochemical signal into an electronic 
output that can be read by simple computational methods.  The surface, to 
which the template specific material is bound, should be able to produce a 
signal in proportion to the amount of recognised template.  Five basic classes 
of transducer exist; optical (e.g. SPR based Biacore chips, (Biacore AB, 
Uppsala, Sweden)), electrochemical (e.g. glucose sensors (Chen et. al., 
1997)); thermometric, piezoelectric (quartz crystal microbalance) and 
magnetic transducers, which have not been researched as much as the latter 
two types. 
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1.8.2 Molecular recognition elements (MRE’s) 
 
Catalytic recognition elements form a smaller group of MRE compared to 
affinity based recognition group, but expansion in this part of the industry has 
become a scientifically exciting as the affinity group.  Enzymes and their 
substrates have been used as catalytic recognition elements in biosensors to 
the point that their engineering and purification have become paramount to 
the current stability and sensitivity of the biosensors they are incorporated 
into.  Examples include enhancement or introduction of thermostability into 
specific dehydrogenase enzymes in an attempt to lengthen enzyme biosensor 
shelf life, which may allow the more cost effective production of stable 
biosensors e.g. glucose biosensor (Kojima et. al., 2000; Sode et. al., 2000; 
Helianti et. al., 2001).  The isolation of proteases from various bacteria 
located in soil at the top of mountains (Morita et. al., 1997) or in salmon 
intestines (Morita et. al., 1998; Yamaura et. al., 1999) may aid biosensing in 
cold environments, such as the food or agricultural industry.  Modified β-
cyclodextrins (oligosaccharides) have been incorporated into biomimetic 
biosensors for use as synthetic dehydrogenase enzyme mimics (Kataki and 
Morgan, 2003), a nicotinamide group allowed the electron transfer to occur 
while the cyclodextrin allowed the hydrophobic reaction to take place.  DNA 
has been used as a catalytic tool for the real time specific biosensing of metal 
ions in solution; such a biosensor could be useful for environmental, clinical 
toxicology and industrial process monitoring (Lu et. al., 2003). Cell based 
biosensors can incorporate the catalytic recognition elements of a cell, in an 
in-vivo array type system (reviewed in Durick and Negulescu, 2001). 
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Affinity recognition elements form a larger group of MRE and have been 
extensively used in biosensing applications.  Antibodies and their antigens 
have been used expansively as immunosensing tools (covered in chapter 
1.7), and molecularly imprinted polymers have also become an important type 
of synthetic catalytic recognition element in the past few decades (covered in 
chapter 1.8).  The four categories of natural receptors, summarised in Table 
1.8.1, have been integrated into biosensors for a variety of applications 
(reviewed in Subrahmanyam et. al., 2002).  Natural recognition elements 
such as enzymes, or those receptors that are enzyme linked are favoured for 
biosensor integration due to the number of measurable parameters that can 
be generated including protons, ions, electrons, heat, light and mass (Lowe, 
1989).   
 
Characteristics 
Ion Channel 
Receptors 
G-protein linked receptors 
Receptors with a single 
transmembrane domain 
Enzyme linked receptors 
Endogenous 
Ligands 
Neurotransmitters 
Neurotransmitters, hormones, 
autocoids, chemotactic factors 
Receptors with a single 
transmembrane domain 
Atrial natriuritic peptide 
ligands, growth factors 
Structure 
Several proteins 
with a pore 
1-2 proteins 
1-2 proteins with catalytic 
domain 
Individual protein linked 
with enzyme 
Transmembrane 
Segments 
Four Seven One 
Single-pass 
transmembrane proteins 
Function 
Regulation of ion 
transport 
Activation of G-proteins, 
regulation of cellular functions 
and protein expression 
Catalytic 
Suppress proliferation, 
stimulate synthesis of 
extracellular matrix, 
stimulate bone formation, 
attract cells by chemotaxis 
Cellular 
Response 
Depolarisation/ 
hyperpolarisation 
Depolarisation/ 
hyperpolarisation 
Regulation of cellular 
functions, proliferation 
and differentiation 
Regulation of cyclase, 
production of cyclic GMP, 
cell signalling and 
regulation of cell cycle 
  
Table 1.8.1 represents the classification of natural receptors (adapted from Subrahmanyam 
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The enzyme-based biosensor generally produces an amplified measurable 
signal, whereas the non-enzyme linked receptor may produce a transducer-
detectable conformational change.  Generally this type of conformational 
change is difficult to measure without the specific attachment of fluorescent 
labels (Kostrzynska et. al., 2002), the linkage to another amplification system 
(Baeumner et. al., 2002; Pei et. al., 2001; Lisdat et. al., 1997) or very 
sensitive detection devices such as the piezoelectric crystals or quartz-crystal 
microbalance (Lin and Tsai, 2003; Wu, 1999; Wong et. al., 2002; Steegborn 
and Skladal, 1997; Halamek et. al., 2002).  One optical transducer technique 
termed surface plasmon resonance (SPR) allows the real-time analysis of 
biospecific interaction or BIA (see chapter 4.1), i.e. without labels or additional 
amplification system. 
 
1.8.3 Transducers 
 
The optical transducer category, which includes surface plasmon resonance 
(Biacore [www.biacore.com], IBIS [www.ibis-spr.nl], Nippon Laser Electronics 
[www.nle-lab.co.jp/English/ZO-HOME.htm], Texas Instruments 
[www.ti.com/sc/docs/products/msp/control/spreeta]) and evanescent wave 
biosensors (Affinity Sensors [www.affinity-sensors.com], Farfield Sensors 
[www.farfield-sensors.co.uk]) monitors the change in refractive index of the 
running buffer near the sensor surface as complexes form and break down in 
real time (Squillante, 1998; Huber et al., 1999).  Optical transducer systems 
allow for labelless real-time biomolecular interaction analysis (BIA), even in 
crude preparations (Baird and Myszka, 2001). 
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Electrochemical transducer systems are those that produce an electrical 
signal due to a direct interaction with the recognition element and generally 
comprise of a biorecognition element incorporated into the electrode material.  
This enables for fast responses to the involved substrates because of the lack 
of recognition element-bound supporting membrane and the close proximity 
of the substrate to the electrode material.  Interesting reviews detailing the 
materials used for and types of biochemical sensors have been produced in 
recent years (Zhang et. al., 2000; Serra et. al., 2002).  The monitoring of 
glucose in diabetic patients has received much assistance with the 
development of the glucose oxidase (GOD) based glucose biosensor.  As the 
nature of diabetes is such that continuous monitoring on blood glucose is 
essential, patients have been able to monitor their own glucose levels using a 
simple “pin prick” method.  However, the ‘idea’ that a GOD based glucose 
sensor could be implanted into the patient to provide continuous online blood 
glucose monitoring has not yet been fully realised, due to biocompatibility 
problems causing inflammation and immune responses (Abel and Woedtke, 
2002).  A non-invasive glucose biosensor based on impedance spectroscopy 
has recently been through primary stage human clinical trials (Caduff et. al., 
2003), it is the size of a wristwatch and may prove constructive in the 
realisation of the continuous blood glucose monitoring ‘idea’. 
 
Thermometric biosensors measure the total heat energy absorbed or evolved 
during a biochemical reaction.  This absorbed or evolved heat energy is 
proportional to the molar enthalpy and to the product stoichiometry of the 
biochemical reaction (Reviewed in Ramanathan and Danielsson, 2001).  
Piezoelectric transducers (or quartz crystal microbalance -QCM) comprise of 
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a specifically cut thin disc of quartz crystal with electrodes plated onto either 
one or both of its surfaces.  If an oscillating electrical potential is passed 
through these electrodes then an acoustic wave propagates perpendicular to 
the surface of the crystal.  If this crystal is placed into an electrical circuit and 
the current is oscillated at a similar frequency to the fundamental mechanical 
oscillation frequency of the crystal then a resonant oscillation may be 
achieved.  In simple terms, the resonant oscillatory frequency is dependent 
on several factors including chemical structure, density and thickness of the 
crystal and similar physical properties of the surrounding medium.  Therefore 
this frequency is also directly related to the amount or mass of material 
immobilised onto the surface of the crystal (Principles and applications 
reviewed in O’Sullivan and Guilbault, 1999).   
 
Magnetic and pressure transducers are both small categories of transducers 
used in biosensing and have not been researched extensively.  Magnetic 
bacterial particles have been incorporated into an automated ELISA type 
format for the detection and discrimination of single nucleotide polymorphisms 
(Tanaka et. al., 2003).  Another example of the magnetic technology was the 
integration of magnetic micro-beads with DNA hybridisation to detect 
pathogenic bioanalytes (Edelstein et. al., 2000).  Theodore Sand and 
colleagues have developed an immuno-sensor coupled to a high sensitivity 
pressure transducer, which measures a small pressure change due to the 
production of CO2 in an airtight chamber.  The use of a thin membrane, into 
which a sandwich immunoassay comprising of haptens and antibodies bound 
with catalase is incorporated, creates a surface for the progression of the 
assay and detection of the gas produced (Sand et. al., 2003). 
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This preliminary work came about as a result of the prothrombin molecular 
modelling.  The aim was to identify a region of the computational prothrombin 
model that would act as an epitope for a synthetic adsorbent, based on an 
imprinted peptide.  This region would be required to be specific for the native 
form of prothrombin and ideally locate to an accessible area of the protein, i.e. 
in a binding pocket or on the surface.  An 8 amino acid region located in the 
thrombin fragment 1 region of the surface of prothrombin presented some 
interest, and was synthesised as an 8-mer peptide.  The imprinted bulk 
polymer synthesised using the peptide as a template, showed a small amount 
of specific binding towards prothrombin at concentrations below 0.05 mgml-1.  
It is known that prothrombin undergoes a conformational transition when 
complexed with calcium ions (Bloom and Mann, 1978); this calcium-binding 
gla domain was also of particular interest.   
 
2.1 Introduction 
 
2.1.1 Thermodynamics 
 
The basis for the memory of molecular imprinted polymers lies in the 
formation of template-monomer associations in the pre-polymerisation 
mixture.  These critical interactions can range from weak van der Waals 
forces to reversible covalent bonds (Nicholls et. al. 2002).  The relative 
strengths of the monomer-monomer, template-template and monomer-
template interactions govern the affinity of the subsequent polymer to its 
template.  The affinity of the polymer to its template during the rebinding step 
is an area undergoing much development.  It is known that high monomer 
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concentrations, lower polymerisation temperatures and the use of non-
competitive solvents promoted increased affinity and selectivity towards the 
template.  Increased pressure also has a beneficial effect on the stability and 
affinity of a polymer with its template (Sellergren et. al. 1996). 
 
A thermodynamic treatment (Equation 1) can be applied as a basis for the 
better understanding of molecular recognition as harnessed by molecular 
imprinting. 
 
Equation 1 
∆Gbind = ∆Gt+r + ∆Gr + ∆Gh + ∆Gvib + Σ∆Gp + ∆Gconf + ∆GvdW   
 
The Gibbs free energy parameters in equation 1 above describe the following 
terms.  Complex formation, ∆Gbind; translational and rotational forces, ∆Gt+r; 
restriction of rotors upon complexation, ∆Gr; hydrophobic interactions, ∆Gh; 
residual soft vibrational modes, ∆Gvib; the sum of the interacting polar group 
contributions, Σ∆Gp; adverse conformational changes, ∆Gconf; unfavourable 
van der Waals interactions, ∆GvdW. 
 
Translational and rotational energy ∆Gt+r is a term that describes the change 
in energy due to the rotation and translation (change of coordinates) of 
components within a molecular complex.  The restriction of rotors ∆Gr, e.g. by 
the rigid alkaloid templates morphine (Fischer et. al. 1991) and yohimbine 
(Berglund et. al. 1996), during complexation promotes the formation of stable 
polymers.  This is because the restriction of rotors also restricts the number of 
possible conformations the polymer can form around the template during 
complexation.  The sum of all the polar group interactions Σ∆Gp, determines 
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the selectivity of the resulting polymer.  As with the relatively strong binding of 
covalent imprinting methods (Khasawneh et. al., 2001), more electrostatic 
interactions between the monomers and template enables stronger, more 
stable complex formation and increased selectivity of the resultant polymer.  
In the work by Matsui and Takeuchi, the more acidic functional monomer 
TFMAA produced a nicotine-imprinted polymer that showed much more 
selectivity than a similar polymer created using MAA (Matsui and Takeuchi, 
1997).   
 
Hydrophobic and strong electrostatic interactions (such as those elicited by 
metal chelation monomers) are important in aqueous imprinting procedures.  
These interactions denoted by the term DGh, contribute to the 
thermodynamics of aqueous or polar pre-polymerisation complex formation.  
Aqueous imprinting procedures are necessary when biomedical or 
environmental templates are used (Kempe and Mosbach, 1995; Kempe et. al. 
1995), where non-polar (organic) solvents cannot be used to dissolve the 
template.  As aqueous imprinting requires hydrophobic interaction or 
electrostatic interaction in a polar environment, monomers (such as 
cyclodextrin) have been specifically designed for the job and have been 
utilised effectively in the recognition of steroids (Asanuma et. al. 1997) and 
amino acids (Piletsky et. al. 1999). 
 
The soft vibrational modes term, DGvib is directly related to the temperature 
of polymerisation, a higher temperature provides the polymerisation complex 
with more energy and therefore more vibration.  In order for solution adducts 
to form effectively, a compromise of template conformation and effective 
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solvation is required in the polymerisation complex, this is reflected in the 
terms ∆Gconf and ∆GvdW.  As we can assume that the template-polymer 
pre-arrangement and rebinding processes are under thermodynamic control 
and that rebinding take place in the polymerisation solvent, the unfavourable 
van der Waals forces and adverse conformational terms are dismissed.  
Therefore equation 1 can be simplified to equation 2, which relates to the 
“central dogma of molecular imprinting”; i.e. the recognition sites formed 
during pre-polymerisation are preserved in the final polymer. 
 
Equation 2 
∆Gbind = ∆Gt+r + ∆Gr + ∆Gh + ∆Gvib + Σ∆Gp 
 
The thermodynamic parameters described above are essential considerations 
for the rational design of MIPs.  The general principles illustrated above 
provide the general basis for the more empirical approaches applied to MIP 
development, despite the fact that complex polymer systems do not perform 
well on the application of complex thermodynamic principles.  Molecular 
modelling, which performs very well, provides the computational theoretical 
platform to which the physical parameters of thermodynamics can be applied 
to complex model systems, such as molecularly imprinted polymers. 
 
2.1.2 Modelling 
 
The definition of a ‘model’ in the Oxford English dictionary is ‘a simplified or 
idealised description of a system or a process, often in mathematical terms, 
devised to facilitate calculations and predictions’.  ‘Molecular modelling’ 
95 
Chapter 2.  Computational Ligand design   Adrian Sylvester 
therefore would be concerned with ways in which molecular systems can be 
simplified and predicted.   
 
For a computational program to be able to modify a molecule, it is obviously 
important to determine the atom positions within molecules.  Cartesian 
coordinates could be used, however internal coordinates, usually written as a 
Z-matrix are an alternative.  Internal coordinates are useful in describing the 
spatial relationship corresponding to atoms within a single molecule, however 
Cartesian coordinates may be more useful for a collection of discrete 
molecules (Leach, 2001).  The information presented in a Z-matrix (see 
Figure 2.2) of internal coordinates describes the atom number, the atom 
symbol, the bond length (measured in angstroms, 1Å≡10-10m ≡100 pm) to the 
next atom and the atom number of that atom.  The angle formed by the atom 
and two other attached atoms, and the torsion angle produced by the atom 
and three other attached atoms. 
 
8
7
6
5 4
3
2
1
 
 
 
 
 
 Figure 2.1.1 represents the staggered conformation of ethane. 
 
The internal coordinates of each atom in the ethane molecule as in Figure 
2.1.1 can be represented in the following Z-matrix.   
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1 C 
2 C 1.54 1 
3 H 1.0 1 109.5 2 
4 H 1.0 2 109.5 1 180.0 3 
5 H 1.0 1 109.5 2   60.0 4 
6 H 1.0 2 109.5 1  -60.0 5 
7 H 1.0 1 109.5 2 180.0 6 
8 H 1.0 2 109.5 1   60.0 7 
 
 
 
 
Figure 2.1.2 represents the Z matrix configuration of the internal coordinates of ethane as 
depicted in Figure 2.1.1. 
 
 
The overall aim of molecular modelling methods is to try to relate biological 
activity to the structure of the molecule.  The computation of the potential 
energy of a molecule as a function of the positions of the atoms is essential 
(Forster, 2002).  The approximation that nuclear and electronic motions of 
molecules can be separated is applied to standard molecular modelling.  
Therefore the energy of a molecule in its ground electronic state can be 
considered as a function of its nuclear coordinates.   So if a nucleus within a 
molecule is moved e.g. by a reaction or simple bond rotation process, then 
the energy of the system will change.  The ‘potential energy surface’ is a term 
used to describe the changes in energy of a molecular system (Leach, 2001).   
 
Many of the problems considered in molecular modelling are too large to be 
tackled by quantum mechanics.  In quantum mechanics, the electrons within 
a system are considered.  As the calculations are so time consuming, such a 
large amount of particles cannot be considered using quantum mechanics.  
For large molecules such as proteins, the approximation known as ‘molecular 
mechanics’ or ‘force fields’ can be used (Burkert and Allinger, 1982).  
Molecular mechanics cannot therefore provide information on the electronic 
distribution of a molecule, but can be as accurate as quantum mechanics with 
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problem evaluation in a fraction of the time.  In this approach there are energy 
terms that describe the deformation of bond lengths, bond angles and torsion 
angles away from their equilibrium values.  Even when simple functions such 
as Fs= -kx (Hookes law) are applied to the system, molecular mechanics force 
fields perform adequately well.   
 
Molecular mechanics, essentially serves to predict the energy of a molecule 
or complex of interacting molecules in a particular conformation.  These 
energies can then be considered as relative values to compare and contrast 
between different molecules or complexes.  The total energy of a particular 
conformation of a complex can be calculated by comparison to the accepted 
bond parameters stored in the molecular mechanics ‘force field’ database.   
The equations that describe the energetic parameters of a complex (Equation 
1) are also stored in the molecular mechanics force field; some force field 
examples include TRIPOS (Clark et. al. 1989), MM2 (Allinger, 1977), and 
AMBER (Weiner et. al. 1984).   
 
 Equation 3 
E Potential Energy = E stretching + E bending + E torsional + E electrostatic + E vdW 
 
Equation 3 describes the energetic parameters used to represent molecular 
structure in molecular mechanics calculations.  The potential energy 
parameter is comprised of the five different force parameters that describe the 
movements of all the bonds in a molecular complex. 
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2.1.3 Ligand design 
 
Dramatic increases in computational power, improvements of methodology 
and algorithms for the calculation of empirical binding energies, has increased 
the rate and quality of biomolecular systems analysis and their atomic 
interactions, beyond that which can ever be achieved manually (Joseph-
McCarthy, 1999).  The application of molecular modelling software such as 
Sybyl 6.9 (Tripos Inc., St. Louis Missouri, USA) or Quanta (Accelrys Ltd. 
Cambridge, UK), can introduce an altogether new ‘rational’ methodology, 
which can greatly enhance ligand design and subsequent production of 
synthetic biochemical adsorbents.   
 
Computational modelling and ligand design involves the simulated fitting of 
functional monomers from a virtual library (Piletsky et. al., 2001a), into 
specific areas of the target biomolecular computational model with computer 
algorithms such as LEAPFROG (Ash et. al., 1996).  Prior to the monomer 
probing, the target molecular model is refined by charging the atoms (e.g. 
Gasteiger-Huckel) and application of molecular mechanics algorithms to 
‘minimise’ the ‘strain’ energy imposed on the atoms in the molecule (e.g. 
MAXIMIN2) (Labanowski et. al., 1986).  Inhibitors, specific for coagulation 
factor Xa have recently been identified and analysed relative to their 
quantitative structure-activity relationships (QSAR’s) using SYBYL® molecular 
modelling software.  Literature values of known interactions between factor 
Xa and established inhibitors provided the basis for the docking of novel 
potential inhibitor molecules from a virtual library (Matter et. al., 2002). 
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Molecular modelling techniques have been used to simulate human protein 
molecular dynamics, with limited use of NMR data and atomic coordinates 
specific for the protein in question.  Currently, NMR crystal structure data 
regarding human prothrombin is limited and centres around predictive 
molecular modelling of human prothrombin fragment-1 based on its significant 
homology (82 %) with bovine prothrombin.  This model was created using 
literature data from the NMR crystal structure of bovine prothrombin fragment-
1 (Soriano-Garcia et. al., 1992) and Sybyl 6.0 (Tripos Inc., St. Louis Missouri 
USA) (Li et. al., 1995).   
 
The rational design of ligands using a computational approach can be applied 
to the design of molecularly imprinted polymers, for use in biomolecular 
assays in various environments.  The computational approach has been used 
to design selective MIPs for ephedrine enantiomers (Piletsky et. al., 2001a), 
creatinine (Subrahmanyam et. al., 2001), microcystin-LR (Chianella et. al., 
2002) and synthetic adsorbents for coagulation factor VII (Morrill et. al., 
2002).  The computational approach can be applied to the generation of 
synthetic adsorbents, based on interactions of ligands with specific regions of 
biomolecules.  A region, analogous to an antibodies epitope, can provide a 
‘handle’ for the synthetic recognition and capture of a complete biomolecule.  
This approach can be termed “the epitope approach”, and is based on the 
imprinting of a short peptide template, which resembles a region (epitope) of 
the protein under investigation (Rachkov and Minoura, 2001).   
 
The peptide FNEKTFGA was selected from initial computational studies of a 
human prothrombin model, as a template for the synthesis of MIPs for the 
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potential recognition of human prothrombin.  This peptide was screened 
against a ‘virtual’ functional monomer database (Figure 2.2.1) using the 
Leapfrog algorithm within Sybyl 6.7.  The two best monomers were selected 
for the production of a MIP that showed selectivity for the synthesised peptide 
template and potentially human prothrombin.  Investigations into the synthesis 
of a second, potentially more interesting region of the human prothrombin 
‘gla’ domain, proved fruitless due to financial and logistical barriers.  However 
evidence exists that makes this one of the most interesting avenues for future 
studies in the development of a novel native prothrombin assay, as will be 
discussed later. 
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2.2 Materials and methods 
 
2.2.1 Molecular modelling of human prothrombin 
 
A Silicon Graphics Octane workstation running IRIX 6.5 was used together 
with Sybyl 6.9 molecular graphics software from Tripos Inc., USA 
(http://www.tripos.co.uk).  The protein data bank (PDB) 
(http://www.rcsb.org/pdb/) was used to acquire the tertiary structure of bovine 
prothrombin and the expert protein analysis server (ExPASy) 
(http://ca.expasy.org/sprot/) was used to search the Swiss-Prot/TrEMBL 
database for the primary (amino acid) sequence of human prothrombin.  The 
primary and tertiary structures of human and bovine thrombin were also 
sourced using the same search engines.   
 
The protein models were charged using Gasteiger-Huckel charges throughout 
and the MAXIMIN2 command was used to refine the molecular mechanics of 
the molecules.  A target minimum energy of 0.05 Kcal mol-1 was used for all 
minimisations.  The Amber95 force field, incorporated into the Sybyl 6.9 
Biopolymer package and corresponding metal parameters (contained within a 
Sybyl programming language script, Amber_metals.spl) were employed in an 
attempt to minimise the calcium complexed gla domain of bovine and human 
prothrombin.   
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2.2.2 Synthesis of rationally designed peptides: FNEKTFGA 
 
Fmoc amino acids utilised for the synthesis of FNEKTFGA included alanine 
(A), 2x phenylalanine (F) and glycine (G) and those with protected side chains 
included O-tertiary-Butyl asparagine (N), glutamic acid (E) and threonine (T) 
and Boc lysine (K).   
 
Alanine preloaded (0.367 g or 0.7 mmol g-1) 2-chlorotrityl-chloride resin was 
used for the attachment of the C-terminal portion of the peptide.  Synthesis 
was carried out using 0.25 mmol Fmoc chemistry on a Perkin Elmer (Applied 
Biosystems-433A) solid phase peptide synthesiser; the nature of the 
chemistry and synthesiser control software consumed four equivalents of 
each amino acid. 
 
2.2.3 Cleavage of resin 
 
The resin (0.62 g) was treated with 5 ml 95 % TFA in 2.5 % TIS and 2.5 % 
water for 2 hours at room temperature.  After this time the resin was filtered 
and washed with 5 ml 95 % TFA in DCM.  Approximately 100 ml of ether was 
added to the resulting filtrate and significant amounts of precipitate were 
obtained.  This mixture was allowed to stand at 4 oC for 1 hour, which 
afforded a white residue.  The ether solution was decanted and the solid 
residue was repeatedly washed with ether until all the TFA had been removed 
resulting in a white solid.   
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The product was obtained and a small sample was sent for mass spectrum 
analysis.  The expected mass was 913 .44185 and the measured mass was 
913.62134, see appendix for mass spectrograph output. 
 
2.2.4 Molecular imprinting 
 
Gasteiger Huckel charges were again used to charge the molecule and the 
bond energies were then minimised to approximately 0.01 kcal mol-1.  The 
peptide (FNEKTFGA) was computationally screened using the LEAPFROG 
algorithm within SYBYL 6.9, against a database containing 20 common 
functional monomers; the database is illustrated in Figure 2.2.1.  This was 
carried out to determine the strongest possible binding interactions with the 
monomers, monomers that interacted strongly with the template were chosen 
for the imprinting process.   
 
Acrylamide was predicted to have a high binding efficiency and therefore 
considered to be the best monomer for imprinting; ethylene glycol 
dimethacrylate (EGDMA) was used as the cross-linking monomer.  A 5 % 
template solution was made by dissolving 50 mg of the peptide (template), 50 
mg of acrylamide and 900 mg of cross-linker in 1057 µl (1 g) of DMF.  
Sonication produced a near clear solution to which 9 mg of initiator 
(1,1,azobis (cyclohexanecarbonitrile)) was added.  Continuous rotation of the 
reaction vessel under a 300 W Cermax, UV-Xenon fibre-optic light source 
(ILC Technology, CA94089, USA) for approximately two hours allowed the 
polymerisation to occur. 
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Figure 2.2.1 is an illustration of the structures of the functional monomers within the database.  The 
LEAPFROG algorithm within SYBYL 6.9 was used for the screening process, between the functional 
library and the peptide template (FNEKTFGA).  The binding energy of each monomer with the template 
was calculated, and the top four are represented in Table 2.3.1.  The monomers with the most non-
covalent interactions also possessed the highest binding energies (Piletsky et al., 2001a). 
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2.2.5 Solid phase extraction 
 
The polymer was carefully ground, after separation from the broken reaction 
vessel, using a pestle and mortar.  The polymer was wet sieved through a 
106 µm and a 38 µm filter using methanol; the 38 - 106 µm and the <38 µm 
(fines) fractions were both collected and a yield of 270 mg of 38-106 µm 
particles was obtained.  An SPE cartridge with 50 mg of polymer was 
prepared with 38 - 106 µm particles.  An SPE cartridge was packed with 50 
mg of the 38 - 106 µm fraction of the MIP.  The template was eluted from the 
SPE cartridge using alternate washes of varying concentrations of acid (10 
mM, 75 mM, 100 mM and 500 mM HCl) and base (10 mM, 75 mM, 100 mM 
and 500 mM NaOH) and RO (Reverse Osmosis) water. 
 
Solutions containing 0.005 mgml-1 to 0.4 mgml-1 of prothrombin, thrombin and 
albumin made using 100 mM phosphate buffer solution (comprising 3.5 g 
Na2HPO4 and 3 g of NaH2PO4 in 500 ml of RO H2O at pH 7.4) were used to 
measure the affinity and specificity of the MIP.  Prior to SPE, calibration 
curves of each protein’s spectral absorbance at 280 nm over the 
concentration range 0.005 mgml-1 to 0.4 mgml-1 were constructed.  
Subsequently 2 ml of each protein solution was filtered through the SPE 
cartridge and the spectral absorbance of the eluant was measured at 280 nm.  
The percentage absorbance of the protein at each concentration was 
calculated using the calibration and the eluant absorbencies.  After each 
filtration the cartridge was washed, to remove any bound protein, it was found 
that water removed the bound protein. 
 
106 
Chapter 2.  Computational Ligand design   Adrian Sylvester 
2.3 Results 
 
2.3.1 Modelling 
 
The tertiary structure of human prothrombin as determined by NMR or X-ray 
crystallography has not, as yet been submitted to the protein database.  
Therefore in order to construct a molecular model of human prothrombin, the 
homologies between human and bovine prothrombin species had to be taken 
into consideration.  Bovine prothrombin shows approximately 80% homology 
with human prothrombin, determined by comparison between the two native 
forms as deposited in the Swiss-Prot/TrEMBL databases (Figure 2.3.1).  
Similarly the complete X-ray crystal structure of bovine prothrombin has yet to 
be recorded in the PDB. Therefore the crystal structure of bovine 
meizothrombin (1A0H) as determined by X-ray diffraction (Martin et. al., 
1997), and the Ca2+-complexed structure of bovine prothrombin fragment 1, 
also determined by X-ray diffraction (Soriano-Garcia et. al., 1992) were both 
used to create a bovine prothrombin molecular model using SYBYL 6.9.   
 
Using the human prothrombin primary sequence (ExPASy accession number: 
P00734), extracted from the Swiss-Prot/TrEMBL databases, the primary 
sequence of bovine prothrombin (ExPASy accession number: P00735) was 
mutated (Figure 2.3.2).  The resulting sequence was minimised until the bond 
energies approximated to 0.05 kcal mol-1; this produced a structure that was 
considered to be a molecular model of human prothrombin based on its 
homology relationship with bovine prothrombin.  After minimisation the 
structure of the newly formed prothrombin model was checked against data 
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from the Swiss-Prot view of human prothrombin (P00734) on the ExPASy 
website.  The human prothrombin structure was then altered to represent the 
established data as necessary and minimised again. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.1 illustrates the homology between the amino acid sequences of human (P00734) 
and bovine (P00735) prothrombin.  The red boxes represent areas of dissimilarity between the
two sequences, which equates to approximately 81.1% homology between human and bovine 
prothrombin.  This homology data was acquired from a BLAST search comparison on the SIB 
BLAST network service using the Uniprot database, where the two sequences were aligned 
using the CLUSTAL W sequence alignment algorithm (http://ca.expasy.org/sprot/).  The 
European Bioinformatics Institute (EBI) produced a similar output when the two sequences were 
aligned (http://www.ebi.ac.uk/).
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Figure 2.3.2 represents the mutations imposed on bovine fragment 1 and meizothrombin 
sequences in order to produce a humanised prothrombin molecular model. 
 
 
Glutamic acid was modified to produce g-carboxyglutamic acid and was 
assigned specific Amber95 parameters and atom types, represented in Figure 
2.3.3 below. 
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NT
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Figure 2.3.3. γ- carboxyglutamic acid.  The extra carboxyl group attached to the Gamma 
carbon CG comprising of CE, OE3 and OE4 was charged with the following respective point 
charges 0.8054, -0.8188 and –0.8188.   
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Figure 2.3.4 represents a graphical output of our computational model of humanised bovine 
prothrombin.  The amino acid sequence of bovine prothrombin was extracted from the PDB 
(http://www.rscb.org/pdb/).  It was mutated manually to the human prothrombin sequence, 
which was retrieved from the ExPaSY molecular biology server (http://www.expasy.ch/). 
The bovine and human prothrombin primary sequences show 80% homology with each 
other, therefore increasing the potential of producing a valid protein model after 
minimisation.  Minimisation was undertaken using Gasteiger Huckel charges and the Tripos 
general-purpose force field.  The exposed area in red represents the 8-mer peptide chosen 
for molecular imprinting (right to left FNEKTFGA).   
As the 3D-structure of human thrombin and prothrombin have not yet been 
elucidated, the bovine structures, which show 80 % homology to the human 
structures, were used as templates for the modelling work.  The primary 
structure of prothrombin fragment 1 was mutated 27 times, which included 1 
deletion, 3 insertions and 23 replacement mutations; 40 amino acids were 
also replaced in prothrombin fragment 2.  Thrombin underwent 31 mutations, 
which included 30 single amino acid replacements and 1 deletion.  The bond 
energies in each structure were minimised over 100 thousand iterations, with 
the minimum target set at 0.05 kcal mol-1.  As the structures were to be used 
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as guides to the identification of potential imprinting sites, 100 thousand 
iterations was considered sufficient.  The bond energies in the last 1000 
iterations of the prothrombin minimisation were in the range 0.4-0.15 kcal  
mol-1.   
 
2.3.2 Molecular Imprinting of Peptide, FNEKTFGA 
 
The imprinted peptide (FNEKTFGA), representing 8 residues close to the 
exposed factor Xa cleavage site on the surface of prothrombin (Figure 1.2.1), 
was considered to be an interesting preliminary imprinting target.  It was also 
considered that the surface location of the site would allow the 8-mer 
imprinted polymer to bind prothrombin relatively easily from solution.  The 
screening of the peptide template (FNEKTFGA) with the 20 common 
imprinting monomers using the LEAPFROG algorithm within the SYBYL 6.7 
package, allowed us to visualise the strongest monomer-template 
interactions, and therefore select the best monomers for imprinting.  The 
binding energies for the strongest interacting four monomers with the 
template are represented in Table 2.3.1.  Acrylamide was chosen as the best 
monomer for imprinting the peptide template, due to the strong binding 
energy of 44.31 kcal mol-1, and therefore predicted strong interaction with the 
template.  A graphical representation of the interaction between the template 
and acrylamide is depicted in Figure 2.3.4. 
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Table 2.3.1 represents part of the table produced by the LEAPFROG algorithm, and shows 
the monomer name, structure and binding energies of the four strongest interacting 
monomers with the template (FNEKTFGA).
 
 
Template Acrylamide 
 
 
 
 
 
 
 
 
 
 
 Figure 2.3.5 is a computational representation of the interactions between acrylamide and 
the peptide template (FNEKTFGA), as predicted by the LEAPFROG algorithm within 
SYBYL 6.7.  The nitrile group (NH2) and the carboxy group (CO) of acrylamide interact 
non-covalently with various residues of the peptide template. 
 
 
 
 
The strongest binding energies are possessed by monomers that produce 
multiple non-covalent interactions with the template; the multiple hydrophobic 
interactions between acrylamide and the peptide are represented above in 
Figure 2.3.5. 
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There were initial concerns over the specificity of the MIP; therefore its affinity 
was assessed by assaying the SPE cartridge packed MIP’s affinity with 
varying concentrations of prothrombin, thrombin and albumin in solution.  The 
results of initial tests with prothrombin and thrombin using the concentration 
range of 0.02 - 0.4 mg ml-1 (or 2.78 x10-7 - 5.56 x10-6 M) are represented in 
Figure 2.3.6.  The experiments were repeated using the protein concentration 
range 0.1 - 0.005 mg ml-1 (or 1.39 x10-6 - 6.94 x10-8 M) and including albumin 
as a control protein to which minimal cross reactivity was expected. 
 
 
 
 
 
 
 
BA 
 
 
 
 
 
 
Figure 2.3.6 represents initial data describing the solid phase extraction of prothrombin (A) 
and thrombin (B) using the peptide (FNEKTFGA) imprinted MIP, which was ground and 
packed into an SPE cartridge.  Red represents the data corresponding to protein injections 
through the cartridge packed with the blank polymer and blue represents the peptide 
imprinted MIP.  Concentrations of prothrombin below 0.05 mg ml-1 seem to bind more 
strongly than the higher concentrations.  The blank polymer however seems not to show 
any trend in binding, and all concentrations of prothrombin and thrombin show trend-less 
binding to the blank polymer. 
 
As shown in Figure 2.3.6 the peptide imprinted polymer showed a small 
amount of selectivity towards prothrombin, however only at very low 
concentrations.  The lower concentration that would be expected in plasma 
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samples is approximately 0.1 mg ml-1, and this concentration of thrombin and 
prothrombin binds equally well in to the blank polymer.  However, the 
percentage of thrombin, compared to the percentage of prothrombin bound to 
the peptide imprinted MIP is higher at all concentrations above 0.05 mg ml-1.  
 
2.4 Discussion 
 
The molecular modelling of a reliable human prothrombin structure was 
attempted, with the aim of providing theoretical information on potentially 
interesting structural characteristics of human prothrombin.  This information 
would have been useful for the identification of structural regions of the 
prothrombin molecule, to provide potential templates for molecular imprinting 
experiments.  The application of molecular imprinting for the recognition of 
specific epitopes has been documented previously (Rachkov and Minoura, 
2001), and shares an analogous relationship with natural biomolecular 
recognition by monoclonal antibodies.  Native human prothrombin shares 
over 90% homology with inactive prothrombin and contains normal glutamic 
acid residues in place of the g-carboxyglutamic acid residues in the gla 
domain.  The modelling of the native human prothrombin gla domain 
therefore could have provided us with a graphical representation of a specific 
epitope.  Which may have provided the necessary target for the synthesis of a 
synthetic recognition element and its integration into an assay for native 
human prothrombin. 
 
Our computational experiments using a humanised form of bovine 
prothrombin produced a structure that possessed limited reliability as a 
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human prothrombin model.  However, useful information was obtained that 
lead to the determination of several interesting sites, which may have been 
useful epitopes for molecular imprinting experiments.  The prothrombin 
fragment 2/thrombin cleavage site was synthesised, and the peptide template 
was used to produce a bulk-imprinted polymer.  This site was considered 
useful because it possessed high prothrombin specific homology and a lack 
of homology with other blood borne proteins, as deduced by a homology 
BLAST-P search (ExPaSY: http://ca.expasy.org/sprot/).  The minimisation of 
our human prothrombin computational model, using the Gastieger-Huckel 
force field together with Tripos atom types and charges, did not accommodate 
long-range ionic forces and protein-metal interactions; therefore the gla 
domain was inaccurately modelled.  The gla domain of native human 
prothrombin contains 10 g-carboxyglutamic acid residues that complex with 8 
calcium ions in a specific structural conformation.  Long-range ionic forces 
restrain the calcium ions with the carboxyl-oxygen atoms of carboxyglutamic 
acids in the gla domain (Li et. al., 1995), which promotes binding of the gla 
domain to phospholipid membranes and the activation of prothrombin to 
thrombin.  
 
The modelling of bovine (Hamaguchi et. al., 1992) and human prothrombin 
fragment 1 (Li et. al., 1995), using the coordinates of corresponding residues 
in the structure of bovine prothrombin has been attempted previously.  In 
1995, Leping Li and colleagues modelled the calcium coordinated ‘gla’ and 
fragment 1 domain of human prothrombin, using the previously elucidated 
crystal structure of bovine prothrombin fragment 1 (Soranio-Garcia et. al., 
1992) as a template.  Careful simulation protocol, which accommodated long-
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range ionic forces between calcium and carboxyl-oxygen atoms, was applied 
to solve the highly ionic gla domain of human prothrombin.  Li et. al., used a 
modified version of the Amber 3 force field for the energy minimisation of the 
gla domain of human prothrombin, however when we attempted to apply the 
Amber 4.1 force field, (Amber95) (Weiner et. al., 1984), modified to include 
parameters for calcium ions, minimisation did not proceed.  The more general 
MMFF94 and Gastieger-Huckel force fields included within the Sybyl 6.9 
package again did not minimise the prothrombin molecule correctly.  The 
parameterisation of calcium ions was a major problem associated with the 
unmodified force fields, as they were only recognised as dummy atoms 
without the correct charges and electrostatic parameters.  Therefore 
minimisation of the metal complexed prothrombin molecule produced an 
unfolded gla domain much like that of abnormal prothrombin, which contains 
glutamic acid residues in place of the g-carboxyglutamic acid residues.  It was 
also found that the Amber95 force field experienced difficulties in assigning 
atomic parameters, such as point charges and atom types to the extra 
carboxyl group of the g-carboxyglutamic acid residues.  Parameters were 
assigned to g-carboxyglutamic acid using glutamic acid as a template; 
therefore both carboxyl groups received identical parameters and sequential 
atom types, which may not have been correct. 
 
The imprinting of protein templates has been achieved many times by 
methods such as surface grafting (Kempe et. al., 1995; Piletsky et. al., 2000a 
and 2000b; Bossi et. al., 2001) and the use of hydrogels (Burow and Minoura, 
1996; Liao et. al., 1996; Hjerten et. al., 1997).  These two methods allowed 
the use of hydrophilic macromolecular templates such as peroxidase 
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enzymes (Bossi et. al., 2001), Ribonuclease A, Myoglobin and Growth 
Hormone (Kempe et. al., 1995; Hjerten et. al., 1997) to generate template 
specific synthetic adsorbents, which could be used in solid phase separation.  
The use of a peptide that represents only part (or an epitope) of a protein in 
molecular imprinting is an attractive idea, due to the removal of the need for 
stringent protein treatment and aqueous imprinting conditions.  The epitope 
approach to MIP production (Rachkov and Minoura, 2001) shares an 
analogous relationship with antibody recognition of protein epitopes, and 
combined with computational methods can enable the synthesis of synthetic 
adsorbents without the use of expensive and chemically cumbersome protein 
templates.   
 
The design of the peptide (FNEKTFGA) imprinted MIP was considered 
rational, due to the completion of initial molecular modelling of human 
prothrombin that allowed the selection of the peptide through the visualisation 
of surface located regions of the protein.  A BLAST search for homology 
relationships with other proteins using the Expert Protein Analysis Server 
website (ExPaSY: http://ca.expasy.org/sprot/), showed that the peptide was 
unique to prothrombin. The MIP did not yield good separation results 
however, which may have been due to the relatively small size of the 
representative peptide compared with the macromolecular size of 
prothrombin.  For this reason it is now considered that the peptide would not 
have allowed the production of sufficient specific covalent binding sites in the 
MIP.  To attempt the capture of such a large protein, within a complex 
medium such as plasma, using such a small specific recognition area would 
be difficult.  Previously the epitope approach has yielded good protein and 
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template binding, however a relatively large proportion (4 amino acids out of 
9) of a small target molecule was used (Rachkov and Minoura, 2001).  But 
the epitope approach to protein imprinting has not been applied to many other 
areas of protein recognition.   
 
It is known that the gla domain of native prothrombin is complexed with 
calcium ions that impose a conformational structure on the N-terminal region 
of prothrombin, which is absent in abnormal prothrombin (Bloom and Mann, 
1978).  Studies have emphasised the fact that the gla domain possesses 
much of the antigenic and structural variation between native and abnormal 
prothrombin (Blanchard et. al., 1983).  Therefore the proposal that the gla 
domain, or a peptide representing a specific region of the gla domain could 
act as a native prothrombin specific antigen is an interesting one.  This idea 
was pursued to the point of contracting out the synthesis of a peptide region 
of the gla domain, incorporating four γ-carboxyglutamic acid residues.  
However this contract could not be fulfilled due to logistical and financial 
complications associated with obtaining modified glutamic acid residues.   
The target, representing the gla domain, was still considered to be interesting 
with respect to potential prothrombin recognition of the ‘gla’-peptide molecular 
imprinted polymer.  However, research has now shown that the gla domain 
may not be the ideal antigenic target for the development of a specific native 
prothrombin assay, due to the significant homology it shares with other gla 
containing proteins in the blood.  This research indicated that antibodies 
directed to the prothrombin gla domain, also recognised proteins such as 
protein C, factor VIII and calcitonin (Brown et. al., 2000), which would 
potentially give false positive results in any assay.  One alternative could be 
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to reliably model the human gla domain and computationally identify synthetic 
ligands, which show strong electrostatic binding to the calcium dependent 
prothrombin conformation.  This has been achieved previously with human 
Factor VII, and a reliable assay was developed from such research (Morril et. 
al., 2002). 
 
A narrow toxic-therapeutic ratio associated with warfarin oral anticoagulation 
therapy (OACT), may induce thrombotic and haemorrhagic complications, 
therefore strict monitoring of such therapy is essential.  Currently the 
monitoring of OACT is achieved through the regular sampling of blood and 
subsequent measurement of the INR (Chapter 1.5).  The current monitoring 
methods however, do not predict all of the complications associated with 
OACT (Palarati et. al., 1996; Palarati et. al., 1997; Pengo et. al., 2001), 
therefore more accurate OACT monitoring methods must be investigated.  
The monitoring of the native prothrombin antigen has been shown to predict 
OACT associated complications with increased accuracy, compared with the 
INR (Furie et. al., 1984; Furie et. al., 1990; Kornberg et. al., 1993).  The 
production of prothrombin specific antibodies, involves the immunisation of a 
laboratory animal with prothrombin.  Therefore the production of a synthetic 
prothrombin antibody, which involves the imprinting or templating effect of the 
complete protein, is also a valuable proposal.  However, molecular imprinting 
is a technology that is not so broadly applicable to aqueous imprinting 
methods or protein recognition.  
 
Molecular modelling of human prothrombin, using bovine prothrombin as an 
initial protein structure, did not produce a reliable model of the calcium-
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complexed human prothrombin conformer.  We have produced a novel 
synthetic polymer, using a computationally identified prothrombin specific 
peptide sequence, located at the thrombin cleavage site.  However, as 
described above, the polymer did not recognise prothrombin as we had first 
anticipated, therefore we will move on to the imprinting of the complete 
prothrombin molecule. 
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Poly-aminophenylboronic acid 
(poly-APBA) and aqueous 
imprinting of prothrombin 
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Here, the aims include the production of polymeric adsorbents in aqueous 
environments that have specificity for prothrombin in homologous solutions.  
The selectivity of these adsorbents should be such, that they should 
selectively bind prothrombin in heterogeneous solutions such as plasma.  The 
prothrombin selective adsorbents should be incorporated into a sensor 
system whose interface would provide comprehensive real time data on the 
binding of prothrombin from various solutions.  The same sensor system and 
interface should be used to incorporate an antibody recognition element 
directed towards the same target protein as with the polymeric absorbents.  
This would allow the direct comparison of biological and synthetic adsorbents 
in the aqueous/biological environment.  The majority of the work will involve 
the use of the monohydrate boronic acid derivative, 3-aminophenylboronic 
acid (APBA), but acrylamide gel will also be used in an aqueous prothrombin 
imprinting study. 
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Figure 3.1 is an illustration of the two dimensional structure of poly-aminophenylboronic acid.  The 
boronic acid residues are negatively charged and interact with any positively charged regions of 
proteins or target molecule. 
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3.1. Introduction 
 
3.1.1 Surface plasmon resonance 
 
Surface plasmon resonance (SPR) is an optical transducer based technique 
that relies on the total internal reflection of light within a prism.  Light energy 
passing beyond the optical interface forms an evanescent field, which can be 
absorbed by free electrons in a thin metal coating on the surface of the optical 
interface.  The angle of incidence at which SPR occurs can be used to 
monitor the rate and extent of biological interactions with surface bound 
materials in real-time.  For example, it is possible to directly visualise the 
binding of injected template to transducer-surface immobilised antibodies; the 
change in the angle of incidence is directly related to the binding of additional 
material to the transducer surface and the medium passing over the surface.  
 
Therefore SPR can be characterised as a label-less real time biospecific 
interaction analysis system, which thus derives the term Biacore.  A surface 
plasmon is a longitudinal or transverse charge density wave propagating 
along the interface between a metal surface and a dielectric (good insulator).  
The electrons in the metal must exhibit free-electron (Boardman, 1982) (or 
gas) like behaviour for optical excitation of the surface plasmon to occur.  The 
electrostatic potential of the metal ion cores must have negligible effect on the 
movement of the electrons in the metal lattice (Liedberg et. al., 1993), 
therefore only metals such as gold, silver, copper and aluminium are useful 
for SPR. 
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Figure 3.1.1 illustrates the equations relating to surface plasmon propagation and excitation.   
 
Equation 1 describes the dispersion relationship for a plasmon propagating 
along the interface between a metal with a complex dielectric function ε (ω) 
and a dielectric with dielectric constant εa, where c is the speed of light and 
ksp is the wave vector for the propagating plasmon.  Equation 2 describes the 
complex dielectric function of the metal film.  As the propagating wave vector 
is always larger than the ambient wave vector (ka = (ω/c)√εa), it is not possible 
to excite a surface plasmon through direct reflection of light on the metal film.  
The use of an attenuated total reflection (or Kretschmann) configuration 
solves this problem, which is illustrated in Figure 3.1.2.  The evanescent 
wave present outside the prism after total reflection sets up a surface 
plasmon at a given angle θsp (Boardman, 1982; Kretschmann, 1971). 
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Figure 3.1.2 is a schematic representation of the Kretschmann (or attenuated total 
reflection) configuration used for optical excitation of a surface plasmon (ksp), which is set 
up at the interface between the metal and the ambient (less dense medium), when kx is 
equal to ksp (adapted from Lundstrom, 1994). 
 
 
 
 
 
The thin metal layer is coupled to the high refractive index prism either by 
direct deposition, or by deposition onto a glass slide that is optically coupled 
to the prism by an index matching polymer or liquid.  The part of the system 
that interacts with the biological molecules and allows the biomolecular 
interaction analysis to occur is the ambient side of the metal layer.  As the 
surface plasmon propagates along the metal/ambient interface an evanescent 
wave extends into the ambient.  This wave, which is influenced by changes in 
the refractive properties of the ambient in turn, influences the surface 
plasmon resonance angle and thus creates a measurable response.  It has 
also been found that changes in the optical properties closer to the 
metal/ambient interface influence the evanescent wave and produce larger 
effects than changes further away.  The mathematical explanation of the 
evanescent wave is described in Boardman, 1982. 
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As specific binding of biomolecules is important in biomolecular interaction 
analysis, it becomes problematic when the bare metal surface does not 
promote specific adhesion of biomolecules.  One method to solve this 
problem is to use a coupling matrix, which may consist of a hydrogel such as 
carboxymethylated dextran.  This hydrogel (illustrated in Figure 3.1.3) allows 
the covalent attachment of specific biomolecules to the metal surface using 
standardised coupling chemistries (see materials and methods) (Liedberg et. 
al., 1993 and Lundstrom, 1994).  The use of a coupling matrix also allows for 
a greater number of interaction sites compared to a monolayer and their 
increased accessibility, all due to the increase in available surface area.  The 
hydrogel matrix and coupling chemistries have been described in detail in the 
following references Lofas and Johnsson, 1990 and Johnsson et. al., 1991. 
 
The SPR based laboratory biosensor system developed by Biacore AB 
(Uppsala, Sweden) is one such system that can accurately monitor the 
binding of template to recognition element in real time.  Molecular recognition 
elements such as antibodies can be amine-coupled to the surface of a gold 
chip coated with carboxymethyl-dextran hydrogel, whereas a molecularly 
imprinted polymer such as poly-APBA can be grafted directly to an 
unmodified gold surface.  A simple schematic of the Biacore SPR system is 
illustrated in Figure 3.1.3 below. 
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Figure 3.1.3 represents a schematic of the Biacore system from Pharmacia Biotech 
(Uppsala, Sweden).  The sensing chip is also represented in an exploded view, which 
details the activated hydrogel matrix allowing specific covalent attachment of ligands.  The 
graph depicted in the figure represents the information produced by the diode array; the 
surface plasmon resonance angle corresponds to the minimum in the graph.  This 
information is then translated into response units by the system software. 
 
 
 
 
 
 
A major benefit that the Biacore system possesses is its ability to allow the 
regeneration of ligands covalently attached to the chip surface, which can 
generally be achieved through the changing of conditions such as pH, Ionic 
strength and the presence of surfactants in a wash buffer (Dillon et. al., 2003; 
Quinn et. al., 1997).  This regeneration allows for prolonged use of the same 
immobilised ligands and therefore study of kinetics and affinity analysis 
through subsequent injections of varied concentrations of analyte.  A change 
in the resonance signal of 1000 RU corresponds to an increase in the surface 
plasmon resonance angle (1000 RU =0.1o). 
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3.1.2 Aqueous protein imprinting 
 
Molecular imprinting, as a technology has grown rapidly over the last 20 
years, the production of synthetic adsorbents that recognise targets ranging 
from pharmaceuticals (ampicillin, erythromycin A, tylosin) to food 
components, additives and contaminants (amino acids, carbohydrates, 
menthol, caffeine, listeria and staphylococcus sp.) to herbicides, pesticides 
and trace metals (atrazine, triazine and Co2+) to name but a few (Reviewed in 
Ramstrom et. al., 2001).  Originally imprinting was achieved through the 
production of bulk polymers, which were ground into smaller particles and 
packed into columns for solid phase extraction purposes.  This strategy 
however is relatively limited with regard to the incorporation of MIPs into 
biosensor-based formats, which can be utilised without the need for complex 
laboratory analysis and methodology.  The incorporation of an aqueous 
imprinted hydrogel comprising of acrylamide and its derivatives, into a solid 
phase extraction cartridge yielded good separation of template molecules 
from a heterogeneous mixture (Hjerten et. al., 1997).  In this study horse 
myoglobin was selectively removed from a mixture also containing whale 
myoglobin by adsorption to the column of horse-myoglobin imprinted 
polyacrylamide gel beads.   
 
The incorporation of enzymes into electrochemical biosensor electrodes first 
demonstrated in 1962 (Clark and Lyons, 1962) has generated new ideas 
whereby MIP technology could in principle, be applied to the development of 
simple biosensors. Currently however, the immobilisation of macromolecular 
biomolecules onto transducer microsurfaces using conventional methods 
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such as cross-linking, covalent attachment and hydrogel or membrane 
entrapment suffers low reproducibility and poor spatially controlled deposition 
(Cosnier, 1999).  This remains to be a major problem for the production of 
synthetic biosensors.  Electropolymerisation of acrylamide and phenylboronic 
acid based monomers onto SPR, QCM and standard gold electrochemical 
electrode surfaces has been achieved, in an attempt to develop a glucose 
sensor based on the swelling properties of such immobilised hydrogels 
(Gabai et. al., 2001).  Boronic acid monomers and the swelling properties of 
hydrogels were used together with a QCM resonator to detect nucleotide 
binding (Kanekiyo et. al., 2000). 
 
Aminophenylboronic acid (APBA) was coated on the inner surface of 
microplate wells in an attempt to produce an affinity matrix, which showed 
specificity for the protein templates, microperoxidase, horseradish-
peroxidase, lactoperoxidase and haemoglobin.  The polymerisation process 
used aqueous ammonium persulfate (APS (aq)) to coat the microplate wells 
with a thin graft of the protein-specific homopolymer.  The stabilising function 
of the polystyrene wells, to which the polymer was grafted, and the spatial 
orientation of template functional groups were critical factors affecting 
polymer formation and recognition of the template (Bossi et. al., 2001).  
Boronic acid functionalised monomers have been used in aqueous molecular 
imprinting, with application to nucleotide detection (Ozdemir and Tuncel, 
2000; Tuncel and Ozdemir, 2000; Kanekiyo et. al., 2000), glycated-protein 
affinity sorbents for HPLC (Koyama and Terauchi, 1996), extraction of B-
blocking drugs from plasma (Martin et. al., 1993) and glucose detection 
(Gabai et. al., 2001).  The boronic acid monomer has desirable functionality 
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with regard to non-covalent template recognition.  Non-covalent imprinting is 
specifically useful when dealing with proteins, as covalent attachment to 
proteins may involve degradation or modification of the target; hence a large 
number of electrostatic and hydrophobic interactions are desirable in large 
molecule or protein imprinting.  Advantages of the APBA approach to protein 
imprinting include its simple integration with the SPR transducer system, as 
polymerisation readily occurs on the gold chip surface.  Due to the real-time 
monitoring capabilities of the SPR transducer system, polymer thickness can 
easily be regulated, which aids in the monitoring of polymer homogeneity and 
template affinity. 
 
3.2.  Materials and methods 
 
The 96 well Maxisorp® plates were supplied by Fisher UK (Loughborough, 
UK).  Prothrombin, thrombin, albumin, acrylamide, N, N-methylene 
bisacrylamide, ammonium persulphate, Ecarin (from Echis carinatus) and p-
nitroanilide were all supplied by Sigma (Dorset, UK). Acros organics 
(Loughborough, UK) supplied the 3-Aminophenylboronic acid monohydrate 
and the UV initiator, 2, 2’-azobis(2-methylpropionamide) dihydrochloride.  
Biacore International SA UK (Stevenage, Hertfordshire, UK) supplied Gold J1 
Biacore chips in a self-assembly kit (BR-1004-05).   
 
3.2.1 Acrylamide gel protein imprinting 
 
A solution comprising of N N-methylene bisacrylamide (16 mM), acrylamide 
(810 mM), 2, 2’-azobis(2-methylpropionamide) dihydrochloride (15 mM) and 1 
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ml of NaHCO3/Na2CO3 buffer pH 6.0 was produced for the blank polymer gel.  
For the prothrombin imprinted polymer gel, the carbonate buffer was replaced 
with 1ml of 2.0 mgml-1 prothrombin solution in pH6.0 NaHCO3/Na2CO3 buffer.  
The mixtures were sonicated under vacuum to remove the majority of 
dissolved gas.  A high intensity UV light source (UV Aprint 100 CVI, Dr. Hölne 
AG) was used to polymerise 40 µl of the acrylamide solution placed into the 
wells of a 96-well microtiter plate; polymerisation took between 5-10 minutes.  
The template was washed from the gel disks overnight with 
NaH2PO4/Na2HPO4 buffer + 1% Tween 20 pH 6.0.  The incubation of serial 
dilutions of prothrombin and thrombin for 90 minutes in the wells containing 
gel disks, was followed by 3 1 hr washes of NaH2PO4/Na2HPO4 buffer to 
remove excess.   
 
Prothrombin activation was achieved using 100 µl of 5.4 Uml-1 of Ecarin 
solution dissolved in pH 8.0 NaH2PO4/Na2HPO4 buffer, subsequently 100 µl 
of 0.25 mgml-1 chromogenic substrate T1637 was added to each gel disk.  
Activated prothrombin and thrombin quantification was then achieved by the 
kinetic monitoring of the optical absorbance at 405 nm of the solution in the 
wells containing the gel disks. 
 
3.2.2 Poly-aminophenylboronic acid imprinting of prothrombin 
 
A Technobiochip Libra mod α (10 MHz) piezoelectric crystal reader using the 
Libra 3.1 control software was used in conjunction with 14 mm piezoelectric 
crystals from Technobiochip for the preliminary stage of this study.  The 
second stage involved the use of a Biacore 3000 (Biacore AB, Uppsala. 
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Sweden) SPR platform with standard gold surface J1 Biacore chips (Biacore 
UK).  The grafting of prothrombin imprinted poly-APBA onto the surface of a 
J1 Gold unmodified chip surface was achieved as follows.  Prothrombin was 
diluted in pH 6.0 phosphate buffer (NaH2PO4/Na2HPO4) and 10 µl was added 
to 10 µl of 100 mM aminophenylboronic acid (aq) (15.5 mg ml-1), 10 µl of this 
mixture was added to 10 µl of 100 mM ammonium persulphate solution (22.8 
mg ml-1).  The mixture was placed on the gold surface of the Biacore chip, 
making sure the four channels were covered, and allowed to polymerise for 
25 - 30 minutes.  This procedure was first implemented to the piezoelectric 
crystal grafting.  After polymerisation the chip/crystal was washed excessively 
with deionised H2O and 10 mM HCl and conditioned in-situ until a stable 
baseline was achieved.  Calibrations using increasing concentrations of 
prothrombin, thrombin and albumin were subsequently achieved. 
 
3.3.  Results 
 
The grafting of the prothrombin imprinted poly-aminophenylboronic acid 
(APBA) onto the non-modified gold surface of a J1 Biacore chip yielded 
interesting results with homogeneous solutions of prothrombin, thrombin and 
albumin, with a concentration range of 0.01 – 15 nM.   Polymerisation of 
imprinted ABPA for 20 minutes produces an increase in the relative SPR 
response of between 20000-40000 RU.  However the material deposited on 
the surface, quickly washes off to a level that is approximately 10000 RU 
higher than a blank chip.  The resulting monolayer surface displayed 
quantitative recognition of homogeneous solutions of prothrombin at a 
concentration range of 0.01 nM to 14.2 nM as shown in Figure 3.3.1A.  The 
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same prothrombin imprinted polymer monolayer displayed a significantly 
reduced recognition of homogeneous solutions of thrombin at a similar 
concentration range of between 0.01nM to 10nM as shown in Figure 3.3.1A.   
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
 
 
 
 
 
Figure 3.3.1A represents the relative SPR response of the injection and subsequent washing of
homogeneous solutions of prothrombin and thrombin onto the gold-surface grafted prothrombin-
imprinted poly-APBA.  It can be seen from the graph that the affinity of the imprinted polymer for
prothrombin (red) is approximately 10 times that for thrombin (blue).  In Figure 3.3.1B, the affinity for
thrombin and prothrombin of a blank polymer grafted to the surface of a similar J1 Biacore chip is
represented.  It can be seen that the response for prothrombin (red) matches that for thrombin (blue),
which suggests a lack of high affinity binding sites that were present in the imprinted polymer.  Not
particularly reproducible on different chips, see Appendix D. 
 
 
The wash procedure for the removal of homogeneous protein samples from 
the imprinted polymer surface utilised 10mM and 100mM HCl.  The majority 
of the homogeneous sample was removed by a single 10 µl injection of 10mM 
HCl, and further injections return the response to the preinjection level.  More 
stubbornly bound protein could be removed with 10 µl injections of 100mM 
HCl. 
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Injections of homogeneous concentrations of albumin at concentrations 
similar to the concentration range used for prothrombin and thrombin, 
suggested minimal non-specific recognition of albumin by the prothrombin-
imprinted polymer.  The non-specific recognition of albumin at plasma 
concentrations i.e. 150 - 750 µM, was as high as that for prothrombin 
concentrations of 10 nM (i.e. 1400 RU), as represented in Figure 3.3.2B. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.2A represents the injection of albumin over a concentration range of 0.01 nM –
10 nM onto both the blank (blue) and the prothrombin-imprinted (red) polymer grafts.  It 
can be seen here that at this concentration range, there is minimal relative response, 
which relates to minimal specific recognition.  
Figure 3.3.2B is a representation of the results obtained from injection of plasma 
equivalent concentrations of albumin (i.e. 150 – 750 µM).  The results show that such high 
albumin concentrations could potentially mask the responses obtained from specific 
recognition of prothrombin in plasma samples. 
BA 
 
The polymers were also tested for their affinity for prothrombin in more 
complex solutions such as plasma and 100 kDa protein depleted plasma.  
The results of these experiments were somewhat disappointing with respect 
to the response elicited from the injection of prothrombin-spiked plasma onto 
the prothrombin-imprinted polymer.  A bulk increase in the SPR response was 
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created on injection of spiked 1:10 diluted whole plasma, indicating that there 
was a deposition of material on the polymer or on the chip surface itself.  
Calibrations using spiked 1:10 diluted whole plasma therefore produced 
insignificant results, due to the bulk deposition effect.  The wash procedure in 
this case did not remove all of the injected plasma sample, and the addition of 
detergents such as 0.1% SDS and 0.1% Tween20 to 10 mM HCl did not 
alleviate the situation with regard to removal of the surface bound material. 
 
Figure 3.3.3 represents the poor quality of the results obtained when spiked filtered 
plasma is injected onto the imprinted polymer graft (red).  The concentration range with 
which the polymer shows any recognition for prothrombin seems to have reduced from 
0.01 nM – 10 nM with homogeneous solutions to 1 nM – 10 nM with spiked filtered 
plasma samples.  The relative response elicited by the polymer due to a prothrombin 
spike of 6 nM is approximately four times smaller than that elicited from an injection of 
a 6 nM prothrombin homogeneous solution.  The blank polymer (blue) gave reduced 
responses to equivalent prothrombin spike concentrations.
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A filtration method was employed to remove the fraction of plasma greater 
than 100 kDa; plasma samples were deposited into a centrifugal cartridge, 
which was spun at 9000 xg for 1 hour and 20 minutes.  Dilutions (1:10) of the 
<100 kDa fraction were spiked with prothrombin and injected onto the 
prothrombin-imprinted polymer graft on the Gold J1 Biacore chip.  The quality 
of the response elicited by spiked filtered plasma injections, does not reflect 
the response elicited due to the injection of homogeneous prothrombin 
solutions. 
 
3.4.  Discussion 
 
 
The use of the piezoelectric crystal platform for the aqueous imprinting of 
prothrombin with poly APBA monohydrate, yielded results that suggested 
affinity of prothrombin imprinted pAPBA for its target.  However the instability 
of this detection platform caused difficulties in obtaining and interpreting these 
results.  Therefore, it was decided to utilise the distinctly more stable and time 
efficient Biacore 3000 platform for the pAPBA imprinting studies. 
 
Gaining useable results from acrylamide imprinting of prothrombin in the 96 
well micro titre plates also proved to be difficult.  Gel discs were produced in 
the wells of the micro titre plates during the imprinting/polymerisation process, 
however gas bubbles were created inside the gel disks, which caused the 
plate reader to give ambiguous results.  When the assay reagents (Ecarin 
and chromogenic substrate T1937) were added, the disks lifted from the base 
of the wells, which amplified the ambiguity of the result from the plate reader.  
It may be suggested that the affinity of the prothrombin imprinted-acrylamide 
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disk surface was not sufficient enough for the capture of prothrombin, and its 
subsequent quantification.   
 
Hjerten and colleagues however showed that acrylamide gel could show 
selective recognition for proteins. In contrast to our work however, the 
acrylamide gel used here was granulated and then packed into SPE beds 
(Liao et. al., 1996; Hjerten et. al., 1996 and 1997).  This granulation allowed 
for an increase of surface area and hence of the higher affinity selective 
protein recognition sites, created during the imprinting process.  Packing of 
the prothrombin-imprinted polymeric gel granules into SPE columns 
increased the efficiency of specific protein recognition, by essentially forcing 
the proteins of interest closer to the high affinity sites contained within the gel.   
 
Molecularly imprinted acrylamide has been used to create hydrogels capable 
of distinguishing between isomerically distinct forms of glucose (Wizeman and 
Kofinas, 2001).  These hydrogels were dried (at 50oC) and washed 
extensively (up to 5 days), the addition of a measured amount of dried 
hydrogel to a solution containing glucose allowed investigators to measure 
the amount of glucose bound to the hydrogel.  This method however would 
not lend itself to simple quantification of prothrombin concentration in complex 
aqueous solutions such as plasma or blood.  The dried hydrogel however 
would promote the efficient uptake of solution, and promote the efficient 
binding of target proteins. 
 
The adaptation of the Biacore platform to acrylamide imprinting of 
prothrombin was unsuccessful.  The gold surface of the Biacore chip allowed 
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for attachment of a monolayer of the imprinted material, which as discussed 
previously did not provide enough specific high affinity sites for prothrombin 
binding.  We then directed our attention to the aminophenylboronic acid 
(APBA) imprinting of prothrombin, which showed some encouraging results 
with the piezoelectric crystal detection system.  The grafting of a thin film of 
imprinted poly-APBA onto an undocked Biacore chip was simple to achieve, 
the mixture of APBA, ammonium persulphate and prothrombin was simply 
placed onto the gold surface and allowed to polymerise.  A rapid 
polymerisation time associated with poly-APBA would cause major fluidic 
damage to the Biacore system.  Therefore, in contrast to the immobilisation of 
antibodies, this procedure was not controlled using the surface immobilisation 
wizard available within the Biacore control software.   
 
Aminophenylboronate has been used previously to distinguish between 
glycosylated and non-glycosylated proteins such as haemoglobin (Middle et. 
al., 1983), albumin, macroglobulin and transferrin (Gould and Hall, 1987).  
APBA has also been use in copolymer studies with acrylamide; the 
recognition of nucleotides and monosaccharides via imprinting was achieved 
here (Sallacan et. al., 2002).  Therefore the use of the phenylboronate ligand 
in affinity recognition/separation studies has produced interesting results in 
the past.   
 
The work here was inspired by the work of Bossi and colleagues, where the 
molecular imprinting of various peroxidase enzymes using APBA, produced 
efficient selective recognition of each target on its reintroduction (Bossi et. al., 
2001).  They showed selective recognition of target proteins by thin layer 
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imprinted APBA grafts on the inner surface of micro plate wells, showing that 
imprinted cavities need not be created to provide selective recognition of 
protein targets.  They also demonstrated the benefits of the imprinting effect, 
when they confirmed that the blank polymer only showed non-specific binding 
of the protein targets.  Similar work using chemical grafting of molecularly 
imprinted poly-APBA has achieved good selective recognition of epinephrine 
and horseradish peroxidase (Piletsky et. al., 2000a). 
 
As a direct comparison to the previous poly-APBA imprinting work (Piletsky 
et. al., 2000; Bossi et. al., 2001), our prothrombin imprinting has produced 
similar results with regard to the rebinding of homogeneous template in 
aqueous solution.  As can be seen from the results in Figures 3.3.1A and B 
the injection of prothrombin onto the imprinted graft generates a much larger 
response than thrombin or prothrombin onto the blank graft, which 
demonstrates the imprinting effect.  The preparation of homologous 
prothrombin solutions in 10 mM sodium acetate buffer pH 4.0 conferred the 
largest responses on reapplication to the immobilised prothrombin imprinted 
polymer.  However the fact that homogeneous solutions of prothrombin could 
be recognised by a prothrombin imprinted MIP is only a starting block for the 
development of a prothrombin diagnostic test.  Such a diagnostic test should 
be able to quantify prothrombin from complex solutions such as plasma or 
blood.   
 
The mechanism of recognition of the prothrombin-imprinted polymer is most 
likely to be via interaction of many weak ionic interactions with the target 
protein.  This explains why the pH of both the polymerisation mixture (pH 6.0) 
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and of the rebinding buffer (pH 4.0), were both critical for selective recognition 
of prothrombin.  At pH 4.0 there is an overall positive charge on prothrombin, 
therefore exposed boronic acid ligands are able to bind more easily to 
prothrombin.  The imprinting effect in this situation is of obvious importance 
for prothrombin selectivity, as the boronic acid ligands would be arranged in 
such a manner to facilitate prothrombin rebinding.  This mechanism however 
does not lend itself to the specific recognition of large proteins in complex 
media, where the potential for non-specificity is high due to the presence of 
various proteins that posses many similar structural and ionic/electrostatic 
characteristics.  This reason would therefore explain why the injection of 
prothrombin spiked plasma samples did not produce such encouraging 
results with respect to the specific recognition of prothrombin.  A major source 
of non-specific binding could have been due to a potentially high 
concentration of fibrinogen, which is known to efficiently bind to gold surfaces 
through strong electrostatic and/or chemical binding upon incubation with 
plasma (Kanagaraja et. al., 1995; Eriksson and Nygren, 1997).   
 
Another reason for the poor response changes on injection of plasma and 
spiked plasma samples maybe due to a buffering effect gained from the 
plasma proteins, which may have created a non favourable pH for 
prothrombin binding, even though the plasma was diluted in buffer.  A buffer 
composed of 10 mM sodium acetate at pH 4.0, would allow prothrombin and 
other plasma proteins of comparable pI (approximately 4.6) to become 
charged in the same way, and therefore possess similar affinities towards the 
imprinted polymer.   
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This chapter describes the production of polyclonal antibodies with specificity 
and affinity for the native prothrombin antigen (NPA), and how they could aid 
in the development of an assay for the monitoring of oral anticoagulation 
therapy using vitamin K antagonists such as warfarin.  The immobilisation of 
these polyclonal antibodies onto an SPR based gold chip surface would allow 
a direct comparison of their template recognition properties with the 
prothrombin imprinted aminophenylboronic acid polymer, as described in 
chapter 3.  Importantly, the antibody should possess the specificity and 
sufficient affinity to recognise and bind to the native form of prothrombin in a 
complex mixture also containing various heterogeneous species of abnormal 
prothrombin. 
 
4.1 Introduction 
 
The routine monitoring of oral anticoagulation therapy in UK hospital 
laboratories is achieved through automated application of the prothrombin 
time (PT).  However, despite current automation technology, point of care 
devices, more stringent regulation of thromboplastin manufacture and efforts 
to improve monitoring standardisation (Reviewed in Poller, 1987; Talstad, 
2000), haemorrhagic and thrombotic complications associated with 
prothrombin time (PT) monitored oral anticoagulation therapy (OACT) 
patients are unacceptably high.  Antibodies possess specificity and affinity 
qualities that make them desirable capture phases for their incorporation into 
highly sensitive assays.  However, the complexity of blood provides a 
stumbling block to most blood-protein assays. The application of native-
prothrombin specific monoclonal antibodies in the development of a 
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monitoring assay, could potentially reduce the complication rate associated 
with OACT and its’ monitoring.  Antibodies for use with such an assay should 
be specific enough to bind native prothrombin in a complex solution such as 
blood or plasma, as well as in homogeneous solutions. 
 
Studies have shown that the Native Prothrombin Antigen (NPA) could provide 
a more efficient method in the monitoring of OACT using vitamin K 
antagonists.  Antibodies directed towards the NPA were incorporated into a 
radioimmunoassay RIA to measure the native prothrombin antigen in warfarin 
treated patients (Blanchard et. al., 1983).  A study using these antibodies 
showed that the native prothrombin concentration correlated well with the 
occurrence of haemorrhagic or thrombotic complications associated with 
OACT.  The results also indicated that the state of anticoagulation of a patient 
could be assessed with greater accuracy using the NPA-RIA, rather than the 
standard INR methodology (Furie et. al., 1984).  Following the preliminary 
work undertaken in the early 80s, Furie et. al. demonstrated, in a randomised 
controlled clinical trial, that the use of their NPA-RIA for the monitoring of 
OACT could reduce the associated complications from 8.8% by 85% to 1.3% 
(Furie et. al., 1990).  These findings were reiterated in 1993 when an ELISA, 
using a similar mono-specific polyclonal antibody for the calcium stabilised 
conformer of native prothrombin, was used to demonstrate decreased OACT-
associated complications compared with the INR (Kornberg et. al., 1993).  
Native prothrombin concentrations in non-anticoagulated individuals as 
determined by the ELISA were 164 ±32 mgml-1 as compared with 108 ±19 
mgml-1, determined by RIA (Kornberg et. al., 1993).   
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The INR has contributed significantly to OACT monitoring and the 
methodology and accuracy has been developed over the years, however the 
associated complication rate is still unacceptably high.  This makes the 
detection of haemorrhagic and thrombotic complications during INR-OACT 
monitoring, difficult for the clinician and for the patient in terms of needless 
stress and worry.  Evidence from the clinical trial carried out by Kornberg and 
his group actually suggested that the probability of the prediction of a 
thrombotic episode by the INR was statistically insignificant, whereas the NPA 
showed statistical significance, where P<0.001 on three out of five days 
during the trial (Kornberg et. al., 1993).  An Italian multicentre inception cohort 
study to assess the risk of bleeding associated with OACT, showed that there 
was a risk of bleeding associated with OACT in elderly patients and those 
with complications, such as diabetes and previous thromboembolism.  
However, the major bleeding risk to benefit ratio of OACT, with regard to the 
treatment of Non-rheumatic Atrial Fibrillation (NRAF), is still very low and the 
treatment efficacy was confirmed (Pengo et. al., 2001).   
 
The adaptability of the Biacore sensor chip surface has been demonstrated 
and can be useful for the immobilisation of many types of ligand.  Antibodies 
may account for a large proportion of the immobilisations, but ligands such as 
recombinant proteins (Yamaguchi et. al., 2003), synthetic receptor mimics 
(Gomes et. al., 2000; Gomara et. al., 2000; Bracci et. al., 2001), synthetic 
enzyme mimics (Kataki and Morgan, 2003), saccharides (Kuziemko et. al., 
1996) and carbohydrates (Maegawa et. al., 2002) have also been used as 
recognition elements on Biacore chip surfaces. 
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Figure 4.1.1A is a graphical output representing the specific chemical (amine) coupling of 
prothrombin polyclonal antibodies one of four channels on the surface of a Biacore chip.  The 
Chip (CM5) is coated with a carboxymethyl dextran hydrogel to allow the covalent attachment 
of the antibodies to the chip surface, using a standard EDC/NHS coupling method (refer to 3.3
for details).  Figure 4.1.1B is the graphical output produced by the Biacore 3000 software when 
increasing concentrations of thrombin are injected through the channel containing immobilised 
prothrombin antibodies.  This figure demonstrates the regenerability of the antibodies and the 
hydrogel dextran matrix to which the antibodies are covalently bound, due to the washing of the 
antibodies with 10mM HCl, allowing the response curve to continually return to the value prior 
to the injection of protein sample.  This can be achieved generally between 50-100 times 
(Jönsson and Malmqvist, 1992). 
 
 
 
Antibody immobilisation onto the carboxymethyl-dextran coated gold surface 
of a CM5 Biacore chip was by the Biacore standard EDC/NHS amine 
coupling method (Johnsson et. al., 1991).  A summary of the methods 
available for ligand immobilisation using the Biacore platform is represented 
in Figure 4.1.2.   
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Figure 4.1.2 represents the coupling chemistry available for application with ligand immobilisation onto 
the modified gold surface of the Biacore chips.  The Amine coupling chemistry utilises free 
carboxymethyl groups on the CM5 chip surface, by activating them with a mixture of EDC/NHS and 
allowing the attachment of antibody ligands to the new free amine (Johnsson et. al., 1991). 
 
4.2 Materials and methods 
 
CM5 research grade Biacore chips (BR-1000-72), HBS-EP buffer (10 mM 
HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% Surfactant P20) (BR-
1001-88), 7 mm diameter plastic vials (0.8 ml) (BR-1002-12) and the Amine 
coupling kit (BR-1000-50) were obtained through Biacore UK (Stevenage, 
Hertfordshire, SG1 2EF).  Vivaspin 2 cartridges were purchased from Fisher 
Scientific UK (product number VS0242). 
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4.2.1 Antibody production 
 
Antibody production was achieved through the standard methodology used by 
Immune Systems Limited (IS-L, Paignton UK.  http://www.is-l.com).  A 
preparation of native prothrombin antigen [2 mgml-1] was prepared using the 
Newfa adjuvant with phosphate buffered saline at physiological pH.  A rabbit 
(IS-L, Paignton UK) was immunised with approximately 0.25 ml of the 
antigen/adjuvant emulsion on days 0, 14, 28 and 42 of the antibody 
production.  (A small sample (1.5 ml) of the serum was taken at day 49 to 
assess the titre of the antibody.  A larger sample of serum (60-80 ml) was 
taken subsequent to the test sample possessing a high antibody titre and 
prior to a terminal bleed of approximately 60-80 ml after 8 weeks of 
maintenance.  Pre and post immune serum samples were screened against 
the target immunogen and a negative control using an ELISA, which allowed 
the cross reactivity of the antibodies to be assessed.   
 
4.2.2 Affinity purification 
 
Approximately 70 ml of serum collected from the rabbit was loaded onto a 
PBS pH 7.4 equilibrated, 3ml agarose linked native prothrombin affinity 
column, at a rate of approximately 8 mlh-1.  The column was then washed 
with 50ml 2M NaCl, pH 7.5, 50ml 0.1M Borate, pH 9.1 and 50ml 0.1M PBS, 
pH 4.5.  Serum containing native prothrombin specific polyclonal antibodies 
was collected by elution using 20mM glycine-HCl/200mM NaCl.  Fractions of 
0.8 ml were collected into tube containing 0.4 ml, 0.1M Tris-HCl, pH 8.5, after 
which the absorbance of each fraction was determined at 280 nm.  The 
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fractions containing peak antibody concentrations were pooled and stored at 
4oC in 0.05% sodium azide (NaN3) solution. 
 
4.2.3 Antibody immobilisation 
 
All Biacore work was undertaken on a Biacore 3000 automated surface 
plasmon resonance (SPR) platform (Biacore AB, Uppsala, Sweden).  
Prothrombin specific polyclonal antibodies were immobilised onto the surface 
of carboxymethyl-dextran coated (CM5) Biacore chips, using Biacore 
standard amine coupling chemistry.  The flow rate was set at a constant 5 
µlmin-1 throughout the antibody coupling procedure, using HBS-EP buffer.  
The CM5 chip was activated using a 7-minute pulse of 200 mM EDC/50 mM 
NHS mix, which allowed the activation of approximately 40% of the 
carboxymethyl groups on the chip surface.  Following activation of the CM5 
chip a 7-minute injection pulse of prothrombin specific antibodies at a 
concentration of approximately 25 µgml-1 in 10 mM sodium acetate buffer pH 
5.0, were injected.  The target immobilisation range of the antibodies was 
approximately 10,000 RU.  A 7-minute injection pulse of 1 M ethanolamine 
hydrochloride pH 8.5 deactivated the chip surface after antibody 
immobilisation.  Similarly, non-specific antibodies were immobilised on a 
separate channel on the same chip, for negative control purposes. 
 
4.2.4 Protein injections 
 
The flow rate varied between 5-10 µlmin-1 during the protein injections.  
Running buffer in this instance was standard Biacore prepared HBS-EP (10 
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mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20).  
Prothrombin (0.01-14.7 µM), thrombin (0.01-10 µM) and albumin (75-757 µM) 
were dissolved in 10 mM sodium acetate pH 4.0 and injected through the 
antibody-immobilised channels.  The concentration ranges reflected those 
present in human plasma.   
 
4.2.5 Plasma injections 
 
Informed consent for the collection of plasma was gained from patients 
undergoing routine INR determination for the strict monitoring of oral 
anticoagulation therapy at Cheltenham general hospital INR clinic.  Plasma 
were frozen on collection and stored at –20oC until required.  The response of 
the immobilised antibodies to serial dilutions of the plasma samples was 
assessed, by the injection of 35 µl of undiluted, 1:10, 1:100 and 1:1000 
plasma concentrations, diluted in pH 5.0 acetate buffer.   
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4.3 Results 
 
The final yield of native prothrombin specific antibodies was approximately 
18.9 mg, which was presented as a 702 µgml-1 solution of approximately 13 
ml.  This solution was separated into 1 ml aliquots and stored at –20 oC until 
required. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.1 represents the graphical output of the Biacore 3000 during immobilisation of 
prothrombin (PT) (red) and microcystin-LR (MC-LR) (blue) antibodies onto the dextran modified 
surface of a CM5 chip.  The level of surface immobilisation depended on the concentration and 
quality of the antibody, but for the prothrombin antibodies varied between 8,000 and 10,000 RU and 
between 18,000 and 25,000 RU for the microcystin-LR antibodies.  The microcystin antibodies were 
immobilised for the control, or non-specific binding element of the rebinding experiments. 
 
A CM5 Biacore chip was prepared by the amine coupling of prothrombin 
specific antibodies on one channel and microcystin-LR antibodies on a control 
channel.  Microcystin-LR antibodies were used as a control antibody, due to 
their proven specificity towards microcystin-LR and hence minimal non-
specificity for other proteins.  The volume and concentration of injected 
antibody and the velocity of each injection regulated the degree of antibody 
immobilisation, which varied between 8,000-10,000 RU for prothrombin 
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antibodies and between 18,000 and 25,000 RU for the microcystin-LR 
antibodies, as represented in Figure 4.3.1 above.  The antibodies were then 
subjected to injections of homogeneous protein solutions ranging in 
concentration from 0.01 – 0.5 nM for prothrombin and 150 – 750 nM for 
albumin. 
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B
 
 
Figure 4.3.2 represents the calibration of the prothrombin (Red) and microcystin-LR (Blue) 
antibodies with homologous protein solutions ranging in concentration from 0.01–0.5 nM for 
prothrombin (A), 0.01–10 nM for thrombin (B) and 150–750 nM for Albumin (C).  The protein 
concentrations tested were representative of those found in normal human blood/plasma samples, 
therefore giving an idea of how the antibodies would react to human samples in a trial situation. 
 
 
 
The immobilised prothrombin antibodies bound homologous prothrombin at 
concentrations of 0.01 nM and seemed to reach a saturation point at 
approximately 0.5 nM, as represented by the red plot in graph A of Figure 
4.3.2.  The response of the prothrombin antibodies to homologous solutions 
of thrombin, at the concentration range 0.01-0.5 nM, was significantly reduced 
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compared with that for prothrombin (Figure 4.3.2 B).  The response obtained 
due to the injection of human plasma like (150-750 nM) concentrations of 
albumin was also minimal, as represented in Figure 4.3.2 C.  The response 
associated with the reaction of prothrombin with microcystin-LR antibodies is 
minimal, and appears to be concentration independent in the concentration 
range 0.01-0.5 nM (Figure 4.3.2 A).  The microcystin-LR antibodies did 
appear to react more strongly to thrombin in the concentration range 0.01-5 
nM compared with the prothrombin antibodies, however above 5 nM thrombin 
the prothrombin antibodies reacted more strongly, as illustrated in Figure 
4.3.2 B.  This may be explained by the reduction in molecular mass of 
thrombin compared with prothrombin, enabling thrombin to bind to more of 
the non-specific binding sites.  The dissociation constant calculated for the 
prothrombin specific antibodies was 1.2 x10-10 with a χ2 value of 3.68 x103, 
calculated using the BIAevaluation software version 3.2 (Biacore AB). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.3 is a representation of the response obtained due to injection of prothrombin-spiked 
plasma, onto the prothrombin and microcystin-LR antibodies.  The injection of 1:10 sodium acetate 
buffer (pH 4.0) diluted plasma, spiked with a concentration range (0 – 0.05 nM) of prothrombin.  It 
can be seen from the graph that both of the immobilised antibodies interact similarly to prothrombin 
spiked-plasma.  The injection of a 0.05 nM concentration of prothrombin produces a response of 
only 200 response units, which is 5 times less than the injection of 0.05 nM homologous 
prothrombin, as represented in Figure 4.3.1A.  As with previous figures the blue trace represents 
microcystin-LR antibodies and the red trace represents immobilised prothrombin antibodies. 
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The response elicited from the interaction between immobilised prothrombin 
antibodies and prothrombin-spiked 1:10 diluted plasma pH 4.0 was much 
reduced compared with the interaction between prothrombin antibodies and 
homologous-buffered prothrombin pH 4.0, as seen in Figure 4.3.3.  The 
injection of prothrombin-spiked 1:10 diluted plasma over both antibody 
surfaces seems to elicit a non-specific response, relative to the antibody type, 
throughout the prothrombin concentration 0-0.05 nM.  However the response 
does increase as the concentration of prothrombin increases (Figure 4.3.3).   
 
Figure 4.3.4 represents the injection of prothrombin spiked (0.1 – 1 nM) filtered plasma 
onto the prothrombin specific (red) and the non-specific (blue) antibodies.  Centrifugal 
filtration was employed to remove the >100 kDa fraction from plasma samples, which were 
then diluted 1:10 with pH 4.0 sodium acetate buffer, and spiked with a (0.1 – 1 nM) range of 
prothrombin concentrations. 
 
 
 
 
 
 
 
 
 
 
 
Prothrombin spiked plasma samples and prothrombin spiked filtered plasma 
samples behaved differently when injected onto the surface of the 
immobilised prothrombin-specific and non-specific antibodies.  When the 
prothrombin spiked whole plasma was injected there was an apparent 
deposition of material onto the chip surface.  This was characterised by a 
153 
Chapter 4.  Polyclonal Antibodies towards Native Prothrombin Adrian Sylvester 
general increase in SPR response and a loss of specificity with respect to 
prothrombin binding.  When spiked filtered plasma was injected, the 
deposition of material was not visible and the specific binding of prothrombin 
was more apparent.  The response elicited due to an injection of 0.05 nM 
prothrombin spiked whole plasma was not produced when spiked filtered 
plasma was used. 
 
4.4 Discussion 
 
Antibodies towards native human and bovine prothrombin have been 
synthesised and utilised in various quantitative and qualitative assays (Tai et. 
al., 1979; Blanchard et. al., 1983; Lewis et. al., 1983; Malhotra and 
Sudilovsky, 1987).  Antibodies to native human prothrombin have been 
utilised in assays specifically designed to evaluate the significance of the 
native prothrombin antigen in monitoring oral anticoagulation therapy (Furie 
et. al., 1983; Furie et. al., 1990; Kornberg et. al., 1993).  These antibodies 
were potentially able to monitor OACT much more efficiently than standard 
clot based assays, however clot based assays such as the prothrombin time 
and activated partial thromboplastin time are still the method of choice for 
OACT monitoring. 
 
Initial attempts at producing a synthetic “epitope”, using the “gla” domain of 
native human prothrombin as a template, were unsuccessful due logistical 
problems associated with the utilization of gamma-carboxyglutamic acid in the 
synthetic process.  After further research of the literature, this method may 
not have been ideal for the application in this case.  Due to a large number of 
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various gla-containing proteins in the blood, the use of the prothrombin gla 
domain could introduce high cross reactivity with respect to the gla domain-
specific antibodies (Brown et. al., 2000).  A commercial preparation of native 
human prothrombin was used as the antigen for rabbit polyclonal antibody 
production; these antibodies were subsequently affinity purified against the 
same commercial prothrombin antigen preparation.  The commercial 
preparation was used to allow a direct comparison of antibody and molecular 
imprinting technology (Chapter 3) during the development of a native 
prothrombin specific assay.  The necessary calcium ions required for the 
correct conformation of native prothrombin would be acquired from the 
rabbit’s blood supply after immunisation, therefore the rabbit would have 
effectively been immunised with the native form of human prothrombin.  
However the affinity purification of these antibodies on a column of the 
commercial prothrombin, may have removed the calcium complexed native 
prothrombin specific antibodies.  Affinity purification of the non-affinity purified 
antibody sample, against prothrombin complexed with calcium could provide 
antibodies specific for the calcium dependent conformation of native 
prothrombin, which could potentially already be present.  However this would 
involve expensive and time-consuming experiments for the development of 
the affinity column and to acquire the specific antibody fraction, and also to 
test the antibody fraction against plasma samples. 
 
Antibodies directed towards abnormal prothrombin species have also been 
produced, and initially it was thought that these could provide the basis of a 
prothrombin assay for OACT monitoring.  The detection of vitamin K 
deficiency has been achieved through the production of an assay containing 
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abnormal prothrombin antibodies (Motohara et. al., 1985), and it was for this 
reason and the fact that vitamin K antagonism is central to the mechanism of 
OACT, that such an assay was initially considered.  Research of the literature 
subsequently suggested that total abnormal prothrombin would be difficult to 
detect in the complex plasma medium, due to its heterogeneity in warfarin 
treated patients (Esnouf and Prowse, 1976; Friedman et. al., 1977).  The level 
of vitamin K dependent protein decarboxylation and the relative proportions of 
decarboxylated prothrombin species were found to be related to the amount 
of vitamin K antagonism received by the patient (Tuhy et. al., 1979).  This 
indicated that increased and prolonged warfarin treatment is proportional to 
the increased levels of completely decarboxylated prothrombin in the blood, 
therefore adding substance to the argument that completely decarboxylated 
prothrombin might be a more suitable antigen for our purpose.  However, 
Blanchard and colleagues in 1983 determined that total abnormal 
prothrombin could not be quantified using a single antibody species, due to 
the presence of variable concentrations of partially carboxylated prothrombin.  
They also discovered that the activity of native prothrombin correlated 
excellently with the native prothrombin antigen, allowing for the development 
of a more convenient approach to prothrombin quantification (Blanchard et. 
al., 1983).  This discovery more importantly, suggested a novel method of 
OACT monitoring using immunoassay technology, instead of the relatively 
inaccurate clot based assays.  Evidence from three separate clinical trials, 
initiated to compare the native prothrombin antigen with prothrombin time and 
OACT monitoring, demonstrated that native prothrombin was a more accurate 
predictor of anticoagulative state (Furie et. al., 1984; Furie et. al., 1990; 
Kornberg et. al., 1993). 
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The immobilisation of affinity purified prothrombin antibodies, using standard 
amine-coupling chemistry and Biacore technology, allowed us to produce a 
real-time immunoassay for human prothrombin.  Immobilisation levels of the 
antibodies, achieved with a standard injection time and flow rate, 
corresponded with an antibody concentration of 8-10 ng mm2 for the 
prothrombin antibodies and 18-25 ng mm2 for the microcystin-LR antibodies, 
which correlated with those obtained previously (Vikinge et. al., 1998; 
Sonezaki et. al., 2000; Dillon et. al., 2003).   
 
Kinetic data corresponding to binding characteristics of the prothrombin 
antibodies could not be obtained due to badly fitting association and 
dissociation curves, which may have been due to the polyclonal nature of the 
prothrombin antibodies.  Multiple antigenic sites on the prothrombin molecule 
would have bound to the CM5 immobilised polyclonal antibodies with variable 
association and dissociation constants, which may have caused badly fitting 
curves and therefore inadequate raw data for simple kinetic analysis (Brown 
et. al., 2000).  The prothrombin antibodies however bound homologous 
solutions of prothrombin at concentrations (0.01–0.5 nM), much lower than 
the concentration of prothrombin in the blood or plasma (1.5-3.2 µM).  In 
keeping with the prothrombin specific properties of the antibodies, 0.1nM 
homologous solutions of thrombin produced a 10-fold decrease in relative 
response compared with prothrombin (see Figures 4.3.2 A and B).  With 
regard to the potential of albumin interfering with the response from 
prothrombin in plasma samples, plasma albumin concentrations of 750 µM 
produced 4-fold decrease in relative response compared to the response from 
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0.1 nM prothrombin.  Thus indicating that there shouldn’t be any interfering 
response from albumin in plasma samples, especially if 1:10 and 1:100 
dilutions of plasma are used.     
 
Prothrombin spiked plasma samples however did not produce a specific 
response, in fact the response of the microcystin-LR antibodies was very 
similar to that of the prothrombin antibodies during the injection of spiked 
plasma samples.  Indicating that there could have been a non-specific binding 
mechanism interfering with the specific binding of prothrombin from the 
samples.  An explanation for this non-specific effect maybe down to the high 
concentrations plasma proteins present in 1:10 diluted plasma, which may be 
reduced by the use of a higher plasma dilution factor e.g. 1:100.  Studies of 
the initial reactions of blood with gold surfaces have shown that surface 
bound fibrinogen is predominant after 5 seconds of incubation (Eriksson and 
Nygren, 1997).  In response to this observation, the binding of fibrinogen from 
plasma samples to the gold CM5 chip surface may block the specificity of the 
prothrombin antibodies, especially if the antibody is not so specific to start 
with.  Therefore a sample pre-treatment that would remove all proteins above 
100 kDa could potentially remove the antibodies’ specific inhibitory effect 
imposed by fibrinogen in the whole plasma samples. 
 
The centrifugal method used for the removal of the >100 kDa fraction from 
whole plasma did not turn out to be ideal.  The instruction sheet provided with 
the filtration cartridges recommended a 50 kDa difference between the 
protein of interest (prothrombin at 70 kDa) and the fraction for removal, in this 
case the fraction above 100 kDa including fibrinogen.  However filtration 
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cartridges with a molecular weight cut off, 50 kDa greater than prothrombin 
(i.e. 120 kDa) and 50 kDa less than fibrinogen (<200 kDa) were unavailable, 
which may have impaired the separation of fibrinogen from prothrombin.    
The sample pre-treatment was employed to remove the non-specific 
fibrinogen binding from the equation, in an effort to quantify specific 
prothrombin binding more easily. 
 
As polyclonal serum contains a mixture of antibodies raised against the same 
antigen, but possess different affinities for a variety of epitopes on the surface 
of the antigen.  If the antigen were a large protein for example, such as 
prothrombin, there would also be a wide variety of polyclonal antibodies 
produced with variable specificity towards the antigen.  With this in mind, the 
use of polyclonal antibodies for Biacore affinity studies is not ideal, badly 
fitting dissociation curves and non-statistically viable dissociation constants 
would be produced.  The dissociation constant of 1.2 x10-10 indicates that the 
antibody possesses high affinity for homologous solutions of prothrombin.  
The statistical significance of the dissociation constant with a χ2 value of 3.68 
x103 is put under question due to heterogeneous binding of the polyclonal 
antibodies.  Over time, it was apparent that there was considerable 
degradation of the antibody, which was characterised by a significant loss of 
affinity to prothrombin, and a reduction in the amount of antibody immobilised 
onto the surface of a CM5 Biacore chip.  As the dissociation constant is a 
measure of the antibodies affinity, its reduction is therefore characteristic of 
the antibodies degradation.  A dissociation constant of 1.08 x10-9 with a χ2 
value of 5.52 x104 suggests a reduction of the antibodies affinity.  However 
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due to the association and dissociation curves badly fitting with the Langmuir 
binding 1:1 model, kinetics calculations were statistically unviable.   
 
What we have presented here is a prothrombin specific polyclonal antibody 
based assay that displays affinity towards homologous concentrations of 
prothrombin, and prothrombin spiked processed plasma samples.  The 
objective now is to determine whether this prothrombin assay can detect 
variable levels of native prothrombin in processed plasma samples, which can 
be achieved through the injection of clinical processed plasma samples 
through the assay, as presented in chapter 5. 
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5.1  Introduction 
 
Oral anticoagulation therapy monitoring is currently achieved through the 
implementation of clot-based assays that allow calculation of the international 
normalised ratio (INR), which is used to determine the dose of oral 
anticoagulant given to the patient.  Despite the development and execution of 
strict standardisation procedure, patients monitored using the INR method 
can have an approximate major bleeding risk of between 3 - 8 % (Palareti et. 
al., 1996; Yuoh et. al., 2001).  This is predominantly down to patient individual 
variation and sensitivity to the reagents of the clot-based assay and the 
limited success of the general practitioners maintenance of the therapeutic 
INR (Duxbury and Poller, 2001).   
 
Comparison of oral anticoagulation monitoring methods in the past has 
provided substance to the argument that quantification of the native 
prothrombin antigen could provide a more efficient method for oral 
anticoagulation therapy (OACT) monitoring.  The root of this idea originated 
from prothrombin specific antibody work, pioneered by Furie and colleagues 
in the early 1980s (Blanchard et. al., 1983; Lewis et. al., 1983).  Conformation 
specific monoclonal antibodies were produced that recognised the calcium 
dependent conformer of prothrombin, and therefore correlated with functional 
coagulant activities.  Many antibodies directed towards abnormal prothrombin 
have been developed in the past (Blanchard et. al., 1979; Tai et. al., 1979; 
Owens et. al., 1984), however it was the native prothrombin antigen that 
provided increased correlation with a patient’s state of anticoagulation (Furie 
et. al., 1984 and 1990; Kornberg et. al., 1993).   
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The INR is a valuable and reasonably accurate method for the monitoring of 
OACT and standard laboratory tests have achieved 97 % accuracy, as 
reported by a recent clinical trial (Yuoh et. al., 2001).  OACT monitoring can 
be inconvenient for patients due to the recurrent clinical visits required for 
blood tests and dose adjustment.  However the development and introduction 
of patient self-test devices, has provided relief for the more inconvenienced of 
patients, by allowing self-OACT management and therefore reducing the 
number of required clinical visits.  The accuracy of the patient self-test 
devices is not as high as the standard laboratory assays (Yuoh et. al., 2001), 
however patients monitoring themselves are able to control their own INR 
more efficiently (Watzke et. al., 2000), and thus able to decrease their general 
OACT complication rate. 
 
The idea that OACT management can be achieved without complication is a 
bold and idealistic one.  However, all therapies relating to human problems 
are prone to complication, which is not necessarily the downfall of the therapy 
itself, but to individual variation associated with the patient.  This chapter will 
describe results obtained from a comparison of two alternative technology 
prothrombin assays, using randomised plasma samples obtained with 
consent from orally anticoagulated patients.  With the objective of determining 
whether immuno or molecular imprinting technology could provide a solution 
to the problems of excessive bleeding or thrombosis, associated with current 
OACT monitoring using INR.  
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5.2 Materials and Methods 
 
Vivaspin 2 PES (polyethersulfone) centrifugal filtration cartridges (catalogue 
number VS0242) with a 100,000 kDa molecular weight cut off were 
purchased from Vivascience (Hanover, Germany) through Fisher, UK 
(Loughborough, UK).  Biacore UK (Biacore International SA UK, Stevenage, 
Hertfordshire, SG1 2EF) supplied research grade CM5 (BR-1000-14) and SIA 
kit Au (BR-1004-05) Biacore chips, together with HBS-EP buffer (BR-1001-
88).  A Beckman model J2-21 centrifuge was used for the sample 
preparation.  A Biacore 3000 automated SPR instrument was used to carry 
out the assays for the entire study. 
 
5.2.1 Sample collection 
 
Informed consent (see appendix 5.1) was gained for the collection of plasma 
samples from patients who routinely attended Cheltenham general hospital’s 
INR clinic for OACT management.  The remainder of the plasma samples 
after the INR had been determined was collected and was stored at –20oC 
until required; the INR data for each labelled samples was also collected and 
stored in an MS excel file (see appendix 5.1). 
 
5.2.2 Sample preparation 
 
Samples (7 at a time) were removed from –20oC storage and placed in a 
36oC water bath for 2 minutes to thaw.  Each sample was aliquoted into the 
upper compartment of a labelled vivaspin 2 cartridge represented in Figure 
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5.2.1.  The cartridges were then centrifuged at 9,000 xg for 75 minutes at 
room temperature.  A 1:10 dilution with 10 mM sodium acetate buffer pH 4.0, 
was made using the filtrate containing the <100 kDa fraction, which was then 
aliquoted into vials for use in the Biacore assays.  The remainder was stored 
at –20oC.  
 
 
Filtrate 
Filter with 100,000 
kDa Mw Cut off Load sample at the 
top of the cartridge 
and centrifuge at 
9,000 xg for 75 
minutes at 25oC. 
Figure 5.2.1.  Vivaspin 2 polyethersulfone cartridge schematic  
 
 
 
 
 
 
5.2.3 Biacore assays 
 
Unmodified gold Biacore chips were used for the prothrombin imprinted poly-
APBA assay and carboxymethyl-dextran modified CM5 chips were used for 
the antibody assay.  The polymer grafting (Chapter 3) and antibody 
immobilisation (Chapter 4) procedures have been described previously.  A 
CM5 Biacore chip with prothrombin specific polyclonal antibodies immobilised 
on channel 1 and non-specific antibodies (Microcystin-LR specific) 
immobilised on channel 2 was docked into the Biacore 3000.  A sensorgram 
was started using HBS-EP buffer at a flow rate 5 µlmin-1 and temperature 25 
oC.  A stable baseline was achieved and 35 µl of 1:10 diluted filtered sample 
was injected through both channels of the CM5 chip.  The change in SPR 
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response (∆RI = RI post injection – RI pre injection) for each sample was 
calculated.  After each sample injection, the channel surface was washed with 
10 mM HCl to remove any bound material from the immobilised antibodies, in 
preparation for subsequent sample injections.  The mild regeneration 
conditions (10 mM HCl) were used in order to preserve the activity of the 
immobilised antibody and allow the surface to be used repeatedly. 
 
A prothrombin imprinted poly-aminophenylboronic acid (APBA) grafted J1 
Biacore chip was docked into the Biacore 3000 and primed with physiological 
pH phosphate buffered solution, prior to starting a sensorgram on one 
channel at a buffer flow-rate of 5 µlmin-1 and 25 oC.  A stable baseline was 
obtained through washing with 10 mM HCl, after which 35 µl of 1:10 diluted 
sample was injected onto a single prothrombin imprinted polymer-immobilised 
channel of the chip.  The SPR response pre-injection was logged so that the 
change in SPR response 500 seconds post-injection could be calculated.  
After 500 seconds the channel was washed using a 10 µl injection of 10 mM 
HCl + 0.1% SDS, followed by a 10 µl injection of 10 mM HCl.  The remainder 
of the samples were processed through the assay in this way, with 1 in 4 
samples repeated.   
 
5.2.4 Statistical analysis 
 
The relationship between the INR and ∆RI of each specific sample was 
plotted on a graph and described using a simple correlation coefficient and 
linear regression.  The student T-test was used to describe the statistical 
significance of the correlation. 
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5.3 Results 
 
Two sets of data were produced from the processing of diluted filtered plasma 
samples with the antibody and prothrombin imprinted MIP based assays, 
which are represented in Figures 5.3.1 and 5.3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.1 represents the change in SPR response (∆RU) from injections of plasma 1:10 
diluted with 10 mM sodium acetate, onto prothrombin specific antibodies (red) and 
microcystin-LR specific antibodies (blue), immobilised onto separate channels of a CM5 
Biacore chip.  The linear trend for the prothrombin specific antibody data can be 
represented by the equation y= 20.946x + 313.89 and has an r2 value of 0.0016.  The non-
specific antibody linear trend line can be represented by the equation y= 10.504x + 85.094 
with an r2 value of 0.005.  The correlation coefficients for the two sets of data were 
calculated as r= 0.0394 and r= 0.0706 for the prothrombin-specific and non-specific 
antibody data respectively. 
 
 
 
167 
Chapter 5.  System Comparison  Adrian Sylvester 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.2 represents ∆RU data corresponding to the injection of 39 plasma samples 
diluted 1:10 with 10 mM sodium acetate, onto the J1 Biacore chip with the prothrombin-
imprinted poly-APBA grafted onto its surface.  The linear trend line on the graph can be 
represented by the equation y= -63.123x + 708.63, and has an r2 value of 0.0109.  The 
correlation coefficient relating the INR data with the change in SPR response of the sample 
injections was calculated as r= –0.10424. 
The response values obtained for the immobilised prothrombin imprinted 
polymer and the filtered plasma samples seem to cluster around the INR 
range 1.5 – 3.5 (Figure 5.3.2), whereas the INR range for the antibody based 
assay varied equally between 1.5 – 4.0 (Figure 5.3.1).  The high SPR 
responses during the antibody-based assay do not correspond with either 
high or low INR values (Figure 5.3.1), whereas in the MIP based assay the 
largest response is obtained from a relatively low INR value of 2.3 (Figure 
5.3.2).  With respect to the INR/prothrombin quantification predictive 
capabilities of the two assays, according to Figure 5.3.2, the MIP-based 
assay seems to perform better than the antibody-based assay.  The 
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correlation coefficient relating INR with the relative response obtained from 
the MIP based assay experiments was calculated as r2= 0.0109, whereas the 
antibody-based assay provided an r2 value of 0.003.  The linear trend line 
drawn on the MIP-based assay filtered plasma results had an r-value of –
0.10424, potentially correlating lower INR plasma samples with higher relative 
SPR results.  The antibody-based assay linear trend possessed a slightly 
positive r-value of 0.0394 suggesting a potential correlation between high INR 
and increased SPR response.  
 
5.4 Discussion 
 
The Biacore platform enabled us to follow in real time the performance of our 
antibody and MIP-based assays, in the analysis of filtered plasma samples for 
native prothrombin quantification.  The fact that the grafted MIP was 
immobilised on an unmodified Biacore chip surface is in itself novel, however 
methods need to be developed that allow on-line monitoring of aqueous 
imprinted polymer surface immobilisation.  This would enable the 
immobilisation of blank and imprinted polymers onto different channels of the 
same Biacore chip, which would further increase the validity of control 
polymer experiments.  During our experiments blank and imprinted polymers 
were grafted to the surfaces of different chips, due the unavailability of a 
suitable off-line channel separation manifold.   
 
The immobilisation of a blank polymer alongside an imprinted polymer (i.e. on 
the same surface) could provide an internal control channel and hence 
increase the validation of our results, however this is currently not possible on 
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our Biacore 3000 system.  Biacore have recently developed an attachment for 
the Biacore 3000 (Biacore 3000 Recovery Upgrade Package, BR-1005-75), 
which enables the on-line monitoring of experiments that would otherwise 
cause harm to the internal fluidics of the system.  This new attachment allows 
the separation of a chip surface into four distinct flow channels as with the 
standard four channels of the normal system, however such an attachment is 
expensive and beyond budget for this project.  The specific order in which the 
testing of samples was conducted (i.e. prothrombin and non-specific 
antibodies immobilised on separate channels of a CM5 chip, followed by 
prothrombin imprinted polymer on a single J1 chip), allowed us to conclude 
that a control (blank) polymer was not required due to the imprinted polymer 
already producing non-correlating results.  However, the use of an imprinted 
and control/blank polymer in the preliminary model assay demonstrated 
increased affinity of homogeneous prothrombin to the imprinted polymer over 
the blank polymer as represented in Figure 3.3.1A. 
 
The question we need to answer now is, from the results of the filtered 
plasma injections, can we correlate increasing INR with ∆RU of the assays, in 
any way?  The statistical information calculated from Figures 5.3.1 and 5.3.2 
suggests that there is no significant correlation between ∆RU and the INR 
value.  Our hypothesis proposed an inversely proportional relationship with 
increasing INR and change in SPR response after injection (∆RU), i.e. as INR 
increased, ∆RU would decrease.  This could be explained by the fact that 
increasing INR corresponds to increased clotting times, which is caused by 
the removal of native prothrombin from the circulation by the action of 
warfarin.   
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Although statistically insignificant (t= 3.94 x10-7), the antibody-based assay in 
Figure 5.3.1 potentially shows the opposite of the proposed relationship and 
suggests instead, a proportional relationship between increased SPR 
response and INR, which would clearly be illogical.  The MIP based assay 
(Figure 5.3.2) shows a closer relationship to the proposed inverse proportion 
for INR and ∆RU, where r= -0.10424.  However there is no statistical 
significance with this relationship, as the students’ t-test gives a value of 1.98 
x10-8 (insignificant even at the lowest confidence interval p= 0.2).  So if the 
data doesn’t correlate with the hypothesis, then it is highly likely that the 
assays are not measuring the native form of prothrombin. 
 
The antibody-based assay could distinguish between increasing 
concentrations of homologous prothrombin and increasing concentrations of 
spiked prothrombin in filtered plasma (Chapter 4, Figures 4.3.2 and 4.3.4 
respectively).  We may also conclude that the antibody-based assay was 
specific enough to detect 0.1 – 1 nM concentrations of prothrombin in filtered 
plasma samples and 0.01 – 0.5 nM concentrations of homologous 
prothrombin.  This level of affinity would have been sufficient to detect the 
levels of prothrombin present in 1:10 diluted plasma (139 – 319 nM).  So why 
did the antibody-based assay function differently to the way we hypothesised 
it could, i.e. that SPR response would correlate with INR?  One option is that 
the antigen to which the antibody was raised was not specific for the native 
calcium dependent conformation of prothrombin, which is known to correlate 
precisely with prothrombin activity (Blanchard et. al., 1983), and therefore 
anticoagulation status.  A second reason why the plasma comparison results 
did not correlate with INR may have been brought about due to the use of 
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polyclonal antibodies in the development of the assay.  The use of a 
heterogeneous combination of antibodies all showing specificity for different 
epitopes of the prothrombin molecule, may not have introduced sufficient 
specificity for the native conformation of prothrombin into the assay.  The 
control antibody however did confirm that the prothrombin specific antibody 
was in fact specific for the prothrombin target. 
 
The imprinted polymer graft showed potential for aqueous protein recognition 
both in this comparison and previously in (Chapter 3.1.2). It also 
demonstrated that the application of synthetic affinity material to the field of 
biosensors and protein recognition is feasible.  Essentially we have created a 
synthetic affinity ligand that can be easily immobilised to gold surfaces, and 
shows affinity towards homologous prothrombin at a range 0.1 – 10 nM.  
However, this was reduced to 1 – 10 nM on application of prothrombin spiked 
plasma samples to the assay, which was still below the plasma prothrombin 
concentration range of 139 – 319 nM.  The magnitude of the response elicited 
from such sample injections was also reduced, indicating that there was a 
loss in affinity, or an increase in non-specificity when plasma was used.  This 
is not surprising, as plasma proteins are designed specifically to participate in 
acid-base equilibria and counteract electrostatic interferences (Figge et. 
al.¸1991).  Non-specific binding of food components and low molecular weight 
plasma proteins to the surface of Biacore chips has been described 
previously (Nedelkov et. al., 2000; Nedelkov and Nelson, 2001).  The 6.5 kDa 
plasma proteins were identified as apolipoprotein C-1 and one of its 
derivatives (Nedelkov and Nelson, 2001), but only after subjecting the SPR-
retained material to matrix-assisted laser desorption/ionisation – time-of-flight 
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mass spectroscopy (MALDI-TOF MS) (Krone et. al., 1997).  Such plasma 
proteins would still be present in the <100 kDa filtered plasma, therefore 
cause non-specific binding to the chip surface, or unreacted carboxyl groups 
of the carboxy-dextran matrix.  SPR biosensors cannot definitively distinguish 
between non-specific binding and specific binding to an antibody-immobilised 
surface, coupled with MALDI-TOF MS however non-specific binding can be 
detected easily (Nedelkov et. al., 2000).  This technology however is beyond 
the scope of our project, but further direction in the development of a specific 
native prothrombin assay may incorporate such technology. 
 
It is proposed that a complex mechanism, composed of many small 
electrostatic interactions together with the imprinting effect may have provided 
the observed affinity of the MIP towards the target protein.  The negatively 
charged boronic acid groups of APBA would potentially interact with positive 
regions located on the surface of the protein, and the imprinting effect would 
specifically arrange these interactions with the target protein.  This has been 
achieved previously using a similar polymer for the specific recognition of a 
variety of haemoglobin isomers (Middle et. al.¸1983; Gould and Hall, 1987), 
peroxidase enzymes (Piletsky et. al., 2000; Bossi et. al., 2001), and using 
acrylamide gels for specific recognition of glucose isomers (Liao et. al., 1996; 
Hjerten et. al., 1997; Wizeman and Kofinas, 2001).  From previous studies it 
does seem that there is the potential for imprinted polymers to provide the 
necessary affinity for the quantification of prothrombin from plasma, however 
these results indicate that further studies are required to provide such an 
assay.  Antibody degradation and loss of affinity was apparent when the 
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antibody-based assay was not stored in ‘running’ buffer, whereas the 
imprinted polymer lost no affinity on dry cold (4 oC) storage.  Once stabilised, 
the MIP-based assay demonstrated increased physical stability over the 
antibody-based assay, due to its improved ability to maintain affinity for the 
target throughout the washing procedure. 
 
Initially it was hoped that the plasma samples could be used raw and without 
any pre-processing, however it became apparent that after each raw plasma 
injection, a deposition of material onto each chip surface occurred, which 
subsequently hindered accurate response reading.  There were indications 
that fibrinogen was a predominant causative agent involved in the bulk 
deposition (Eriksson and Nygren, 1997), therefore a pre-processing step was 
employed to remove the >100 kDa fraction from each plasma sample.  In 
keeping with the initial design of the study, a rapid and uncomplicated pre-
processing step was required, as extensive and complex protein purification 
techniques such as affinity chromatography and dialysis would utilise large 
amounts of laboratory time and expense.  The Vivaspin-2 cartridges provided 
a simple solution to the pre-processing problem.  The temperature regulation 
efficiency of the centrifuge used to process the samples was however, 
insufficient to prevent large fluctuations in temperature during filtration.  This 
problem could not be overcome without significant expense, and it is thought 
that such temperature fluctuations could potentially have interfered with 
prothrombin quantification in the plasma samples. 
 
In conclusion therefore, the assays developed here have shown quantifiable 
affinity for prothrombin (as provided by Calbiochem, UK), in homologous 
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solution (Chapters 3 and 4) and in prothrombin spiked, filtered plasma.  The 
∆RU from both assays did not correlate significantly with the INR data 
obtained for each sample.  However, the application of monoclonal antibodies 
to the antibody-based assay could potentially remove non-specific plasma 
protein interactions and increase specificity and affinity for the native calcium 
dependent conformation of prothrombin (Lewis et. al., 1983; Malhotra and 
Sudilovsky, 1987).   
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6.1 General project summary 
 
The global project aim for this project was: 
• The development of an assay that shows specificity towards native 
prothrombin in homologous solutions and in complex matrices such as 
plasma and blood and the initialisation of a randomised clinical trial using 
ethically obtained plasma samples from orally anticoagulated patients 
allowing comparison with patient specific INR data. 
  
This PhD thesis has presented evidence, which directly addresses the project 
aim and is summarised as: 
• A computational model of human prothrombin was constructed using the 
tertiary bovine prothrombin structure and the primary amino acid 
sequence of human prothrombin, which was then used to design an 
epitope specific to prothrombin.  
• The surface located peptide epitope was synthesised using standard 
Fmoc synthetic chemistry and was used as the template for an imprinted 
bulk polymer, which showed some specificity towards prothrombin, 
however showed substantial non-specificity at thrombin concentrations 
above 0.05 mgml-1. 
• Subsequently the complete prothrombin molecule was used as the 
template for polymeric adsorbent synthesis. 
• Polymeric adsorbents using acrylamide and its derivatives did not produce 
the required affinity towards a commercial preparation of prothrombin, 
despite several previous successful attempts using different protein 
templates. 
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• The complete prothrombin molecule was again used as the template for 
poly-APBA homo-polymer imprint grafting, which allowed simple, but novel 
integration with the surface plasmon resonance transducer system 
(Biacore). 
• The synthetic poly-APBA adsorbent showed specificity towards 
homologous prothrombin at concentrations between 0.01 – 14.2 nM, 
however this affinity concentration range was reduced by a factor of 10 
when prothrombin spiked plasma was used.  
• The production of polyclonal antiserum showing specificity towards the 
same commercial preparation of prothrombin was achieved, for the direct 
comparison of imprinting and immuno technologies with respect to 
prothrombin specificity and affinity.  In comparison with the synthetic MIP 
adsorbent, the polyclonal antibodies showed affinity towards homologous 
prothrombin at a concentration range of 0.01 – 0.5 nM, which was again 
reduced when prothrombin spiked plasma was used. 
• Biacore immobilisation technology was used to create synthetic imprinted 
polymer and immuno based assays for prothrombin. 
• A clinical trial was conducted using the new assays, which comprised of 
81 plasma samples with corresponding INR data, obtained with informed 
consent from patients regularly attending the INR clinic at Cheltenham 
General Hospital. 
• The responses obtained from the injection of plasma samples through the 
prothrombin assays were compared to corresponding INR data.  It was 
found that assay response did not significantly correlate with plasma INR 
data. 
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6.2 Global discussion and final conclusions 
 
Why did the two assays not function the way we hypothesised they 
could? 
 
We developed the MIP based assay with the aim that it would be specific 
enough to capture or bind prothrombin in plasma.  As mentioned previously 
good recognition of epinephrine and peroxidase enzymes has been achieved 
using APBA homo-polymeric grafts in a microtiter plate format (Piletsky et. al., 
2000; Bossi et. al., 2001).  Therefore it was hypothesised that prothrombin 
could be recognised in complex solutions, such as plasma if the polymeric 
graft were fused with a highly sensitive transducer such as the Biacore.  
Recognition of various concentrations of homogeneous prothrombin, resulted 
in proportional SPR responses relative to the prothrombin concentration, 
therefore calibration of the assay was possible.  The prothrombin imprinted 
MIP-based assay produced much smaller responses to thrombin than to 
prothrombin, whereas the blank polymer responded similarly towards both 
proteins, thus indicating the importance of the imprinting effect.  Albumin 
concentrations of similar magnitude (0.05 – 10 nM) did not produce significant 
assay response with the prothrombin imprinted MIP, however albumin 
concentrations similar to those present in plasma produced responses 
equivalent to 10 nM prothrombin.  Hence, the masking effect seen with 
prothrombin spiked whole plasma samples could potentially be attributed to 
saturating concentrations of albumin. 
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The dilution of plasma may have reduced the albumin concentration, however 
the relative concentration of prothrombin was also reduced, and therefore a 
dilution alone was insufficient to promote prothrombin specific binding.  It was 
then noted that fibrinogen presented a major non-specific binding problem 
(Eriksson and Nygren, 1997), due to diluted plasma samples producing a bulk 
binding effect on the chip surface, which could not be removed by washing.  
The removal of the >100 kDa fraction of plasma, which contained fibrinogen, 
was achieved through centrifugal filtration, and the resulting plasma sample 
filtrate, did not produce the permanent bulk binding effect seen with whole 
plasma samples.  Similar albumin saturation and bulk binding effects were 
apparent with the antibody-based assay; sample dilution and removal of 
fibrinogen reduced background non-specificity.  The antibody-based assay 
bound homologous prothrombin solutions with increased affinity compared 
with the MIP-based assay, which was expected.  In contrast to the MIP-based 
assay, it was apparent that environmental conditions, such as temperature 
and number of washes had significant effect on the ability of the antibodies to 
specifically bind prothrombin. 
 
The polyclonal nature of the antibodies may have promoted the binding of 
abnormal prothrombin species in plasma samples.  Due to the relatively large 
size of the antigen (prothrombin), the antiserum produced by the rabbit would 
have contained a variety of antibodies that show specificity towards a variety 
of epitopes located on the prothrombin molecule.  And, due to the similar 
nature of native and abnormal prothrombin, i.e. the calcium dependent 
conformational change in the N-terminus of the protein, polyclonal antibodies 
may not have provided adequate specificity.  In contrast, the efficiency of the 
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synthetic adsorbent mechanism providing affinity for prothrombin may not 
have been adequate in complex solutions.  It is proposed that such a 
mechanism involves many weak electrostatic interactions between the 
template and the polymer, and that the imprinting process together with the 
solid gold surface allows their specific arrangement.  Higher levels of binding 
were displayed when the pH of the binding buffer was kept at pH 4.0, 
indicating that the binding mechanism was strongly influenced by electrostatic 
interactions and environmental pH.  Plasma proteins are involved in pH 
regulation and are able to control the electrostatic environment in the blood, 
which could explain the high level of non-specific binding with plasma 
injections onto the MIP-based assay.   
 
 
Why is INR still the method of choice for anticoagulation clinics? 
 
The INR is still the preferred method for OACT monitoring, due to its level of 
standardisation and amount of development it has received over the years 
(Talstad, 2000).  Antibody–based assays have been produced that claim to 
be able to monitor OACT with increased efficiency over INR (Blanchard et. 
al., 1983; Furie et. al., 1984; Furie et. al., 1990; Kornberg et. al., 1993), 
however none have been implemented in OACT clinics.  The use of bedside 
INR monitoring devices such as the Ciba Corning 512 system (Ciba Corning 
Diagnostics Corp., Medfield, MA), Hemochron 801 system (International 
Technidyne Corp., Edison, NJ) or the Coaguchek plus system (Roche 
Diagnostics) has enabled the self-monitoring of a patients INR.  These 
devices are in fact less accurate than the laboratory tests (Yuoh et. al., 2001), 
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however due to the fact that patients self-monitor and are able to dose adjust 
themselves every week, target INR levels are maintained efficiently (Watzke 
et. al., 2000). 
 
Complication rates, due to major bleeding episodes associated with OACT 
monitoring using INR, have recently been calculated at 1.2 – 2.8% in younger 
patients (<75 years) to 9.6 – 10.8% in patients aged 75 and over (Pengo et. 
al., 2001).  The incidence in younger patients is relatively low and can be 
attributed to the individual variation in sensitivity to thromboplastins and assay 
reagents.  The higher incidence in older patients can arguably be attributed to 
a general deterioration of health with age, thinning and stiffening of 
vasculature and decreased recuperation efficiency with age.  However, the 
complication incidences are still unacceptable and methods should be put in 
place to reduce them.  The INR determining assays are in themselves 
relatively accurate, and standardisation since 1983 (WHO, 1983) has allowed 
extensive development of the PT and aPTT assays, but still the complications 
remain!  Dedicated INR clinics have provided an increase in the quality of 
patient care relating to OACT monitoring in the UK and the Netherlands and 
some other European countries.  Computer assisted dose adjustment and 
patient home testing have also provided increased efficacy of INR monitoring 
(Duxbury and Poller, 2001).  It may be that the INR monitoring method has 
become as accurate as it can be, and that further developments of the 
anticoagulant, or as with the aim of this project further monitoring methods will 
have to be found.  
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What have we produced? 
 
We have produced a synthetic adsorbent that shows specificity towards 
homogeneous prothrombin solutions, at a concentration range of 0.05 – 14.2 
nM.  The adsorbent also displays specificity towards prothrombin in spiked 
filtered plasma samples within a range of 1 – 10 nM, however the degree of 
binding was much reduced.  The adsorbent however did not display any 
significant correlation to corresponding INR data, leading to a conclusion that 
the adsorbent was not solely specific for native prothrombin, but recognised 
many prothrombin species.  The adsorbent however was considerably more 
stable than the polyclonal antibodies raised against an identical antigen, and 
showed comparable specificity towards homogeneous prothrombin and 
prothrombin spiked plasma samples.  The adaptation of MIP technology to a 
variety of transducer systems, from microtiter plates, to SPR biochips, makes 
them an interesting and potentially lucrative technology for application in 
biosensor and diagnostic manufacture.   
 
Further development of MIP technology in synthetic recognition of bio-
molecules is required, along with the study of mechanisms that provide 
specific protein – ligand interactions.  Molecular modelling, using NMR and 
protein crystallography data can provide an important starting block for this 
development.  The molecular modelling of human prothrombin, in the early 
stages of this project, was initiated to provide structural information relating to 
potentially antigenic regions of the prothrombin surface.  With such 
computational/structural information, there may have been the potential to 
model conformational changes of the protein, on calcium binding for instance.  
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The coupling of such data with a virtual library comprising of functional 
monomers for use in aqueous molecular imprinting, may have provided a 
more specific synthetic recognition element for use in OACT monitoring. 
 
Essentially we have raised more questions about the efficacy of OACT 
monitoring using INR than we have answered in this study, and prior to the 
production of a synthetic native prothrombin assay that is robust and efficient, 
we are required to answer at least some of them.  INR is not a ‘gold standard’ 
of OACT monitoring; it is a simplified ratio relating the coagulation time of a 
sample with that of a thromboplastin standard.  Would the comparison of a 
native prothrombin assay against an established assay measuring native 
prothrombin enhance the validity of the study?  The antibodies used by 
Kornberg et. al. (1993) were incorporated into an enzyme linked native 
prothrombin immunoassay by Diagnostica Stago (France), however this 
ELISA is now not produced and similar assays are rare, or unavailable.  
However, the work undertaken by Furie et. al. (1984 and 1990) and  Kornberg 
et. al. (1993) indicated that OACT can be monitored more effectively through 
quantification of the native prothrombin antigen.  So why haven’t native 
prothrombin specific antibodies been incorporated into an assay suitable for 
the monitoring of OACT?  The use and maintenance of animals in the 
production of antibodies is both costly and time consuming, ranging from 
£3000 – £10000 (IS-L, Paignton, UK) and a minimum of 12 weeks for the 
production of antiserum.  The relatively large amount of development and 
standardisation that has been applied to the INR system has also put a 
restraint on the introduction of new OACT monitoring technology.  Such novel 
assays are required to be cost effective and robust, which generally implies a 
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synthetic based assay and more importantly, more effective at OACT 
monitoring than the INR.  Antibodies, generally possess the affinity and 
necessary specificity for their incorporation into assays, but do not possess 
the robustness of synthetic adsorbent materials.  So with the rapid 
development of molecular imprinting technology, the production of a synthetic 
native prothrombin recognition element, with the specificity and affinity 
characteristics of antibodies is certainly foreseeable. 
 
Departmental biotechnological tools, such as Sybyl 6.9 computational 
molecular modelling software, could not successfully model the human 
prothrombin structure.  The necessary software (Sybyl 6.9.2) and force field 
updates (Amber 7) that accommodate long range ionic forces associated with 
metal ion-protein complexation are required for successful modelling to be 
carried out.  Software such as Quanta (Accelrys, Cambridge, UK), may 
provide an alternative for the computational simulation of prothrombin 
conformational change and the identification of synthetic binding ligands, for 
the specific recognition of native prothrombin.  Software updates alone may 
not provide the necessary tools for successful human prothrombin simulation; 
X-ray crystallographic data of the calcium complexed human prothrombin gla 
domain is essential for the reliable modelling of such a complex protein 
structure.  This data would provide the necessary information to allow 
consistent molecular mechanics simulations of synthetic binding elements 
with potentially interesting regions of the protein structure, such as the 
complexation of carboxyglutamate residues within the gla domain.   
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So currently, INR is still the preferred OACT monitoring method purely due to 
the high costs incurred from its development and standardisation.  One 
alternative to the development of OACT monitoring could lie with further 
development of the anticoagulative drugs used in the therapy.  The use of 
computational methods to design a synthetic warfarin analogue, with 
increased therapeutic benefits such as slow release, may lead to reduced 
associated complication rates purely due to a potential decrease in the 
necessity for INR monitoring.  The development of oral anticoagulant 
cocktails with increased anticoagulant potential may lead to a general dose 
reduction, potentially lowering complication rates.  The questions raised by 
this study lead us to conclude that; the development of a novel native 
prothrombin assay may provide an answer to the complication rate 
associated with current anticoagulation therapy.  However, it may be that 
further development to increase the efficacy of anticoagulant therapy could 
lessen the need for a more accurate monitoring assay; oral anticoagulants 
have such a narrow therapeutic ratio that any new monitoring method is 
required to be almost 100% accurate.  Such questions require deliberation 
and research prior to formulating any decision on the future of oral 
anticoagulation therapy. 
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7.1 Future directions 
 
Future directions for the development of a novel native prothrombin assay 
would initiate with the acquisition of NMR and protein crystallography data of 
the calcium complexed conformation of prothrombin.  I feel that a reliable 
computational model of the human prothrombin gla domain, based on real 
data would allow interactions of synthetic ligands with the gla domain to be 
consistently modelled.  This computational data would provide the obvious 
financial benefits to the research, however will also allow us to visualise the 
mechanisms of interaction, prior to synthesis in the laboratory.  The 
implementation of upgraded force fields and computational modelling 
software is an integral part of this recommendation, where the correct 
parameters for metal ions and modified amino acids are explicitly 
characterised.  After the identification of native prothrombin specific-
interaction ligands, rigorous specificity testing using homologous and spiked 
complex samples must be undertaken.  Such investigations would potentially 
reduce non-specific binding of plasma proteins.  With regard to non-specific 
binding, efforts to utilise more haemo-compatible surfaces in the development 
of blood-based biosensors, may also alleviate the challenge of non-specific 
binding from fibrinogen (Grunkemeier and Horbett, 1996, Eriksson and 
Nygren, 1997). 
 
One major point that was illuminated in the previous chapter was that of the 
efficacy of oral anticoagulant therapy itself for the majority of patients, i.e. 
those over the age of 60 years.  The therapeutic ratio of warfarin and its 
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analogues is extremely narrow, which puts increased emphasis on the 
accuracy of the monitoring methods used for its control.  The INR system was 
developed from Armand Quick’s prothrombin time (Quick et al., 1935), which 
was a crude measurement of the time taken for blood to form a clot.  The 
current INR system developed by the world health organisation (WHO, 1983), 
has received extensive standardisation and automation since the 1980s, but 
essentially has not changed since then.  With 20 years worth of 
biotechnological developments and new scientific research tools, surely the 
time has come (and gone) to either enhance the INR system, introduce a 
novel monitoring methodology or introduce a novel anticoagulation drug, or 
cocktail of drugs. 
 
The brainchild of the late Dr Bob Dalton served initially to fuel this project, but 
after three years of trying to develop a novel native prothrombin assay to 
allow the more accurate management of OACT with INR, more questions 
have been raised regarding the efficacy of such an assay, than have been 
answered.  For example, why hasn’t the enzyme-linked assay developed by 
Kornberg et. al. (1993), using the monoclonal antibodies produced by 
Blanchard et. al. (1984) received the standardisation that INR has received, 
even though it has been suggested as a more efficient OACT management 
assay?  One can only pose the answer that the financial implications of 
producing such an assay far outweigh the complications associated with the 
current methods. 
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Results
Initial results suggest that prothrombin-imprinted poly-APBA preferentially binds prothrombin over thrombin. The results
also show that corresponding blank poly-APBA (prepared in the absence of template) does not bind prothrombin equally 
well in the same experimental conditions. The cold dry storage capability of the MIP presented an advantage over the 
antibodies, which required a steady cold flow of running buffer for storage purposes. 
Prior to rebinding the removal of excess material from the chip 
surface was achieved using 10 mM HCl, which was also used 
to regenerate the polymer after rebinding experiments. The 
regeneration and washing of immobilised anti human 
prothrombin polyclonal antibodies was also achieved using 10 
mM HCl. Rebinding of the template to the polymer was 
achieved in 100 mM sodium acetate buffer pH 4.0. The relative 
SPR response corresponding to the addition of protein 
samples was monitored using the Biacore® 3000.
Figure 1: The 2D molecular structure of poly-
aminophenylboronic acid.
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Figure 2: Prothrombin imprinted poly-APBA and blank 
poly-APBA, prothrombin and thrombin rebinding.  
Prothrombin imprinted polymer can detect prothrombin 
levels from 0.1 nM.
Figure 3: Prothrombin and Microcystin-LR polyclonal 
antibodies, prothrombin and thrombin rebinding.  
Prothrombin antibodies can detect prothrombin levels 
from 0.01 nM.
MIP and Antibody Based Prothrombin 
Assays for Monitoring Oral Anticoagulation 
Therapy
A.J. Sylvester*, S. A. Piletsky, K. Karim, A.C. Woodman,  Cranfield Biomedical Centre, Silsoe, UK 
Introduction
The existing online protocol for measurement of the International Normalised Ratio (INR) allows rapid multiple sample 
analysis, however it suffers from the inaccuracy of the prothrombin time test. It has been proven that native prothrombin 
concentration is a more accurate predictor of anticoagulation status in warfarin treated patients. The objective of this 
work is the development of a novel direct native prothrombin assay utilising molecular imprinting technology. However, 
molecular imprinting of large protein molecules continues to be a challenging task. 
Our strategy is based on developing homologous MIPs capable of template recognition through the combination of weak 
molecular interactions and the geometrical shape of the imprinting cavity, rather than through the strong interactions 
between the template and a few carefully positioned functional monomers. We used a surface grafting method, which 
allowed the non-covalent adsorption of prothrombin imprinted poly-aminophenylboronic acid (monohydrate) to the gold 
surface of a standard J1 Biacore Chip. The selective material described here offers attractive potential for the 
development of a real time prothrombin biosensor. The MIP performance was also compared with that of monoclonal 
antibodies.
© Cranfield University 2003
www.cranfield.ac.uk/ibst/cbmc(*) a.j.sylvester.s00@cranfield.ac.uk
Conclusions
The rebinding of varying concentrations of homologous prothrombin solution to the surface grafted prothrombin 
imprinted polymer produced a larger SPR response compared with the blank polymer. The prothrombin polyclonal 
antibodies showed much higher affinity for prothrombin compared with the prothrombin imprinted MIP. The polymeric 
material and the polyclonal antibodies also showed (although significantly reduced) non-specific binding to thrombin. 
The MIP displayed increased stability to 10 mM HCl regeneration compared with the polyclonal antibodies which showed 
significant denaturation after 30 washes. Preliminary tests show that both the antibodies and prothrombin imprinted 
polymer can detect prothrombin in prothrombin spiked diluted plasma solutions.  
The prothrombin imprinted polymer produced has the ability to detect normal levels of native human prothrombin in 
plasma samples. A clinical trial is currently underway to assess the potential to detect the levels of native human 
prothrombin in plasma samples from orally anticoagulated patients.
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Appendix D. 
A 
B 
Appendix D represents the results obtained when the prothrombin (red) and thrombin (blue) 
calibrations are repeated on different chips.  Graph A represents a calibration on the pAPBA 
coated J1 chip and graph B represents a calibration using immobilised prothrombin 
antibodies.  The relative response change on injection of 0.5 nM prothrombin on the 
prothrombin imprinted polymer coated chip is much higher than that in Figure 3.3.1A. 
Similarly there are vast differences with the antibody calibration, thus indicating that the 
coating of different chips with prothrombin imprinted pAPBA and prothrombin antibodies 
does not give highly reproducible calibration results.  
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 Cranfield Biomedical Centre Institute of Bioscience and Technology 
Cranfield University 
Silsoe 
Bedfordshire 
MK45 4DT 
Date of sampling: 
Patient Number: 
Pathology Number: 
Study Sample ID Code: 
INR Data Sent: Yes / No 
INR Value: 
 
 
 
Consent Form 
 
Title of Project: The development of a novel normal prothrombin 
assay for the more accurate monitoring of oral 
anticoagulation therapy. 
 
Name of Researchers: Mr Adrian J Sylvester BSc. MSc. and Dr Gill 
Rouse. 
 
 
1. I confirm that I have read and understand the information sheet dated 
21.07.03 for the above study. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without my medical care or legal rights being 
affected. 
3. I am willing to allow access to my medical records by Dr Gill Rouse for 
the duration of the study but understand that strict confidentiality will be 
maintained.   
4. I agree to take part in the above study 
 
 
I understand that no information from which I could be 
recognised will leave Cheltenham General Hospital (CGH). 
 
 
 
Name of Patient    Date   Signature 
 
 
 
 
Name of Person Taking Consent  Date  Signature 
(If different from researcher)  
 
 
 
 
Researcher     Date   Signature 
Copies of the consent form will be held by Dr Gill Rouse (with patient Data), Adrian Sylvester (without 
patient data) and the patient. 
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 Cranfield Biomedical Centre 
Institute of Bioscience and Technology 
Cranfield University 
Silsoe 
Bedfordshi  re
MK45 4DT  
Patient Information Sheet 
 
Title:   
 
The development of a novel native prothrombin assay for the more accurate 
monitoring of oral anticoagulation therapy (OACT) 
 
 
Invitation to participate: 
 
You are invited to participate in a research project.  Before you decide it is 
important for you to understand why the research is being done and what it 
will involve.  Please take time to read the following information sheet carefully 
and discuss it with friends and relatives.  Ask us if there is anything that is not 
clear or if you would like more information.  Take time to decide whether or 
not you wish to take part. 
 
 
What is the purpose of the study? 
 
The aim of this study is to use two new methods for the development of a new 
improved method for monitoring OACT.  Current monitoring techniques 
involve measurement of the clotting time in a patient’s blood sample and its 
comparison to a standard clotting time, which gives the International 
Normalised Ratio (INR) result.  This is then used to calculate the warfarin 
dose that the patient should receive. 
 
We are looking more closely at prothrombin, which is the major blood clotting 
protein and is more directly related to the clotting state of the blood.  By 
measuring the levels of prothrombin in a blood sample we believe that we 
could improve dosing of warfarin.   
 
We are going to use two new methods to measure the levels of prothrombin 
and then we will compare these results with the INR data from each sample.  
This study is jointly run between scientists at Cranfield University, Silsoe and 
staff at Cheltenham General Hospital (CGH). 
 
 
Why have I been chosen? 
 
You have been chosen because you are undergoing routine anticoagulation 
monitoring at CGH INR clinic.  Blood samples are taken regularly from 
outpatients to determine the patients INR and subsequent warfarin dose.  
Once the routine INR data has been obtained the remainder of the sample 
will analysed at Cranfield Biomedical centre as part of the research. 
CGH Information Sheet, Version 1, 21.07.03 
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Do I have to take part? 
 
It is entirely up to you whether you take part or not.  If you do decide to take 
part you will be asked to sign a consent form, however you are free to 
withdraw at any time and without reason, and this will not affect the standard 
of care you receive.  If you choose to withdraw, all data collected about you 
and all your samples will be destroyed. 
 
 
What will happen to me if I take part? 
 
You will attend the INR clinic consultation as normal and your INR will be 
calculated as normal from the blood sample you give.  However, the 
remainder of this sample will be analysed in the laboratory in a new novel 
system that will detect the amount of normal prothrombin in the sample.  We 
will only require part of this one sample from you and this will not be used for 
any other purpose other than for this research study.  No additional blood 
samples will need to be taken from you. 
 
  
What do I have to do? 
 
We would like you to give your permission to allow some of the routine blood 
sample to be used for this study.  This research will in no way affect the 
treatment you would normally receive. 
 
 
What are the side effects of taking part? 
 
There are no side effects of taking part in this study. 
 
 
What are the possible disadvantages and risks of taking 
part? 
 
There are no disadvantages or risks associated with agreeing to allow the use 
of your blood in this study. 
 
 
What are the possible benefits of taking part in this study? 
 
There is no specific clinical benefit to you from taking part in this study.  The 
results will however, hopefully lead to further research that may better allow 
the more accurate prescription of oral anticoagulant dose, therefore helping 
future patients.  
CGH Information Sheet, Version 1, 21.07.03 
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What happens when the research study stops? 
 
The information gathered will be analysed and published as a scientific thesis 
to contribute to further research.  Any remaining research material will be 
destroyed. 
 
 
What if something goes wrong? 
 
If taking part in this study harms you in any way, there are no special 
compensation arrangements.  Regardless of this, if you wish to complain 
about any aspect of the way in which you have been approached or treated 
during the course of the study, the normal National Health Service complaints 
mechanisms will be available to you. 
 
 
Will my taking part in this study be kept confidential? 
 
All blood specimens will be kept confidential.  If you consent to take part in 
this study then your medical documents maybe examined by the INR 
consultant, but of course this information will remain confidential.  No 
personal information about you will leave Cheltenham General Hospital. 
 
 
What will happen to the results of the research study? 
 
The results will be analysed and written up in a scientific PhD thesis.  This will 
take approximately 1 year to produce and will be available in the libraries of 
the participating hospital.  You will not be identified in any report or 
publication. 
 
 
Who is organising the funding? 
 
Cheltenham General Hospital Trust and Cranfield Biomedical Centre, Silsoe 
have jointly funded the research. 
 
 
Who has reviewed the study? 
 
The Gloucestershire Research Ethics Committee has reviewed this study. 
CGH Information Sheet, Version 1, 21.07.03 
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Contacts for further information: 
 
 
 Dr Gill Rouse  
Department of Pathology 
Cheltenham General Hospital  
College Road 
Cheltenham 
GL55 7AN 
 
Tel: 08454 224057 
Email: Gill.Rouse@egnhst.org.uk  
 
 
 
 
 
 
 
 
 
Mr Adrian Sylvester  
Cranfield Biomedical Centre  
Cranfield University 
Barton Road 
Silsoe 
Bedfordshire.  MK45 4DT 
 
Tel: 01525 863002 (Ext: 3776) 
Email: a.j.Sylvester.s00@cranfield.ac.uk 
 
 
 
Thank you for taking the time to read this information 
sheet! 
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Cranfield Biomedical Centre 
Institute of Bioscience and Technology 
Cranfield University 
Silsoe 
Bedfordshire 
MK45 4DT  
 
Protocol for Sample Analysis 
 
 
Title:   The development of a novel native prothrombin assay for the 
more accurate monitoring of oral anticoagulation therapy 
(OACT). 
 
 
1) Patients will be asked to participate by Dr Gill Rouse or their nurse 
during a routine International Normalised Ratio (INR) clinic at 
Cheltenham general Hospital (CGH). 
2) The patients will be given an information sheet, which provides 
relevant information about the study and Dr Rouse or the nurse will 
explain the study to them.  They will then have until their next INR 
clinic appointment (up to 2 weeks) to decide if they wish to participate. 
3) Patients arriving at the next INR clinic will be asked of their decision 
regarding the study.  The study participants will then be given a 
consent form to sign, and three copies will be made, 1 for the 
researcher, 1 for the patient and 1 for the health records. 
4) The patients’ blood sample will be taken for INR determination. 
5) The consultant or the nurse will take and label the blood sample tubes 
using a study ID code sticker.   
CGH study Protocol, version 1, 21.07.03 
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6) The data obtained from the sample collection at CGH will be stored in 
an electronic password protected database on Dr Anthony Woodman’s 
computer.   
7) The following data will be required: year of birth, gender and the results 
of the INR determination.  Only the following researchers will have 
access to the data: Mr Adrian Sylvester and Dr Anthony Woodman.  All 
data will be held until the end of the project (PhD) and subsequently 
destroyed by Dr. Anthony Woodman. 
8) A sticker with the following data will be attached to each hospital copy 
of the consent form for cross-referencing purposes: date of sampling, 
patient number, pathology number, sample ID code and whether INR 
data was sent with the sample.   
9) The hospital copies of the consent forms will be held by Dr Gill Rouse 
for a period of 1 year from sampling and will be destroyed after this 
period.  Access will not be provided to anyone else other than Dr Gill 
Rouse. 
10) Samples will be analysed using the newly developed polymer based 
method and with the antibody based method using a surface plasmon 
resonance (SPR) based detection device. 
11) Statistical analysis and their comparison with the INR data from each 
sample will enable the calibration of the method with respect to it 
potential in monitoring oral anticoagulation. 
CGH study Protocol, version 1, 21.07.03 
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Gloucestershire Royal Hospital 
Great Western Road  
Gloucester 
GL1 3NN 
Telephone: 08454 225660 
Fax: 08454 224590 
Email: SueDennis@gloucr-tr.swest.nhs.uk 
 
5 August 2003 
DATA PROTECTION COMPLIANCE 
 
Mr Adrian Sylvester 
Cranfield University 
Barton Road 
Silsoe 
Bedfordshire 
MK45 4DT 
 
Dear Mr Sylvester 
 
Re: Study  - The development of a novel native prothrombin assay for the monitoring of oral and 
anticoagulation therapy (OACT) 
 
In my capacity as Data Protection Officer for Gloucestershire Hospitals NHS Trust I have received details of the 
above Study.  I do not have any major issues related to Data Protection but would ask you to confirm the details 
raised in point 3 below and if you could just note and the amend the documentation accordingly as advised in 
points 1 and 2: 
 
1 Could I suggest that for future reference to the documentation and to assist patients you do not use 
abbreviations such as on the Protocol, Patient Information Sheet and Consent Form the use of CGH  or 
INR unless they have previously been written out in full on the documents. 
 
2 Consent Form 
 
Please note the above comments and could you record on the bottom of the form where and by whom copies of 
the Consent Form will be retained. 
 
3 Security and retention 
 
You have covered the issues of security and retention related to electronic data but it is not clear as to where the 
manual cross referencing data will be held, by whom, for how long, who will have access to it and who will take 
responsibility for its ultimate destruction. Please could you clarify this detail? 
 
I will await your reply but am happy in the meantime for this Study to proceed through for Trust approval and 
submission to the Ethics Committee. 
 
Yours sincerely 
 
 
Sue Dennis 
Clinical Information and Data Protection Manager 
 
Cc: 
Dr Sally Pearson, Director of Clinical Strategy, Gloucestershire Hospitals NHS Trust 
Dr Guy Routh, Medical Director, Gloucestershire Hospitals NHS Trust 
Dr Colin Roch-Berry, Caldicott Guardian, Gloucestershire Hospitals NHS Trust 
Julie Hapeshi, Research & Development Co-ordinator, Gloucestershire Hospitals NHS Trust 
Dr Anthony Woodman, Cranfield Biomedical Centre 
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